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ABSTRACT 
 
Gene Silencing in Cancer Cells Using siRNA: Genetic and Functional Studies. 
 (May 2004) 
Ma’en Ahmad Abdel Rahim, B.S., Al-Isra University 
Chair of Advisory Committee:  Dr. Stephen H. Safe 
 
Sequence-specific small interfering RNA (siRNA) duplexes can be used 
for gene silencing in mammalian cells and as mechanistic probes for 
determining gene function.  Transfection of  siRNA for specificity protein 1 (Sp1) 
in MCF-7 or ZR-75 cells decreased Sp1 protein in nuclear extracts, and 
immunohistochemical analysis showed that Sp1 protein in transfected MCF-7 
cells was barely detectable. Decreased Sp1 protein in MCF-7 was accompanied 
by a decrease in basal and estrogen-induced transactivation and cell cycle 
progression. These results clearly demonstrate the key role of Sp1 protein in 
regulating growth and gene expression of breast cancer cells. 
The aryl hydrocarbon (AhR) is a ligand-activated nuclear transcription 
factor. siRNA for the AhR decreased TCDD-induced CYP1A1 protein, CYP1A1-
dependent activity, and luciferase activity in cells transfected with an Ah-
responsive construct. 17β-Estradiol (E2) induces proliferation of MCF-7 cells, 
and this response is inhibited in cells cotreated with E2 plus TCDD.  The effects 
of TCDD on E2-induced cell cycle progression were partially blocked in MCF-7 
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cells transfected with siRNA for AhR.  The decrease in AhR protein in MCF-7 
cells was also accompanied by increased G0/G1 → S phase progression. 
Surprisingly, TCDD alone induced G0/G1 → S phase progression and exhibited 
estrogenic activity in MCF-7 cells transfected with siRNA for the AhR.  In 
contrast, degradation of the AhR in HepG2 liver cancer cells resulted in 
decreased G0/G1 → S phase progression, and this was accompanied by 
decreased expression of cyclin D1, cyclin E, cdk2 and cdk4.  In the absence of 
ligand, the AhR exhibits growth inhibitory (MCF-7) and growth promoting 
(HepG2) activity that is cell context-dependent.   
Sp family proteins play a complex role in regulation of pancreatic cancer 
cells growth and expression of genes required for growth, angiogenesis and 
apoptosis. Sp1, Sp3 and Sp4 cooperatively activate VEGF promoter constructs 
in these cells; however, only Sp3 regulates cell proliferation. siRNA for Sp3 
inhibits phosphorylation of retinoblastoma protein, blocks G0/G1 → S phase 
progression of Panc-1 cells, and upregulates p27 protein/promoter activity.  
Thus, Sp3 plays a critical role in angiogenesis (VEGF upregulation) and the 
proliferation of Panc-1 cells by a novel mechanism of Sp3-dependent 
suppression of the cyclin-dependent kinase inhibitor p27. 
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INTRODUCTION 
 
RNA INTERFERENCE  
The phenomenon of sequence-specific gene silencing with RNA 
interference (RNAi) was first discovered in the nematode worm Caenorhabditis 
elegans (C. elegans) as a response to double-stranded RNA (dsRNA) (1). 
Antisense RNA has been extensively used to inhibit gene expression and it has 
also been reported that sense RNA was as effective as antisense RNA for 
suppressing gene expression in worms (2). Fire and coworkers (1) were the first 
to show the synergy of sense and antisense RNAs by demonstrating  that  
dsRNA was at least ten-fold more potent for gene silencing in the worm than 
were sense or antisense RNAs alone. Silencing genes by dsRNAs exhibited a 
number of remarkable properties: RNAi could be observed by feeding the worm 
with either dsRNA itself or by using bacteria which expressed the dsRNA (3). 
Exposure of the parental animal to only a few molecules of dsRNA per cell 
triggered gene silencing throughout the treated animal (systemic silencing) and 
in its F1 (first generation) progeny. This discovery suggested that a number of 
previously characterized, homology-dependent gene-silencing (HDGS) 
mechanisms might share a common biological root.  
HDGS was first discovered with the introduction of transgenes coding for  
_____________________ 
This dissertation follows the style of the Journal of Biological Chemistry. 
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chalcone synthase into petunia plants. Although the expectation was increased 
flower pigmentation, in many of the plants, the result was in fact the opposite, 
with white or variegated petunia petals. This observation, suggested not only 
that the introduced transgenes were inactive but also that exogenous genetic 
elements affected the constitutive chalcone synthase locus. This apparent 
communication between unlinked but homologous loci was termed 
cosuppression (4). It is now recognized that HDGS is a commonly observed 
outcome of transgenesis in plants. Communication can occur between 
transgenes and endogenous genes (5), between two related transgenes (6), and 
even between silenced and active endogenous loci (7). A similar phenomenon, 
called paramutation, describes an interaction between two endogenous alleles, 
in which an active locus is repressed by exposure to a silenced locus in a 
manner that is stable even after alleles are separated by subsequent genetic 
crosses (8). Communication occurring solely between endogenous loci has also 
been observed in Drosophila. For example, one study showed that crossing flies 
containing a silenced copy of an I element (a transposon similar to mammalian 
LINE elements) to flies containing active I elements repressed transposition. 
Furthermore, such repression was heritable (9).  It is possible that paramutation 
and cosuppression are mechanistically related phenomena that differ only in the 
source of the silencing trigger. The first report of transgene cosuppression in the 
animal kingdom was observed in Drosophila (10). Introduction of repeated white-
Adh fusion transgenes into Drosophila lead to considerable repression of the 
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transgene and also of endogenous Adh expression. The degree of silencing was 
proportional to transgene copy number.  
  Transitive RNAi. Systemic silencing phenomena have been observed in 
C. elegans where RNAi can spread throughout the organism, even when 
triggered by minute quantities of dsRNA (1). Plants also exhibit systemic 
silencing which can be observed throughout the plant or be transferred to a 
naive grafted scion (11). These phenomena require a system that transmit 
signals between cells and amplifies the signal. Recently, a phenomenon termed 
“transitive RNAi” has provided some useful insights regarding this process. 
Transitive RNAi refers to the movement of the silencing signal along a particular 
gene. In C. elegans, targeting the 3' portion of a transcript results in suppression 
of that specific mRNA and in produces siRNAs homologous to the targeted 
region. In addition, siRNAs complementary to regions of the transcript upstream 
from the area targeted directly by the silencing trigger also appear and 
accumulate (12).  In plants, the ability of the silencing agent to move within the 
plant is called Systemic Acquired Silencing (SAS) (13). For example tobacco 
plants transgenic for the green fluorescent protein (GFP) can be infiltrated with 
Agrobacterium tumefaciens carrying a GFP reporter construct. This results in 
rapid suppression at the infiltration zone, and, by 18 days postinfiltration, the 
upper leaves of the plant also silence the GFP transgene (14).  
Systemic transmission of silencing was perhaps most strikingly 
demonstrated by the grafting of a nonsuppressed scion (the upper vegetative 
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tissues) onto a cosuppressed stock (lower tissues and the root system), which 
resulted in the scion becoming cosuppressed. In fact, in a three-way graft, 
silencing can be passed between a silenced stock and an engrafted scion 
through a central stock that completely lacks sequences corresponding to the 
targeted gene (11). In both plants and C. elegans, dsRNA-induced silencing 
requires proteins similar in sequence to a tomato RNA-directed RNA polymerase 
(RdRP) (15), which could be involved in amplifying the RNAi signal. However, 
only the tomato enzyme has been shown to possess polymerase activity, and 
biochemical studies will be required to definitively establish the role of these 
proteins in RNAi.  
A model for transitive RNAi in which siRNAs might prime the synthesis of 
additional dsRNA by RdRPs has been predicted from genetic studies. RdRP 
activity has been reported recently in Drosophila embryo extracts (16), whereas  
transitive RNAi has not yet been observed in flies. While numerous experiments 
suggest that an RdRP is not required for RNAi in Drosophila extracts, the 
possibility remains that such an enzyme might act, for example, in triggering 
RNAi by the production of dsRNA from dispersed, multicopy transgenes. In 
plants, transitive RNAi travels in both 3' 5' and 5' 3' directions (17), which is 
inconsistent with the simple notion of siRNAs priming dsRNA synthesis. It is 
believed that genomic loci may serve as a reservoir for silencing. In some 
systems, alterations in chromatin structure can be predicted from exposure to 
dsRNA, which could lead to the production of 'aberrant' mRNAs that are 
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substrates for conversion to dsRNA by RdRPs. This model would permit bi-
directional spread and expansion of altered chromatin structure is an established 
phenomenon (17). Moreover, a similar model could explain co-suppression that 
is occasionally triggered by single-copy, dispersed transgenes. This model 
would be consistent with transitive effects that have been observed for both 
transcriptional and post-transcriptional silencing in Drosophila, which operate in 
the absence of any homology in the transcribed RNA, and thus differ from 
'transitive RNAi' in C. elegans (10,18).  
Two types of transmission must be considered in plants. The first is short-
range, cell-to-cell transmission. Plant cells are intimately connected through 
cytoplasmic bridges known as plasmodesmata. Movement of RNA and proteins 
via these cell–cell junctions is well known, and it is likely that either long dsRNA 
or siRNAs could be passed through these connections. However, the silencing 
signal must also be passed over a longer range through the plant vasculature 
(19). Evidence against siRNAs being critical for systemic silencing in plants has 
been provided from studies of a viral silencing inhibitor. Hc-Pro suppresses 
silencing and also interferes with the production of siRNAs from dsRNA triggers 
(20). Expression of Hc-Pro does not interfere with transgene methylation. This 
methylation could leads to transcriptional gene silencing (TGS) or may 
contribute to post-transcriptional gene silencing (PTGS) depending on the 
location of methylation. Hc-Pro expression in a silenced rootstock relieves 
silencing and inhibits siRNA production, but a systemic signal can still be passed 
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from this rootstock to an engrafted scion lacking Hc-Pro expression. A protein 
has been identified in C. elegans that is required for systemic silencing. This 
transmembrane protein that may act as a channel for import of the silencing 
signal is encoded by sid-1. Expression of sid-1 is largely lacking from neuronal 
cells, explaining initial observations that C. elegans neurons were resistant to 
systemic RNAi (21). SID-1 homologs are absent from Drosophila, consistent 
with a lack of systemic transmission of silencing in flies. These homologs are 
present in mammals, raising the possibility that some aspects of RNAi may act 
non-cell autonomously in mammals. 
Mechanism of dsRNA-induced silencing. Exposure to dsRNAs in C. 
elegans resulted in loss of corresponding messenger RNAs (mRNAs). Promoter 
and intronic sequences were largely ineffective as silencing triggers and this 
observation is consistent with dsRNA-induced silencing operating at the post-
transcriptional level (1). A post-transcriptional model also explains data from 
plant systems in which exposure to dsRNA (22), for example in the form of an 
RNA virus, triggered depletion of mRNA sequences without an apparent effect 
on the rate of transcription (23). Indeed, viral transcripts themselves were 
targeted, despite the fact that these were synthesized in the cytoplasm by 
transcription of RNA genomes (24). These studies support the hypothesis that 
RNAi induces degradation of homologous mRNAs, and this has been validated 
by biochemical analysis. On the other hands, RNAi machinery affects gene 
expression through additional mechanisms (Fig. 1). For example it is clear from 
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studies in plant systems that phenomena related to RNAi [Viral Induced Gene 
Silencing (VIGS) and cosuppression] also produce effects at the transcriptional 
level. Interactions between dsRNA and the genome could serve as the basis for 
such silencing phenomena.  
DNA methylation - Production of dsRNA in plant cells induces methylation 
of homologous DNA sequences. RNA-directed DNA methylation (RdDM) was 
first discovered in plants infected with recombinant viroids (25). It has been 
found that genomic targets with as few as 30 bp of sequence complementary to 
the viroid RNA are methylated during infection (26).  In fact, genomic 
methylation commonly accompanies PTGS. However, if cells are exposed to 
dsRNA that is homologous to the promoter region, rather than the expressed 
region of the gene, methylation is also evident and silencing occurs at the 
transcriptional level. In plants, virus-induced PTGS is not heritable, but TGS is 
heritable and is correlated with the inheritance of methylation (23). 
Methylation of the targeted gene in response to dsRNA did not require MET1 
(the major maintainance methylase of Arabidopsis); however, both heritable 
silencing and maintenance of methylation in progeny required an intact MET1 
gene (23). These findings suggest a model in which dsRNA initiates PTGS, and 
independently, methylation of the genome in a MET1-independent manner. 
Heritable silencing occurs when methylases, such as MET1, maintain the 
methylated state following DNA replication through preferential recognition and 
modification of hemi-methylated DNA. 
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Fig. 1. A schematic representation of RNAi-related gene silencing 
mechanisms.  dsRNAs are recognized and processed by Dicer. The douplex siRNAs 
are passed to RISK which upon activation can regulate gene expression at different 
levels. Modified from (27).  
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Chromatin modification - Recent studies have suggested that the RNAi 
machinery may also affect gene expression at the level of chromatin structure in 
Drosophila, C. elegans and fungi (10,18,28,29). Connection between the RNAi 
machinery and the genome, and mechanistic links between PTGS and TGS has 
been investigated in many systems. For example, in C. elegans, mut-7 and rde-
2 mutations de-repress transgenes that are silenced at the level of transcription 
by a polycomb-dependent mechanism (28). Polycomb-group proteins function by 
organizing chromatin into 'open' or 'closed' conformations, creating stable and 
heritable patterns of gene expression. Recently, it has been found that the 
polycomb proteins MES-3, MES-4 and MES-6 are required for RNAi (29).  
Mutant worms were deficient in the RNAi response if high levels of dsRNA were 
injected, but were not deficient in the presence of limiting dsRNA. The effects of 
these mutants could be indirect, altering the expression of other elements or 
regulators of the RNAi pathway. However, links between altered chromatin 
structures and dsRNA-induced gene silencing have also emerged from plant 
and Drosophila systems. In particular, alterations of either methyltransferases 
(MET1) or chromatin remodelling complexes (for example, DDM1) can affect 
both the degree and persistence of silencing in Arabidopsis (23,30). Conversely, 
mutations in genes required for PTGS (for example, AGO1 and SGS2) decrease 
both co-suppression and transgene methylation (13). Furthermore, mutation of 
piwi, a relative of the RISC component Argonaute-2, compromises co-
suppression of dispersed transgenes in Drosophila at both the post-
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transcriptional and transcriptional levels (18). One model suggests that a variant, 
nuclear RISC carries a chromatin remodelling complex rather than a 
ribonuclease to its cognate target. RNAi machinery may have to form 
heterochromatic domains in the nucleus that are critical for genome organization 
and stability (31). 
Translation inhibition - In C. elegans, endogenously encoded inducers of 
the RNAi machinery (for example, lin-4) operate at the level of protein synthesis 
(32). Although translational control by dsRNA has not been established 
definitively in other systems, the conservation of let-7 and related RNAs (33) 
suggests that this regulatory mode may be a further common mechanism 
through which RNAi pathways control the expression of cellular genes. 
Post-transcriptional gene silencing   It has been shown that injection of dsRNA 
into Drosophila embryos induced sequence-specific silencing at the post-
transcriptional level (34). The possibility that Drosophila embryo extracts, 
previously used to study translational regulation, might be competent for RNAi 
has been tested (35). Incubation of dsRNA in these cell-free lysates reduced 
their ability to synthesize exogenous luciferase from a synthetic mRNA. This 
suggests that dsRNA might bring about silencing by triggering the assembly of a 
nuclease complex that targets homologous RNAs for degradation. These 
findings support a link between transgene co-suppression in plants and RNAi in 
animals. A model for RNAi and related silencing phenomenon began to emerge 
(Fig. 2). According to this model, initiation of silencing occurs upon recognition of 
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dsRNA by machinery that converts the silencing trigger to ~21–25 nucleotide 
RNAs. These small interfering RNAs (siRNAs) are a signature of this family of 
silencing pathways and, by joining an effector complex RISC; they guide that 
complex to homologous substrates. 
In the initiation step, the dsRNA silencing trigger is cleaved to produce 
siRNAs (Fig. 2). Support for this step emerged first from studies of Drosophila 
embryo extracts, which contained an activity capable of processing long dsRNA 
substrates into ~22-nucleotide fragments (36). These RNAs were shown to be 
double-stranded and contained 5'-phosphorylated termini (36,37). The enzyme 
that initiates RNAi is a member of RNase III ribonuclease family, which displays 
specificity for dsRNAs and generates such termini. RNase III enzymes can be 
divided into three classes based upon domain structure: bacterial RNase III 
contains a single catalytic domain and a dsRNA-binding domain; Drosha family 
nucleases contain dual catalytic domains (38); and a third family also contains 
dual catalytic domains and additional helicase and PAZ motifs (39). Members of 
the third class of RNases were found to process dsRNA into siRNAs and were 
therefore proposed to initiate RNAi (39). This family, now named the Dicer 
enzymes, are evolutionarily conserved, and proteins from Drosophila, 
Arabidopsis, the insect Spodoptera frugiperda, tobacco, C. elegans,  
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Fig. 2. Initiation and effector complexes in post-transcriptional gene 
silencing. RNAi is initiated by the dimeric enzyme Dicer which cleaves long dsRNA into 
siRNAs. Activation of RISC produce smaller complex with the antisense strands of 
unwinded siRNA. Modified from (40). 
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mammals and Neurospora have all been shown to recognize and process 
dsRNA into siRNAs of a characteristic size for the relevant species (39,41). 
Recently, the structure of an RNase III catalytic domain has led to a model for 
the generation of ~22-nucleotide RNAs by Dicer cleavage (42). It is thought that 
bacterial RNase III functions as a dimeric enzyme and, in the structural model, 
antiparallel RNase III domains produce two compound catalytic centres, each of 
which is formed by contributions from both monomers. The sequences of Dicer 
and Drosha RNase III domains reveal deviations from the consensus in both 
enzymes. Introduction of these alterations into bacterial RNase III permitted a 
genetic test for domain function: defects were noted upon introduction of 
residues that form part of the catalytic centre from the second RNase III domain 
of Dicer family members. Antiparallel alignment of Dicer's RNase III motifs on a 
dsRNA substrate could produce four compound active sites, but the central two 
of these would be inactive. In this way, cleavage would occur at 22-base 
intervals (42) (Fig. 2). 
 In the effector Step, RNAi is enforced by RISC, a protein–RNA effector 
nuclease complex that recognizes and destroys target mRNAs. The first subunit 
of RISC to be identified was the siRNA, which presumably identifies substrates 
through Watson–Crick base-pairing (43,44). One study showed that RISC is 
formed as a precursor complex of ~250K; which becomes activated by the 
addition of ATP to form a ~100K complex that can cleave substrate mRNAs 
(45). Cleavage occurs only in the region homologous to the siRNA. siRNAs 
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configuration of two-nucleotide 3' overhangs and 5'-phosphate termini (36,37) 
are functionally important for incorporation into RISC complexes (37,45). 
However, single-stranded siRNAs should be most effective at seeking 
homologous targets, and one intriguing correlation with the transition of RISC 
zymogens to active enzymes is siRNA unwinding (45).  Another study showed 
that RISC purified from Drosophila S2 cells was ~500K ribonucleoprotein with 
slightly different characteristics (43,46). RISC* (the 100K active RISC species) 
cleaves its substrates endonucleolytically (45).  
Intermediate cleavage products are never observed in even the most 
highly purified RISC preparations from S2 cells, suggesting the presence of an 
exonuclease in this enzyme complex. RISC from S2 cells co-purifies with AGO2, 
a member of the Argonaute gene family (46). These proteins are characterized 
by the presence of two homology regions, the PAZ domain and the Piwi domain, 
the latter being unique to this group of proteins. The PAZ domain also appears 
in Dicer proteins, and may be important in the assembly of silencing complexes 
(39). Argonaute proteins were linked to RNAi by genetic studies in C. elegans, 
whose genome contains >20 related genes. The rde-1 gene was isolated from a 
mutant worm that was unable to sustain RNAi in germline or soma (28). Genetic 
studies showed a requirement for RDE-1 and RDE-4(small dsRNA binding 
protein) for initiation of silencing in a parental animal (47); however, neither 
function was required for systemic silencing in F1 progeny. It is believed that 
RDE-4 initially recognizes dsRNA and delivers it to the Dicer enzyme. This 
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would be consistent with the observation that siRNA levels are greatly reduced 
in worms that lack RDE-4 function, but are abundant in worms that lack RDE-1 
(48). In Neurospora, mutations in the Argonaute family member qde-2 eliminate 
quelling (transgene co-suppression), but do not alter accumulation of siRNAs 
(49). Thus RDE-1 and perhaps other Argonaute proteins might shuttle siRNAs to 
appropriate effector complexes (RISCs).  
Biological role of RNAi. Since the discovery of this evolutionarily 
conserved phenomenon, there has been a major question about the biological 
function(s) of RNAi. Three distinct roles for this process have emerged. First, 
RNAi clearly acts as an antiviral defense. Second, genetic studies have 
considered RNAi as a geno-protective mechanism. Third, recent findings have 
demonstrated a role for components of the RNAi machinery in the regulation of 
cellular gene expression and developmental timing. 
Antiviral response - In mammals, there exist well-characterized responses 
to dsRNA that act as an antiviral defense. Therefore, one obvious role for the 
RNAi/PTGS machinery was as a functional homolog of such systems. Indeed 
definitive evidence for the use of RNAi as a viral defense comes from genetic 
studies in plants. Arabidopsis mutants that lose the ability to mount a PTGS 
response are hyper-susceptible to virus infection (50). Just as plants have 
evolved a defense against viral invasions, viruses have evolved a counterattack. 
For example, proteins such as cucumber mosaic virus 2b and p25 of potato 
virus X inhibit the spread of silencing within the plant (51). As expected if PTGS 
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is considered as a primary defense mechanism against such viruses, these 
inhibitors are essential determinants of virulence. Numerous mammalian viruses 
have evolved the ability to block PKR as an aid to efficient infection. For 
example, adenoviruses express viral RNAs, which mimic dsRNA with respect to 
binding but not to activation of PKR (52). Vaccinia virus uses two strategies to 
evade PKR. First is expression of E3L, which binds and masks dsRNAs (53). 
The second is expression of K3L, which binds and inhibits PKR via its ability to 
mimic the natural substrate of this enzyme, eIF2α (53). 
Genome defense - In all complex genomes, a significant fraction of 
sequence is formed by endogenous repetitive elements, including numerous 
copies of defective and intact transposons. Suppression of these elements 
contributes to genetic stability in two ways. First, intact transposons are potential 
mutagens. Second, both defective and intact transposons provide potential sites 
for nonhomologous crossovers that could occur during DNA repair. Genomic 
stability requires that they be packaged into heterochromatin (31). In C. elegans, 
some RNAi-deficient strains are “mutators” owing to increased mobility of 
endogenous transposons (28,54). In many systems, transposons are silenced by 
their packaging into heterochromatin (31). Therefore, RNAi may stabilize the 
genome by sequestering repetitive sequences such as mobile genetic elements, 
preventing transposition and making repetitive elements unavailable for 
recombination events that lead to chromosomal translocations. However, it 
remains to be determined whether RNAi regulates transposons through effects 
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at the genomic level or by post-transcriptionally targeting mRNAs (for example, 
those encoding transposases) that are required for transposition. 
Regulation of endogenous genes and developmental timing - a role for 
RNAi pathways in the normal regulation of endogenous protein-coding genes 
was originally suggested through the analysis of plants and animals containing 
dysfunctional RNAi components. Mutations in the Argonaute-1 gene of 
Arabidopsis, for example, cause pleiotropic developmental abnormalities that 
are consistent with alterations in stem-cell fate determination (55). A 
hypomorphic mutation in Carpel Factory, an Arabidopsis Dicer homologue, 
causes defects in leaf development and overproliferation of floral meristems 
(56). Mutations in Argonaute family members in Drosophila also impact normal 
development. In particular, mutations in Argonaute-1 have drastic effects on 
neuronal development (57), and piwi mutants have defects in both germline 
stem-cell proliferation and maintenance (58). This should not be interpreted as a 
demonstration that PTGS pathways regulate endogenous gene expression per 
se. In fact, separation-of-function ago1 mutants have recently been isolated that 
preferentially affect PTGS without affecting development. Mutations in Zwille, 
another Argonaute family member, also alter stem-cell maintenance (59), and 
this occurs without perceptible impact on dsRNA-mediated silencing. Thus, 
components of the RNAi machinery, and related gene products, may function in 
related but separable pathways of gene regulation. A possible mechanism 
underlying the regulation of endogenous genes by the RNAi machinery emerged 
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from the study of C. elegans containing mutations in their single Dicer gene, 
DCR-1. Unlike most other RNAi-deficient worm mutants, dcr-1 animals were 
neither normal nor fertile: the mutation induced a number of phenotypic 
alterations in addition to its effect on RNAi (41,60-62).  
Dicer mutants showed alterations in developmental timing similar to those 
observed in let-7 and lin-4 mutants. The lin-4 gene was originally identified as a 
mutant that affects larval transitions (63), and let-7 was subsequently isolated as 
a similar heterochronic mutant (33). These loci encode small RNAs, which are 
synthesized as ~70-nucleotide precursors and post-transcriptionally processed 
to a ~21-nucleotide mature form. Genetic and biochemical studies have 
indicated that these RNAs are processed by Dicer (41,60-62).  
The small temporal RNAs (stRNAs) encoded by let-7 and lin-4 are negative 
regulators of specific protein-coding genes, as might be expected if stRNAs 
trigger RNAi. However, stRNAs do not trigger mRNA degradation, but regulate 
expression at the translational level (64,65). This raised the possibility that 
stRNAs and RNAi might be linked only by the processing enzyme Dicer. A 
model in which the effector complexes containing siRNAs and stRNAs are 
closely related, but regulate expression by distinct mechanisms is illustrated in 
Figure 3. Neither LIN-4 nor LET-7 forms a perfect duplex with their cognate 
target (66). Thus, in one possible model an analogous RISC complex is formed 
containing either siRNAs or stRNAs. In the former case, cleavage is dependent 
upon perfect complementarity, while in the latter, cleavage does not occur, but 
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the complex blocks ribosomal elongation. Alternatively, siRNAs and stRNAs may 
be discriminated and enter related but distinct complexes that target substrates 
for degradation or translational regulation, respectively. Consistent with this 
latter model is the observation that siRNAs or exogenously supplied hairpin 
RNAs that contain single mismatches with their substrates fail to repress, rather 
than simply shifting their regulatory model to translational inhibition (37,67,68). 
 RISC may be viewed as a flexible platform upon which different regulatory 
modules may be superimposed. The core complex would be responsible for 
receiving the small RNA from Dicer and using this as a guide to identify its 
homologous substrate. Depending upon the signal (for example, its structure 
and localization), different effector functions could join the core: in RNAi, 
nucleases would be incorporated into RISC, whereas in stRNA-mediated 
regulation, translational repressors would join the complex. Transcriptional 
silencing could be accomplished by the inclusion of chromatin remodelling 
factors. 
Recent findings show that let-7 and lin-4 are archetypes of a large class 
of endogenously encoded small RNAs (Table I). Over 100 of these microRNAs 
or miRNAs have now been identified in Drosophila, C. elegans and mammals, 
although most of their functions are unknown, their prevalence hints that RNAi-
related mechanisms may have pervasive roles in controlling gene expression 
(69-72). 
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Fig. 3. Small interfering RNA versus micro RNA gene silencing 
mechanisms.  siRNAs but not microRNAs have perfect complementarity to their target 
mRNA which cause different mechanism of gene silencing. Modified from (68). 
 
 
AAA AAA 
Dicer
AAA 
RISC
mRNA Degradation         Translation inhibition          
dsRNA  Hairpin precursor        
 21
 
 
Table I 
Types and functions of microRNAs. Modified from (73). 
Process Example Function 
Transcription 184-nt E. coli 6S Modulates promoter use 
 331-nt human 7SK Inhibits transcription elongation factor P-TEFb 
 875-nt human SRA Steroid receptor coactivator 
Gene silencing 16,500-nt human Xist Required for X-chromosome inactivation 
 ~100,000-nt human Air Required for autosomal gene imprinting 
Replication 451-nt human 
telomerase RNA 
Core of telomerase and telomere template 
RNA 
processing 
377-nt E. coli RNase P Catalytic core of RNase P 
 186-nt human U2 
snRNA 
Core of spliceosome 
RNA 
modification 
102-nt S. cerevisiae 
U18 C/D snoRNA 
Directs 2'-O-ribose methylation of target rRNA 
 189-nt S. cerevisiae 
snR8 H/ACA snoRNA 
Directs pseudouridylation of target rRNA 
 68-nt T. brucei gCYb 
gRNA 
Directs the insertion and excision of uridines 
RNA stability 80-nt E. coli RyhB 
sRNA 
Targets mRNAs for degradation? 
 Eukaryotic miRNA? Targets mRNAs for degradation? 
mRNA 
translation 
109-nt E. coli OxyS Represses translation by occluding ribosome 
binding 
 87-nt E. coli DsrA 
sRNA 
Activates translation by preventing formation of 
an inhibitory mRNA structure 
 22-nt C. elegans lin-4 
miRNA 
22-nt  C. elegans let-7 
miRNA 
Represses translation by pairing with 3' end of 
target mRNA 
Protein 
stability 
363-nt E. coli tmRNA Directs addition of tag to peptides on stalled 
ribosomes 
Protein 
translocation 
114-nt E. coli 4.5S RNA Integral component of signal recognition 
particle central to protein translocation across 
membranes 
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Heritable nature of RNAi. The classification of RNAi/PTGS as an 
epigenetic phenomenon rests largely upon its ability to provoke heritable 
changes in gene expression. Inheritance of silencing could be derived from 
either of two sources. The first is the persistence of the signal. The second is 
persistence of the silenced state. The former case refers to instances such as 
stable incorporation of transgene arrays into the genome, the presence of 
endogenous repetitive elements such as transposons, or the enforced 
expression of hairpin RNAs. Such cases require no additional mechanisms to 
explain heritable silencing because the trigger is expressed from an endogenous 
and heritable genetic element. The latter case is more provocative and requires 
consideration of mechanisms that propagate either the signal or the silenced 
state independently of the silencing trigger. 
The classical example of silencing that is inherited after a transient 
introduction of the silencing trigger comes from observation with C. elegans. 
Worms that have been injected with dsRNA can impart the silenced state to the 
next generation, and this has been demonstrated for numerous genes (1). 
Experiments targeting genes that are expressed in the maternal germline 
demonstrated interference in the F2 generation; however this effect waned in 
later generations (74). So far, no genetic mutants have emerged that specifically 
affect the heritability of silencing without affecting the interference process itself. 
Small interfering RNA as a tool for the analysis of genes function. 
Although RNAi has been used in diverse systems, harnessing RNA to study 
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gene function in mammals seemed potentially problematic. Indeed, mammals 
have evolved robust systems for responding to dsRNAs, specifically as an 
antiviral defense (75,76). In somatic cells, dsRNA activates a variety of 
responses. Predominant among these is PKR, a kinase that is activated by 
dimerization in the presence of dsRNA (52). PKR, in turn, phosphorylates EIF2α, 
causing a nonspecific translational shutdown (75).  Double stranded RNA also 
activates 2'-5' oligoadenylate polymerase, the product of which is an essential 
cofactor for a nonspecific ribonuclease, RNase L that non-specifically degrade 
all mRNA (77). In some situations, several-hundred-base-pair long dsRNA 
represents an alternative to siRNAs. Long dsRNA effectively silences genes 
expressed in insect cells (43,78-81) and in embryonic mammalian cells that have 
not yet established the interferon system (82-85). In somatic mammalian cells, 
the application of long dsRNA is prohibited, because these cells trigger a 
sequence-nonspecific innate immune response (interferon-mediated defense) 
when exposed to dsRNA greater than thirty base pairs (86). The use of siRNAs 
of 21-23 nucleotides bypass the interferon response and produce extraordinary 
effect in gene silencing in mammalian cells (37). 
Characteristics of functional siRNA. siRNA duplexes produced by the 
action of Dicer contain 5'-phosphates and free 3'-hydroxyl groups. The central 
base-paired region is flanked by two-to-three nucleotides of single-stranded 3'-
overhangs (37). The 5' -phosphate termini of siRNAs is essential for guiding 
mRNA degradation (45). Nevertheless, for their practical application in gene 
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targeting experiments, siRNAs may be used without 5'-phosphate termini 
because a kinase activity in the cell rapidly phosphorylates the 5' ends of 
synthetic siRNA duplexes (37,45,87). Under certain circumstances (e.g., 
injection experiments in D. melanogaster), 5'-phosphorylated siRNA duplexes 
may have slightly enhanced properties as compared to 5'-hydroxyl siRNAs (87). 
In gene targeting experiments using human HeLa cells, no differences in siRNA-
mediated "knockdown" of gene expression were observed, as a function of 5'-
phosphorylation (88). The sequencing of the human genome has greatly 
stimulated research on gene function for validating new targets for drug 
discovery and development of therapeutic strategies for many common 
disorders including infectious, cardiovascular, neurological diseases and cancer. 
siRNAs are excellent tools for target validation in biomedical research , because 
of their exquisite specificity, efficiency and endurance of gene-specific silencing. 
siRNAs are probably also suitable for the design of novel gene-specific 
therapeutics by directly targeting mRNAs of disease-related genes. 
Small interfering RNAs have brought reverse genetics to mammalian 
cultured cells, and have made large-scale functional genomic analysis a 
possibility (89). For example targeting of  essential and non-essential genes 
resulted in cellular phenotypes that were identical to phenotypes previously 
observed in cells derived from transgenic knockout mice (89), illustrating the 
value of siRNA methodology for the analysis of mammalian gene function. 
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Until recently, the application of siRNAs in somatic cells was restricted to the 
delivery of chemically or enzymatically synthesized siRNAs (37,84,90), however, 
methods for intracellular expression of small RNA molecules have now been 
developed. The use of RNA polymerase III (Pol III) promoters to direct in vivo 
synthesis of functional siRNAs has been reported (84,91-97). There are several 
reasons for using Pol III. Unlike RNA Pol II, Pol III normally transcribes small, 
noncoding transcripts that are not capped or polyadenylated at the 5' and 3' 
ends, respectively. Pol III initiates transcription at defined nucleotides, and 
terminates transcription when it encounters a stretch of four or five thymidines 
(98). Consequently, it is possible to design small RNAs synthesized by Pol III 
that carry 3' overhangs of one to four uridines, a structural feature resembling 
that defined for siRNAs to be effective in vitro (37).  
Two approaches using Pol III promoters have yielded robust gene-
specific inhibition (Fig. 4). In the first case, the design is modeled after the 
naturally occurring microRNAs (miRNA) that are ~22-nt hairpins and can 
modulate gene expression in vivo (99). Pol III promoter, U6 or H1, is used to 
direct transcription of small inverted repeats separated by a spacer region of 
varying lengths. The U6 or the H1 promoter initiates transcription at guanine or 
adenine, respectively. The resulting RNAs are predicted to form hairpins 
containing 19- to 29-nts stems that match target sequences precisely, three- to 
nine-nt loops and 3' overhangs of four or fewer uridines). It is believed that these 
hairpin RNAs are processed by Dicer into active siRNAs in vivo (84). In the 
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second case, two U6 promoters are placed in tandem(94,96) or on two separate 
vectors (93)to direct transcription of a sense and an antisense strand of a small 
RNA with 19 nt matching the target gene sequence precisely and four or fewer 
Us as 3' overhangs. The sense and antisense strands are believed to form a 
duplex in vivo similar to the chemically synthesized siRNAs described by 
Elbashir and coworkers (67). However, the hairpin siRNA strategy appears to 
inhibit gene expression more efficiently than the duplex siRNAs expressed from 
two separate plasmids (93). Another way of generating small RNAs that can 
function as siRNAs from DNA templates is through the generation of modified 
miRNAs. Naturally occurring miRNAs are noncoding RNAs that have been 
identified in a range of organisms from C. elegans to humans (98). The best 
characterized miRNAs (also known as stRNAs for small temporal RNAs) are C. 
elegans lin-4 and let-7, both of which are crucial in the control of developmental 
timing (63,100). Artificial miRNAs whose sequences are completely 
complementary to the target RNAs have been shown to function as siRNAs that 
inhibit gene expression by reducing RNA transcript levels (97,101). 
Unlike the small hairpin RNAs directed by U6 or H1 promoters, the 
siRNA-acting miRNAs are generated from ~70-nt miRNA precursors. The 
artificial miRNA precursor contains a substitution of the stem sequence with a 
sequence entirely complementary to the intended target gene, enabling the 
resulting miRNA to function as a siRNA to induce target RNA degradation (101). 
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Fig. 4. Approaches for in vivo synthesis of functional siRNA. [A] Generation 
of hairpin siRNA from inverted repeat. [B] Generation of siRNA from two complementary 
strands. Modified from (68). 
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An important advantage of the DNA vector-based RNA approach is that it can be 
used to express siRNAs stably in cells and thus provide long-term gene 
inhibition. This principle was demonstrated recently by Brummelkamp and 
coworkers (92) who reported sustained inhibition of p53 by stably integrated 
siRNA-expressing DNA templates. Another advantage of the DNA vector system 
is that it can be useful for inducible knockdown of gene expression. One study 
has shown that doxycycline-regulated form of the H1 promoter of RNA 
polymerase III allows the inducible knockdown of gene expression by siRNA. β-
Catenin in colorectal cancer was used as target in this study as  a proof-of-
principle (102). The resistance of important cell types to transfection using the 
previous approaches, both in vivo and in vitro, has limited the use of siRNA 
(103).  Recently, several viral vectors have been developed for efficient delivery 
of siRNA into mammalian cells (104,105). Retroviral vectors were designed to 
produce siRNA driven by either U6 or H1-RNA promoter for efficient, uniform 
delivery and immediate selection of stable knock-down cells (104,106). 
Adenovirus vectors using RNA polymerase II CMV promoter (105) and the well 
defined pol III promoter (91) were also developed and shown to mediate gene 
silencing both in vitro and in vivo.  Recently, a lentiviral system has been used 
for delivery of siRNA into cycling and non-cycling mammalian cells, stem cells, 
zygotes and their differentiated progeny (107).  Lentiviruses have two key 
advantages over other gene delivery system. Firstly, they can infect non-cycling 
and post-miotic cells (108,109). Secondly, transgenes expressed from 
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lentiviruses are not silenced during development and can be used to generate 
transgenic animals through infection of embryonic stem cells or embryos 
(110,111). 
Small interfering RNAs as therapeutic agents. siRNAs are highly 
sequence-specific reagents and discriminate between single mismatched 
targeted RNA sequences (67,92), and may represent a new avenue for gene 
therapy for several diseases.  
Infectious disease - Viral inhibitors of the mammalian RNAi machinery 
have not yet been described and it is feasible that the application of siRNAs 
could extend our understanding of viral protein function and viral life cycle and 
could be used as antiviral therapy. One study reported suppression of HIV-1 
infection and replication in permanent cell lines and primary activated CD4 T 
cells by siRNA specific for different regions of HIV-1(112). Cells harboring 
proviral HIV, such as reservoir or acutely infected cells that have progressed 
past proviral integration, can also be targeted by RNAi-mediated inhibition of 
viral replication by targeting viral RNA transcripts produced from the provirus 
(112). Other studies have reported efficient inhibition of hepatitis C (113) and B 
(114) viruss replication as well as protein synthesis by using both synthetic and 
vector derived siRNAs.  Although viral replication was inhibited and mRNAs 
transcribed from the viral genome were effectively silenced, it was not possible to 
cleave the viral genomic or antigenomic RNA because of its chromatin-like 
condensed structure. Recently one study reported effective siRNA-mediated 
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degradation of HIV-1 rev transcripts in a cell assay by co-transfection of proviral 
DNA and siRNA expression vectors, thus raising the possibility that siRNAs can 
be developed for treating HIV infection (94).  
Genetic disorders and neoplastic disease - The expression of mRNAs 
coding for mutated proteins, which give rise to dominant genetic disorders and 
neoplastic growth, might be decreased or blocked completely by specific siRNAs 
(Table II). In leukemias and lymphomas (the most frequent cancers in 
childhood), oncogene activation frequently occurs through reciprocal 
chromosomal translocations. These translocations lead to juxtaposition of gene 
segments normally found on different chromosomes, and the creation of a 
composite gene (115). Translocation of the BCR gene from chromosome 22 and 
ABL gene from chromosome 9 creates an oncogenic BCR-ABL hybrid gene 
(116). The BCR-ABL fusion protein has dramatically increased tyrosine kinase 
activity compared to that of the normal ABL protein, leading to aberrant 
phosphorylation of several downstream molecules. RNAi was used to target the 
BCR-ABL mRNA, and this approach was effective in reducing the expression of 
BCR-ABL mRNA, followed by a reduction of BCR-ABL oncoprotein, leading to 
apoptosis in leukemic cells (117). Silencing of these tumor-specific, chimeric 
mRNAs by siRNAs might become an effective fusion gene-specific tumor 
therapy. The extraordinary sequence specificity of the RNAi mechanism may 
also allow for the targeting of individual polymorphic alleles expressed  
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Table II 
Suggested targets in human malignancy for siRNA-mediated therapy.  
Genes or Fusion Genes Aberration Tumors 
RAS Point mutations Pancreatic 
carcinoma, chronic 
leukemia, colon 
carcinoma, lung 
cancers 
c-MYC, N-MYC Overexpression, 
translocation, point 
mutation, amplification 
Burkitt’s lymphoma, 
neuroblastoma 
ERBB1 Overexpression Breast cancer 
ERBB2 Overexpression Breast cancer 
MLL fusion genes Translocation Acute leukemias 
BCR-ABL Translocation Acute and chronic 
leukemia 
TEL-AML1 Translocation Acute and chronic 
leukemia 
EWS-FLI1 Translocation Childhood acute 
leukemia 
TLS-FUS Translocation Ewing sarcoma 
PAX3-FKHR Translocation Myxoid liposarcoma 
BCL-2 Overexpression, 
translocation 
Alvelolar 
rhabodomyosarcoma 
AML1-ETO Overexpression, 
translocation 
Lung cancers, Non-
Hodgkin lymphoma, 
prostate cancer 
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in loss-of-heterozygosity tumor cells, as well as targeting point-mutated 
transcripts of transforming oncogenes such as Ras and tumor suppressor genes 
such as P53. P53 which is called the guardian of the genomes inactivated by 
point mutation in 50% of human cancers. One study has demonstrated that a 
single base difference in siRNAs discriminates between wild type and mutant 
P53 in cells expressing both forms, resulting in restoration of wild type protein 
function (118). RNAi also can be useful in decreasing overexpressed apoptosis 
inhibitors such as Bcl-2 and c-Myc which may be beneficial in cancer therapy. 
siRNA-mediated therapy can be used to silence many gene targets that 
contribute to human malignancy (Table 2).  
Neurological disease - Another potential application of siRNA is in the 
treatment of neurodegenerative disorders, siRNAs were recently directed against 
a mutated mRNA associated with the spinobulbular muscular atrophy in tissue 
culture (119). Spinobulbular muscular atrophy, together with Huntington Disease, 
belongs to a growing group of neurodegenerative disorders caused by the 
expansion of trinucleotide repeats (120). Targeting the CAG-expanded mRNA 
transcript with dsRNA may be an alternative to commonly used therapeutic 
strategies (119). 
Use of siRNA as a tool is advancing in almost every field of biomedical 
research as mentioned before, but some of the most dynamic and exciting 
applications of siRNA are in cancer research in particular functional validation of 
tumorigenic genes in cell culture and animal tumor models. Research in this 
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laboratory has focused on different types of cancers including hormone-
dependent cancers such as breast, endometrial and prostate cancers as well as 
hormone-independents cancers such as pancreatic and colon cancers. siRNAs 
will be used in this research to knock down selected genes in mammalian 
cancer cells as an approach for determining their role in cancer cells growth and 
progression. In addition, this approach will be used to understand the 
mechanism of action for some of the compounds that are being synthesized in 
this laboratory such as PPARγ agonists. 
 
WHAT IS CANCER? 
Cancer is the second leading cause of death in the United State and one 
half of all men and one- third of all women in the United States will develop 
cancer during their lifetime (121). The term cancer describes a subset of lesions 
of a disease termed neoplasia. Neoplasia literally means “new matter” and refers 
to any abnormal growth of cells. Neoplasms can be classified as benign or 
malignant. Benign tumors do not metastasize to other tissues and they usually 
grow very slowly, their cells are often well differentiated and tend to stay 
together because they are surrounded by a capsule of dense tissue. Benign 
tumors are usually not life threatening unless they disrupt the function of a vital 
organ. Unlike benign tumors, malignant tumors or cancers have undifferentiated, 
rapid growing cells that are not encapsulated and tend to metastasized to other 
regions of the body through blood and lymphatic vessels. For example cells from 
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malignant breast cancer usually form new (secondary) tumors in bone, brain, 
and lung tissues (122). Benign tumors that arise from epithelial tissues include 
papilomas, adenomas, and nevus while those that arise from connective tissues 
include lipomas, osteomas and chondromas. Malignant tumors from epithelial 
cells are generally called carcinomas while those that arise from connective 
tissues are called sarcomas (122). There are three types of changes that occur 
when a cell becomes tumorigenic. First, immortalization, where the cells have 
the property of indefinite growth without any other changes in the phenotype. 
Second, transformation, which describes the failure to observe the normal 
constrains of growth, where the transformed cells become independent of 
factors usually needed for cell growth. Finally, metastasis, where cancer cells 
gain the ability to invade normal tissues and form new colony elsewhere in the 
body away from the tissue of origin (123) (Fig.5). 
The etiology of various forms of cancer is not well defined; it is known that 
cancer involves hyperplasia (too many cells) and/or anaplasia (abnormal, 
undifferentiated cells) but it is unclear what causes  these phenotypes. There are 
several factors  known to play a role in cancer development. These include 
genetic factors (123), exposure to carcinogens (123), physical agents such as 
ionizing radiation (124) and ultra violet light (125). In addition, infection with 
oncogenic viruses (such as human immunodeficiency and hepatitis C viruses) is 
associated with a number of human cancers (126). Lifestyle plays a major role 
for increasing risk of cancer. For example tobacco smoke is the principle cause  
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Fig. 5. Sequential changes that distinguish a cancer cell from a normal cell. 
Modified from (123). 
 
 
 
 
 
 
Primary cells 
Crisis Immortalization
Majority of cells die,
a few cells grow out
Cells divide indefinitely,
require serum, and are 
Inhibited by contact.  
Transformation
Cells are independent of  
anchorage, serum, and  
contact inhibition. Cells  
Change shape, round up,  
and grow into a focus 
Metastasis
Tumor cells become  
mobile and can migrate to 
start new colonies    
 36
of lung cancer (127). On the other hand, consumption of certain phytochemicals 
found in a complex human diet, such as carotenoids (green, yellow-red, and 
yellow-orange vegetables), phytoestrogens (soy and some soy products), 
organosulfides (garlic), phenolic acids (green tea, citrus) has exhibit anti-
mutagenic and anti-carcinogenic effects (128). 
 
BREAST CANCER 
Breast cancer is an endocrine-responsive tumor that accounts for one in 
four of all female cancers, making it by far the most common cancer in women in 
the Western world. One in eight or nine women in the United Kingdom will 
develop breast cancer at some time in their lives (129). About 211,300 women in 
the United States will have invasive breast cancer in 2003 and about 39,800 
women will die from the disease (121). 
The breasts lie over the pectoral muscles and are attached to them by a 
layer of connective tissue, each breast consist of several lobes separated by 
septa of connective tissue. Each lobe consists of several lobules which are 
composed of connective tissues in which are embedded the secreting cells 
(aloveoli) of the gland, arranged in grapelike clusters around the minute ducts. 
Ducts from various lobules unite form a single luciferous duct for each lobe. 
These main ducts converge toward the nipple (Fig. 6). There is large amount of 
adipose tissue deposited around the surface of the glands; the breast size is 
determined by amount of this fat around the glandular tissue. There is an 
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extensive network of lymphatic vessels and nodes that receive lymph from the 
breast. The breast is drained by two sets of lymphatic vessel, one originate in 
and drain the skin over the breast with the exception of areola and nipple and 
the other drains the substance of the breast itself, as well as the skin of the 
areola and nipple (122). Knowledge of the lymphatic drainage of the breast is 
important in clinical medicine because cancerous cells from malignant breast 
tumors often spread to other areas of the body through the lymphatics. 
Normal breast development and breast cancer. Mammary 
development begins during embryogenesis; in humans, males and females have 
a similar rudimentary mammary gland at birth. Subsequent mammary 
development is initiated with the onset of female puberty and is dependent on 
the high levels of estrogen. The most abundant circulating form of estrogen is 
17β-estradiol (E2) which primarily produced along with progesterone in the 
ovary (Fig. 7). After puberty, the mammary gland undergoes cycles of growth 
and involution, which are regulated with the menstrual cycle, and with cycles of 
pregnancy and lactation. Post-pubertal development results in cyclical increases 
in ductal branching, resulting in a ductal tree that fills the mammary fat pad. 
During pregnancy, further branching and end-bud development lead to an 
appearance that is like bunches of grapes. After weaning, mammary-gland 
regression to a near pre-pregnancy state occurs through massive programmed 
cell death or apoptosis (130,131). 
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Fig. 6. Anatomy of female breast. Adapted from (122). 
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Fig. 7. Chemical structures of progesterone and estrogen. 
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Shedding of placenta after delivery of the baby cuts off a major source of 
estrogen. The resulting rapid drop in the blood concentration of estrogen 
stimulates anterior pituitary secretion of prolactin which stimulates alveoli of the 
mammary glands to secrete milk. Also, the sucking movement of a nursing baby 
stimulates anterior pituitary secretion of prolactin and posterior pituitary secretion 
of oxytocin which stimulates alveoli of the braest to eject milk into the ducts 
which is accessible to the infant by sucking (122). Epithelial cells seem to be the 
main site of estrogen action in the breast. Immunohistochemical analysis reveals 
that the epithelial cells contain the receptor that mediates the action of estrogen 
(132). Histologically, it is the luminal epithelial cells that are responsible for most 
breast tumors, and this is also supported by biochemical comparisons (133). 
Risk factors for breast cancer. The cause of breast cancer remains 
unknown in the majority of patients despite identification of numerous risk factors 
in epidemiological studies. A family history of breast cancer is one of the 
strongest risk factors, especially in families with multiple first-degree relatives. 
About 5%-10% of breast cancer cases are due to inheritance of highly penetrant 
mutations in breast cancer susceptibility genes. These include BRCA-1 and 
BRCA-2 genes, p53 gene mutations in Li-Fraumeni syndrome, PTEN mutations 
in Cawden’s disease, and the AT gene in ataxia teleangiectasia (134). BRAC1 is 
one of the most common breast cancer susceptibility genes which was first 
identified in 1994 as an autosomal dominant mutation for breast cancer and it 
was later shown to increase risk for ovarian cancer (135,136).  Women that 
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carry the mutation in BRCA1 have a 60-80% lifetime risk for developing breast 
cancer and a 20-40% lifetime risk of developing ovarian cancer (137-139).  
BRCA1 is believed to be a tumor suppressor gene which functions to regulate 
transcription, cell cycle control, and DNA repair. BRCA1 can interact with RNA 
polymerase II, as well as to enhance p53 transactivation (133,140). Like BRCA1, 
mutations in the BRCA2 gene increase lifetime risk of breast and ovarian cancer 
in carriers of this mutation (141,142). Unlike BRCA1 gene, the function of 
BRCA2 is not well defined, but may be involved in some of the same processes 
as BRCA1 (143).   
There is considerable evidence that associates increased breast cancer 
risk with lifetime exposure to estrogens. Risk for breast cancer in women is 
associated with early menarche, late first full-term pregnancy and late 
menopause. Oral contraceptives and estrogen-replacement therapy have also 
increase the risk for breast cancer. In addition, dietary and environmental agents 
that can act as estrogens have been linked to breast cancer risk (144,145). 
Moderate alcohol consumption (146) and smoking in women with genetic 
defects in aromatic amine metabolism modestly increase breast cancer risk 
(147). Women with a history of prior invasive breast cancer or a history of 
noninvasive breast lesions such as atypical hyperplasia and lobular carcinoma in 
situ (LCIS), carry an increased risk for developing invasive breast cancer (148). 
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Breast cancer treatment. There are many different classes of drugs that 
have been approved for the treatment of breast cancer both in the presence or 
absence of surgery and radiotherapy.  
 Chemotherapeutic drugs - This type of therapy is based on the fact that 
cancer cells are rapidly dividing cells, and these drugs interfere or inhibit cancer 
cell proliferation. There are three major classes of chemotherapeutic drugs for 
treating different types of cancer including breast cancer and these include 
anthracyclins such as doxorubicin and epirubicin, taxanes such as paclitaxil and 
docetaxil and alkylating agents such as cyclophosphamide (149). The 
disadvantage of using such drugs is the lack of specificity, since these also kill 
normal cells in our bodies that have rapid dividing nature such as blood cells and 
epithelial cells of intestine and skin. 
Endocrine therapy - Two-thirds of breast cancers are ER-positive and 
most of these respond to endocrine therapy (150). Several drugs have been 
used to block the effects of estrogen in ER-positive breast cancer (Fig. 8). The 
anti-estrogen tamoxifen was first used in the treatment of metastatic breast 
cancer, and led to disease regression in approximately 30% of these cancers 
(151). In ER-positive breast cancer, tamoxifen is now the principal form of 
adjuvant treatment in pre- and post-menopausal women. In addition, medical 
ovariectomy with luteinizing-hormone-releasing hormone (LHRH) agonists such 
as goserelin is also a commonly used treatment in pre-menopausal women. 
LHRH agonists decrease luteinizing-hormone secretion by the pituitary, leading  
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Fig. 8. Chemical structure of tamoxifen, raloxifene, and ICI 182,780. 
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to a block in follicular activity and consequent reduction in estrogen production 
by the ovaries (152). Tamoxifen was originally developed as an oral 
contraceptive, but the potential of its anti-estrogenic action in breast cancer was 
recognized (153) and this drug is now become the most widely used endocrine 
agent for the treatment of breast cancer. Tamoxifen treatment for one or two 
years provides some reduction in recurrence and death for women with operable 
breast cancer. Treatment for five years provides a maximal benefit with a 51% 
reduction in recurrence and about 28% reduction in deaths during years 0–4. 
Reduction in recurrence and mortality is sustained in year 5 and beyond. The 
benefits of adjuvant tamoxifen treatment are independent of age, but are 
restricted to women with ER-positive breast cancer (150,151). Because of this 
success with tamoxifen, several other anti-estrogens have been developed and 
clinically tested. Raloxifene and faslodex (ICI 182, 780) (Fig.8) (154) are 
examples of the new generation of anti-estrogen. Raloxifene, like tamoxifen, is 
mixed ER agonists/antagonists, with antagonistic activity in the breast. Unlike 
tamoxifen which has estrogenic activity in endometrial tissue and results in 
increased risk for endometrial cancer, raloxifene had reduced estrogenic activity 
in the endometrium and is now being tested as chempreventive agent for breast 
cancer (155). On the other hand, Faslodex is a 'pure' ER antagonist, and is 
active in patients with metastatic breast cancer who had relapsed on tamoxifen 
therapy. Several Phase III studies with ICI show higher efficacy compared with 
other endocrine therapies (156). The use of raloxifene in breast cancer 
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prevention is also being investigated. Aromatase is responsible for local 
estrogen synthesis in post-menopausal women. Aromatase inhibitors are now 
being used to reduce peripheral estrogen synthesis as second- and third-line 
agents for treatment of hormone-sensitive disease, once resistance to tamoxifen 
has developed. Recent study indicates that third-generation aromatase inhibitors 
might be superior to tamoxifen in causing regression of breast cancers, in terms 
of both response rates and duration of response (157). 
Retinoids - Many studies have shown that retinoids such as trans-retinoic 
acid or 9-cis retinoic acid can be used to inhibit breast tumor promotion and/or 
progression (158,159). This effect is mediated by transcribtional activation of 
nuclear retinoic acid receptor (RAR) and retionoid X receptor (RXR). Many 
genes that are important for growth and cell cycle progression are regulated by 
the active RAR/RXR complex. Examples of these genes include p27 (158), 
(160), cyclin D1 and cdk-2 (161).  It is worth noting that ER (-) breast cancer 
cells are more resistant to retinoid treatment than ER (+) cells and this maybe 
due to different expression patterens of RARα (162). 
PPAR γ agonist - Many PPAR γ ligands have been used for the treatment 
of different types of cancer including breast cancer. PPAR γ is expressed in 
many cancer cell lines (163) and in both primary and metastatic carcinomas 
(164). Elstner and coworkers had shown that PPAR γ agonist troglitazone can 
inhibit cellular proliferation by 50 % (165). These agonists produce their effect by 
binding to PPAR γ followed by heterodimerization with RXR (166). 15-deoxy-
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∆12,14-prostagladin J2 (15dPGJ2) is another PPAR γ ligand that also has a 
potential use in breast cancer treatment. Like troglitazone, 15dPGJ2 inhibits cell 
proliferation and promotes apoptosis (167). On going research in this laboratory 
has investigated a new class of PPARγ agonists as a potential treatment for 
breast cancer. These compounds include 1,1-bis(3’-indolyl)-1-(ρ 
trifluoromethylphenyl)methane (DIM-C- ρPhCF3) and several ρ-substituted 
phenyl analogs. Compounds containing para t-butyl, cyano, dimethylamino and 
phenyl substitutents were the most active PPARγ agonists. 
Vitamin D analogs - Vitamin D or its analogues has been investigated as 
drugs for treatment of breast cancer. 1alpha, 25-Dihydroxyvitamin D-3 (1α, 
25(OH)2D3), the active metabolite of vitamin D, inhibits growth of many cancer 
cell lines including those from the breast cancer (168,169). 1γ,25(OH)2D3 
produces its effect by activating the vitamin D receptor (VDR) which is another 
member of nuclear receptor superfamily (170).The active VDR heterodimerizes 
with RXR and binds the vitamin D-responsive element on vitamin D responsive 
gene promoters. 
Treatment with antibodies - Another potential treatment for breast cancer 
is the use of humanized monoclonal antibodies against growth factor and/or 
growth factor receptors. One of the important characteristic of ER(-) and SERM 
resistant breast cancers is the upregulation of receptor tyrosine kinases on the 
surface of these cells and this mimics the action of the growth factors (171-175).  
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The EGF family of structurally related receptor tyrosine kinases known as the 
ErbB receptors mediate proliferation of breast cancer cells/tumors primarily 
through activation of the MAP kinase and PI3-K signal transduction pathways 
(174,176).  Four ErbB receptors have been identified:  ErbB1 (HER1), ErbB2 
(also known as Her2neu), ErbB3 (HER3), and ErbB4 (HER4) (177). ErbB2 
(HER-2/neu) is a potential target for drugs since this receptor is overexpressed 
in 20-30 % of mammary tumor (178). Herceptin is one of the humanized 
monoclonal antibody, which binds to and downregulates the Her2/neu receptors 
on the cell surface by causing them to be endocytosed into the cell and thereby 
limiting tumor growth regulated by these signaling pathways (179,180).   
 Gene therapy - One of the most promising treatments for several types of 
cancer including breast cancer is the use of gene therapy. Gene therapy can be 
used to replace and/or knockout defective genes or alleles in tumor cells with the 
prospect of causing cancer remission. Target genes for this therapy include 
tumor suppresser genes, cell cycle kinase inhibitors, or genes that inhibit growth 
factor receptors. P53 is one of these targets since it is mutated or deleted in 
almost 50% of all cancers (181,182). P53 mutations are also present in many 
breast cancer cells and tumors (182). Gurnani and cowrkers have used 
adenovirus constructs to introduce a wild type copy of p53 into a breast cancer 
cell line (MDA-MB-231) which express mutated p53 and in vivo into athymic 
nude mice injected with MDA-MB-468 cells. Results of this study showed that 
the growth of MDA-MB-231 cells expressing Adp53 was inhibited compared to 
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cells treated with empty vector Moreover, adenoviral p53 expression prevented 
tumor growth in the nude mice (183). Recently, siRNAs have been used as a 
new avenue for gene therapy. These siRNAs are highly sequence-specific that 
are high discriminatory in targeting specific mRNA. siRNA has been used to 
target mutant p53 allele in cancer cells and this results in restoration of wild type 
protein function (118) .    
 
TRANSCRIPTION  
The sequential changes that occur during development of cancer are 
related in changes in levels of gene transcription. The remarkable diversity 
between cancer and normal cells is achieved through deregulated expression of 
genes involved in cell cycle regulation, DNA synthesis and tumor suppression 
and transformation. The fact that more than 5% of our genes are predicted to 
encode transcription factors underscores the importance of this protein family in 
normal and cancer cell biology (184). When activated, transcription factors bind 
to gene regulatory elements and, through interactions with other components of 
the transcription machinery, promote access to DNA and facilitate recruitment of 
the RNA polymerase enzymes to the transcriptional start site. RNA transcription 
is multi-step process that involves several factors. Briefly, soon after RNAP II 
initiates transcription, the nascent RNA is modified by the addition of a “cap” 
structure at its 5′-end. This cap serves initially to protect the new transcript from 
attack by nucleases and later serves as a binding site for proteins involved in 
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export of the mature mRNA into the cytoplasm and its translation into protein 
(185).The capping process appears to coordinate early transcriptional events by 
regulating the transition between transcription “initiation,” during which RNAP II 
begins RNA synthesis, and transcription “elongation,” in which the polymerase 
moves 5′ to 3′ along the gene sequence to extend the transcript. A family of 
“elongation factors” is responsible for regulation of the elongation phase of 
transcription (186). Coding sequences in the gene (exons) are often interrupted 
by long noncoding sequences (introns), which are removed by pre-mRNA 
splicing. Once a gene has been transcribed, RNAP II stops transcription 
(“termination”), the newly synthesized RNA is cleaved (“cleavage”) and a 
polyadenosine poly (A) tail is added to the 3′ end of the transcript 
(“polyadenylation”) (185). 
Cellular DNA is not naked, but packaged into a highly organized and 
compact nucleoprotein structures known as chromatin. Nucleosome, the basic 
organizational unit of chromatin, is consists of 146 bp of DNA wrapped almost 
twice around a protein core containing two copies each of four histone proteins: 
H2A, H2B, H3, and H4 (187). These small, positively charged proteins are highly 
conserved among eukaryotes and are the protein building blocks of 
chromosomes. Further compaction of genes is achieved via poorly defined 
levels of higher-order nucleosome folding.  It is clear now that chromatin plays a 
crucial role in regulating gene transcription by marshalling access of the 
transcriptional apparatus to genes (188). All chromatin is not equal; for example 
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untranscribed regions of the genome are packaged into highly condensed 
“heterochromatin,” while transcribed genes are present in more accessible 
“euchromatin” (189). To activate gene expression, transcriptional activator 
proteins must, therefore, contend with inaccessible and repressive chromatin 
structures. It is clear now that many transcriptional coregulators are enzymes 
that modulate chromatin structure and this underlines the importance of DNA 
packaging in gene expression. Coregulators that act on chromatin can be 
divided into two general classes: ATP-dependent nucleosome remodeling 
complexes and activities that catalyze posttranslational modification of histones. 
ATP-dependent chromatin remodeling complexes facilitate access of DNA 
binding proteins to DNA by repositioning nucleosomes at the promoter or by 
inducing conformational changes in nucleosomes (188). There are four classes 
of histone modifiers that have been implicated in transcriptional regulation. 
These are the histone acetyltransferases (HATs), the histone deacetylases 
(HDACs), the histone methyltransferases (HMTs), and the histone kinases 
(188).  
Histone acetylation was the first modification shown to correlate with 
transcriptional competence and this process initiates the breakdown of 
chromatin structure (190). After being recruited to promoters by different 
activator, HATs and HMTs will cause the acetylation and methylation, 
respectively, of residues located in the N-terminal tails of histones and this is 
crucial for activation of many classes of gene (190-194). Conversely, recruitment 
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of HDACs by transcriptional repressors leads to deacetylation of histone tails 
and this is required for gene repression. However, gene expression and histone 
tail modifications exhibit a complex relationship.  
Decompaction of chromatin at the promoter is not sufficient for efficient 
transcription. RNAP II often needs to travel thousands of base pairs of 
compacted chromatin downstream of the promoter. Two protein factors have 
been involved in this process. The first is the chromatin-specific transcription 
elongation factor, FACT, which facilitates RNAP II elongation through 
nucleosomes and plays a role in elongation in vivo (195,196). The second 
complex implicated in disrupting chromatin downstream of the promoter is the 
elongator, originally isolated as a component of elongating RNAP II (197) and 
recently shown to promote transcription through chromatin (198). Unlike the 
prokaryotic enzymes, eukaryotic RNA polymerases cannot recognize the 
promoters of their target genes and instead rely on a series general transcription 
factors (GTFs) (199-201).These protein factors recognize the conserved “TATA” 
box and “initiator” sequences present in most protein-coding genes and recruit 
RNAP II to the start site of transcription. Different biochemical assays have been 
used for purification of transcription factors from mammalian cells. This revealed 
the existence of large families of sequence-specific activators (Sp1, AP-1, 
C/EBP, NF-B, GR, etc.) as well as a host of accessory factors (TFIIA, TFIIB, 
TFIID, TFIIE, TFIIF and TFIIH) necessary to program a functional RNA Pol II 
complex (202-207). Most genes are regulated by mixing and matching different 
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types of activators and repressors in a coordinated fashion. Studying the 
mechanisms by which co-activators and co-repressors interface with gene 
regulators and the transcription machinery has become essential for 
understanding transcriptional regulation in eukaryotes. Generally, transcriptional 
co-factors are divided into five classes (Table III) that differ in both structure and 
number. 
Mechanism of transcriptional machinery assembly. The process of 
how the transcriptional machinery may be assembled and targeted to specific 
promoters is still not clear. However, there are two models suggested for this 
process.   
A stepwise assembly model - This model proposes an ordered assembly 
of the transcription pre-initiation complex and this is based on the formation of 
active transcription complexes in vitro (208). It was observed that a stepwise 
addition of purified basal factors was required for promoter binding and 
transcription initiation from naked DNA templates (Fig.9). Steps leading to Pol II-
dependent transcription include: first, formation of a metastable complex 
between TFIID, TFIIA, and TFIIB (DAB) capable of recognizing and binding to 
the TATA promoter element; second, a more stable closed complex containing 
DAB, hypophosphorylated RNA Pol II and TFIIF; third, an activated open 
complex formed by the further addition of TFIIE and TFIIH, which stimulate ATP-  
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Table III 
Classes and properities of transcription co-factors. Modified from (209). 
Class       General properties      Examples     
I activator and repressor targets inherent to the 
core machinery, promoter recognition, and 
enzymatic functions 
TAFs, TFIIA, NC2, PC4 
II activator and repressor adapters, modulate 
DNA binding, target other co-regulators and 
the core machinery 
OCA-B/OBF-1, Groucho, 
Notch, CtBP, HCF, E1A, 
VP16 
III multifunctional structurally related but highly 
divergent co-regulators: some interact with 
RNA Pol II and/or multiple types of activators, 
some also appear to have inherent enzymatic 
functions or chromatin-selective properties 
yeast: Mediator, SRBs 
human a: CRSP, PC2 
human b: 
ARC/DRIP/TRAP human 
c: NAT, SMCC, 
Srb/Mediator 
IV chromatin-modifying activator and repressor 
adapters, acetyltransferase or deacetylase 
activities with multiple substrates: histones, 
histone-related proteins, activators, other co-
regulators and the core machinery 
CBP/p300, GCN5, 
P/CAF, p160s (SRC1, 
TIF2, p/CIP, etc.), 
HDAC-1 and HDAC-2 
(rpd3), Sir2 
V ATP-dependent chromatin remodeling 
activities 
SNF2-ATPase 
(SWI/SNF, RSC) and 
ISWI-ATPase (NURF, 
ACF, ChrAC, RSF, etc.) 
 
 
 
 54
 
Fig. 9. Stepwise assembly model for gene transcription.  [A] Chromatin 
remodeling and template access. [B] Stepwise recruitment of core machinery. [C] 
Activated initiation complex and transcription. Modified from (209). 
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dependent isomerization and promoter-melting. Finally, promoter clearance and 
nascent RNA synthesis occurs upon hyperphosphorylation of the RNA Pol II C-
terminal domains (CTD) (199,210-212). Many studies have shown that direct or 
indirect interaction of activators with constituents of the general machinery affect 
rates of complex formation and transcription (213-215). This stepwise model for 
assembly of the core initiation machinery is consistent with the observed 
biochemically defined steps and could satisfy a biological requirement for 
dynamic regulation. However, it is now understood that the RNA Pol II core 
initiation machinery is more elaborate than previously anticipated and contains 
up to 40 polypeptides comprising separable activities that govern the distinct 
steps leading to transcription described above. 
Pre-assembly complex model - This model proposes recruitment of a 
completely pre-assembled RNA Pol II holoenzyme for transcription initiation 
(Fig.10). This model was first proposed when certain preparations of RNA Pol II 
were observed to co-purify with subsets of the basal machinery along with some 
co-regulators, including chromatin remodeling factors such as SWI/SNF and 
CBP, and even proteins involved in DNA replication and repair (216-219). 
Despite considerable heterogeneity of these RNA Pol II preparations, one 
invariant property has been the absence of TFIID in these holoenzyme 
conglomerates. Consequently, at least two targeted steps are required to form 
an active pre-initiation complex with the holoenzyme model since recruitment of 
TFIID (or a functional equivalent) is a prerequisite for transcription.  
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Fig. 10. Pre-assembly complex model for gene transcription.  Holoenzyme 
recruitment. Modefied from (209). 
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One possible advantage of a holo-complex is the ability to obviate the 
limited cellular concentrations of individual transcription factors. A pre-
assembled RNA polymerase complex could, in principle, facilitate rapid 
responsiveness to arrayed regulators that might cooperatively recruit the 
transcriptional machinery via targeting of multiple interfaces. On the other hand, 
the recruitment of a monolithic universal holoenzyme does not fit well with the 
observed need for the vast diversity of co-regulators in animal cells. It would be 
more favorable to employ multiple regulators that act at different stages of the 
transcription reaction. Such a multi-faceted mechanism could impose controls at 
different barriers to the transcription process and thereby provide greater 
flexibility for modulating rates of transcription. Since the basal machinery and co-
regulator activities are separable and can be reconstituted biochemically with 
distinct rate-limiting steps, it is likely that there are multiple stages employed by 
sequence-specific DNA-binding factors to exercise regulation in vivo that cannot 
be explained by the simple binary recruitment of an RNA Pol II holoenzyme. This 
suggests that eukaryotes have evolved adaptable and interchangeable 
transcriptional complexes along with attendant co-regulators that incorporate 
subsets of multifunctional polypeptides.  
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Sp1 TRANSCRIPTION FACTOR 
  Sp1 was one of the first transcription factors to be purified and was 
cloned from mammalian cells in the early 1980s (202,220). Sp1 was shown to 
bind DNA via three Cys2His2 zinc-finger motifs. A similar DNA-binding domain 
had been found in many developmental regulators, including the Drosophila 
embryonic pattern regulator Krüppel (220). Krüppel-like factors have been 
named after the Drosophila segmentation gene Krüppel that shows a similar 
arrangement of zinc fingers (221). Sp1-like/KLF members recognize the same 
GC-(GGGGCGGGG) and GT-(GGTGTGGGG) boxes albeit with different 
affinities due to the substitutions of amino acids in the zinc fingers. GC and GT 
boxes are important for the expression of many different ubiquitous as well as 
tissue-specific cellular and viral genes (222). In addition, these motifs are 
involved in the maintenance of the methylation-free status of the CpG islands in 
several genes (223,224). Many members of the Sp1-like/KLF family have 
acquired multiple names over time and because of this the nomenclature for 
these proteins is currently being revised and standardized. In this Dissertation, 
we follow the current nomenclature of Sp1-Sp6. 
At least 21 Sp1-like/KLF genes have been identified in humans by a 
variety of cloning approaches (Table IV). So far, homologs of 17 of the 21 
human Sp1-like/KLF proteins have been identified in mouse, and 11 in rat.  
Several subgroups have been defined within the Sp1-like/KLF family and this is 
based on sequence and functional similarities (Fig.11). One subgroup contains 
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the factors that are highly related to Sp1, namely Sp1-Sp6 (the 'Sp' proteins or 
subgroup I). The other Sp1-like/KLF proteins make up additional subgroup. 
According to the rules of nomenclature, these proteins are numbered as KLF  
 
 
 
Table IV 
Characteristics of Sp/KLF family members. Modified from (222). 
Protein KLF 
number 
Species Chromos-
omal 
localizati-
on 
Transcriptional 
activity (and 
functional 
domains) 
Expressio-
n pattern 
Cellular 
functions 
Sp1 ------- Human, 
mouse, 
rat and 
Drosophil
a 
12q13 Transcriptional 
activity (and 
functional 
domains) 
Ubiquitous Embryogen
esis 
Sp2 -------- Human, 
mouse 
and rat 
17q21 Unknown (Q-rich 
domain) 
unknown Unknown 
Sp3 -------- Human, 
mouse 
and rat 
2q31 Activator and/or 
repressor (Q-rich 
domains) 
Ubiquitous Unknown 
Sp4 -------- Human, 
mouse 
and rat 
7p15 Activator (Q-rich 
domains 
Brain-
enriched 
Post-natal 
survival and 
male fertility 
mSp5 ------- Mouse  Unknown Ubiquitous Unknown 
Sp6 KLF14 Human 
and 
mouse 
17q21 Activator Ubiquitous Unknown 
EKLF KLF1 Human 
and 
mouse 
19p13 Activator (acidic 
domain) 
Erythroid 
and mast 
cells 
Erythropoie
sis 
LKLF KLF2 Human 
and 
mouse 
19p13 Activator (acidic 
domain) 
Lung, 
blood 
vessels, 
lymphocyt
es 
Blood 
vessel, lung 
developmen
t, T-cell 
survival 
BKLF   4p14 Activator/repress
or (PVDLS/T 
motif) 
Erythroid  
and brain-
enriched 
Unknown 
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Table IV. Continued. 
 
GKLF KLF4 Human, 
mouse, 
rat and 
zebrafish 
9q31 Activator and/or 
repressor (acidic 
domain) 
Gut-
enriched 
Anti-
proliferation, 
survival 
IKLF KLF5 Human, 
mouse 
and rat 
13q21 Activator Gut and 
epithelial 
tissues 
Cell growth 
CPBP KLF6 Human 
and 
mouse 
10p15 Activator Ubiquitous Putative 
tumor 
suppressor 
UKLF KLF7 Human 
and 
mouse 
2q32 Activator (acidic 
domain) 
Ubiquitous Cell-cycle 
arrest 
BKLF3 KLF8 Human Xp11 Repressor 
(PVDLS/T motif) 
Ubiquitous Unknown 
BTEB1 KLF9 Human, 
mouse 
and rat 
9q13 Activator/repress
or (SID) 
Ubiquitous Neurite 
outgrowth 
and 
carcinogen 
metabolism 
TIEG1 KLF10 Human Xp11 Repressor 
(PVDLS/T motif) 
Ubiquitous Apoptosis, 
anti-
proliferation 
TIEG2/ 
FKLF 
KLF11 Human 2p25 Activator and/or 
repressor (SID, 
R2, R3) 
Ubiquitous Anti-
proliferation 
AP-
2rep 
KLF12 Human, 
mouse, 
rat and 
zebrafish 
13q21 Repressor 
(PVDLS/T motif) 
Brain, 
kidney, 
liver and 
lung 
Unknown 
BTEB3
/RFLA
T-
1/FKLF
-2 
KLF13 Human, 
mouse 
and rat 
15q12 Activator/repress
or (SID, R2 and 
R3) 
Ubiquitous Anti-
proliferation 
and 
carcinogen 
metabolism 
KKLF KLF15 Human, 
mouse 
and rat 
3q13 Repressor Ubiquitous Unknown 
BTEB4
/ 
mDRR
F 
KLF16 Human 
and 
mouse 
19q13 Repressor (SID) Ubiquitous Carcinogen 
metabolism 
BTEB5 ------- Human 7 Unknown Unknown Unknown 
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Zinc Finger
AD Activation Domain ID Inhibitory Domain
Btd Box Sp Box
N C
N C
N ADAD C
IDADAD CN
N AD C
N ADAD C
A B C D
606
769
784
398
452
Sp1
Sp2
Sp3
Sp4
Sp5
Sp6
785
 
R3R2SID
SID NLS
Acidic NLSInhibitory
PVALS/T
KLF10 and KLF11
KLF9, KLF13 and KLF16
KLF1, KLF4 and KLF2
KLF3, KLF8 and KLF12  
SID – Sin3 Interaction Domain.    NLS – Nuclear Localization Signal. 
                             R – Repression domain.                PVALS/T – Repression motif. 
 
Fig. 11. Structural features of Sp/KLF family members. Modefied from 
(222,225). 
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factors, corresponding to the approximate order in which the genes were 
described (KLF1-KLF16). 
There are three domains required for a functional site-specific 
transcription factor: a DNA-binding domain, a nuclear localization signal, and a 
transcriptional regulatory domain. The defining feature of Sp1-like/KLF proteins 
is a highly conserved DNA-binding domain (more than 65% sequence identity 
among family members) at the carboxyl terminus that has three tandem 
Cys2His2 zinc-finger motifs. The zinc-finger motifs may also function in protein-
protein interactions that modulate DNA-binding specificity (226,227). The amino-
terminal regions of the Sp1-like/KLF proteins are much more variable and 
contain transcriptional activation or repression domains. Nuclear localization 
sequences have been found in Sp1-like/KLF proteins, which can occur 
immediately adjacent to, or within, the zinc-finger motifs (228,229). 
Many DNA binding studies have shown that most Sp1-like/KLF proteins have 
similar affinities for different GC-rich sites (230-232). Importantly, several 
Sp/KLF proteins have identical amino acids sequence that interact with DNA and 
competition for DNA binding has been shown for some of these members.For 
example, Sp1 and Sp3 compete for the same sites in many promoters, as do 
Sp1 and KLF9 (BTEB1), Sp1 and KLF13 (BTEB3), Sp1 and KLF4 (GKLF), and 
KLF1 and KLF3 (BKLF) (231,233-236). There are some differences in DNA 
binding among Sp proteins: For example, Sp2, which has a leucine residue 
within the first zinc-finger motif in place of the histidine found in the 
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corresponding region of Sp1, preferentially recognizes GT box (5'-
GGTGTGGGG-3'), found in many different promoters, rather than GC box 
(233,237).  
 Based on their similar modular structures, Sp1, Sp2, Sp3, and Sp4 form 
a subgroup. Sp1, Sp3, and Sp4 contain two major glutamine-rich transactivation 
domains A and B that are essential for transcriptional activation. 
Serine/threonine-rich sequences that may be targets for post-translational 
modification are located adjacent to these A and B domains. While Sp2 has only 
one glutamine-rich domain, it does share a highly charged domain C and a 
serine/threonine-rich region with the other factors (237). The so-called 
Buttonhead box is located N-terminal to the zinc finger domain in all Sp proteins 
(238). This conserved stretch of 11 amino acid residues was originally identified 
in the Drosophila Sp1 homologue Buttonhead (Btd) (239). It is believed that this 
box may contribute to the transactivation potential of these factors, since a 
deletion of an overlapping region results in reduced activity of Sp1 in vitro (240). 
One study has shown that Btd element within domain C is involved in synergistic 
activation by Sp1 or Sp3 with sterol-regulatory element-binding proteins 
(SREBP) (241). Another stretch of conserved amino acids consisting of the 
sequence SPLALLAATCSR/KI (Sp box) has been identified at the N-terminus of 
the proteins (238). This element contains an endoproteolytic cleavage site and is 
situated close to a region at the N-terminus of Sp1 that targets proteasome-
dependent degradation in vitro (242). The fact that the Sp box is highly 
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conserved indicates that it may have a function in regulation of Sp protein 
proteolysis. 
Sp factors- physiological function and transactivation properties. 
Although Sp1-like/KLF proteins have high degree of similarity in their DNA-
binding activities, however, transcriptional regulation among different family 
members can be highly variable. 
Sp1 - Sp1 stimulates transcription from both proximal and distal 
enhancers (243). Sp1 tetramers may be involves in the synergistic activation via 
distant sites (244), looping out the intervening DNA (244-246). For 
multimerization, activation domain B appeared to be of critical importance (247). 
Together with domain A, domain B also mediates superactivation of Sp1-
dependent transcription and this can be achieved by non-DNA-binding mutants 
in case of multiple binding sites (243,248). For synergistic activation via binding 
to multiple sites, domain D on both transactivation domains are required (247).  
Heterotypic interactions of Sp1 with different classes of nuclear proteins have 
been reported. These include general transcription machinery factors, such as 
the TATA-box binding protein TBP (249) and the TBP-associated factors 
dTAFII110/hTAFII130 (250,251), and hTAFII55 (252). Sp1 can bind to its target 
sequence in assembled nucleosomes (253), and so it is interesting to note the 
interaction with a large coactivator complex called CRSP (cofactor required for 
Sp1 activation) which stimulates Sp1-mediated transcription in vitro (254). Sp1 is 
involved in the activation of a very large number of genes, such as 
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housekeeping, tissue-specific and cell cycle-regulated genes, and is required to 
prevent methylation of CpG islands (223,255).  
Mouse model with genetically engineered disruption or “knockout” of Sp1 
protein has shown that Sp1-deficient embryonic stem cells (ES cells) are viable, 
have normal growth characteristics and can be induced to differentiate and form 
embryoid bodies as efficiently as wild type ES cells (256). Nevertheless, Sp1 is 
essential for normal mouse embryogenesis. The Sp1-knockout embryos are 
severely retarded in development and died around day 11 of gestation. They 
displayed a marked heterogeneity in phenotype indicating that Sp1 has multiple 
functions in many cell types. Sp1 appears to be a transcription factor whose 
function is essential for differentiated cells after day 10 of development. The only 
genes which were found to be expressed at a lower level in Sp1-/- mice are the 
thymidine kinase and the methyl-CpG binding protein 2 (MeCP2) genes (256). It 
was suggested that the MeCP2 gene might be a key target of Sp1 (257). 
However, whether Sp1 acts as a direct regulator of MeCP2 expression by 
binding to the promoter, enhancer or local control region elements in the MeCP2 
gene, or whether additional proteins mediate downregulation of MeCP2 remains 
to be established. 
Sp2 - unlike Sp1, Sp2 is unable to activate promoters containing GC 
boxes because the binding site specificity of Sp2 differs from that of the other Sp 
proteins (237,258,259). It has been shown in one study that Sp2 represses Sp1- 
and Sp3-driven activation of a construct containing the murine 
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CTP:phosphocholine cytidylyltransferase γpromoter in Drosophila cells but 
activates the same construct in C3H10T1/2 mammalian cells (260). It is likely 
that Sp2 has different characteristics than Sp1, 3 and 4 since it has only one 
glutamine-rich transactivation domain, whereas two domains are required for 
superactivation and synergistic activation by Sp1 (247). 
Sp3 - Unraveling the transcriptional role of Sp3 is complicated by the fact 
that three Sp3 isoforms exist, a 110-115 kDa Sp3 protein and two approximately 
60-70 kDa Sp3 species. The two smaller Sp3 species arise from the first two 
internal AUG codons (261).  Several reports have shown that Sp3 act as a 
transcriptional activator similar to Sp1 (262-264). In other studies, Sp3 remained 
inactive or acted only as a very weak activator (265-267). Most of these reports 
are based on co-transfection experiments into the insect cell line SL2. Usually, a 
distinct promoter fragment containing appropriate Sp-binding sites fused to a 
reporter gene has been co-transfected along with expression plasmid for Sp1, 
Sp3 or both in combination. If Sp3 is expressed to the same extent as Sp1 but 
does not act as a strong activator, it will compete for the same binding site and 
thus lower Sp1-mediated activation. Decreased endogenous Sp3 expression in 
the myelomonocytic cell line HL60 using antisense oligonucleotides showed that 
Sp3 participates in activation of the CD11c and CD11b promoters (268). The 
experimental conditions required for Sp3 to act as a strong activator or a 
transcriptional inactive molecule which represses Sp1-mediated activation are 
not completely understood. The structure and arrangement of the recognition 
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sites appear to determine whether Sp3 is transcriptionally inactive and can 
repress Sp1-mediated activation or whether it acts as a strong activator. 
Promoter analysis studies have shown that promoters containing a single 
binding site are activated, whereas promoters containing multiple binding sites 
often are not activated or respond weakly to Sp3 (269,270). Whether Sp3 acts 
as an activator or as a repressor of Sp1-mediated activation may also depend 
on cell context. Transfected Sp3 stimulated transcription from the HERV-H long-
terminal repeat in the teratocarcinoma cell line NTera2-D1 but acted as a 
repressor in HeLa and insect cells (270).  
In insect and in mammalian cells, it is clear that both N-terminal 
glutamine-rich regions of Sp3 can act as strong activation domains (270,271). 
The molecular basis for the inactivity of Sp3 under certain conditions has been 
linked to an inhibitory domain located between the second glutamine-rich 
activation domain and the first zinc finger. To have repressor function, the amino 
acid triplet KEE within this domain is absolutely essential (270). Mutation of 
these amino acids to alanine residues converted almost inactive Sp3 to a strong 
activator. The inhibitory domain of Sp3 can act independently and after transfer 
to other activation domains there is a loss of transactivation properties (270). It is 
not clear how this domain functions mechanistically, however, it is possible that 
additional proteins such as SIF-1 (Sp3-interacting protein 1) which acts as co-
repressors are involved in the inhibitory function of Sp3 (272). 
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Sp4 - Sp4 is a tissue restricted member of the Sp-family. It is 
predominantly expressed in the brain but also detectable in epithelial tissues, 
testis and developing teeth (232,273). Despite obvious structural similarities, the 
functional properties of Sp4 are different from those of Sp1. Like Sp1, Sp4 
shows similar transactivation potential through its glutamine-rich activation 
domains. In addition, Sp4 can be superactivated by fingerless Sp1 and 
repressed by Sp3 (248). Although Sp1 can synergistically activate promoters 
containing multiple binding sites, transactivation by Sp4 only occurs in an 
additive manner (248). Unlike Sp1 and Sp3, the transactivation potential of Sp4 
has not been intensively investigated with respect to different promoters and cell 
types. Several promoters are activated by Sp4 in mammalian cell lines as well 
as in Drosophila cells (248,266,274), but others only appeared to respond to 
different Sp family members (275,276). Disruption of the mouse Sp4 gene 
revealed that it is important for early post-natal survival (273). Approximately two 
thirds of the Sp4-/- mice die within a few days of birth. The cause of the early 
death remains unknown and survivors of these mice are significantly smaller 
than their wild type littermates. It is believed that the reduced body weight results 
from an unknown growth hormone-independent mechanism (273). In addition, 
surviving mice exhibit a striking sex-specific abnormality. Fertility of the female 
mutants appears normal. In contrast, although male reproductive organs are 
fully developed and apparently normal, they do not breed and it is possible that 
male Sp4-/- mice have lost their ability to copulate. The most likely cause of this 
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abnormal behavior is a neurological defect. The hypothalamus and the 
vomeronasal organ are known to play important roles in reproductive physiology 
and behavior. However, both structures are histologically normal in Sp4-/- mice 
and further studies are required to understand the role of Sp4 and to identify its 
target genes.                   
Co-operative interactions of Sp1 with other proteins. Regulation of 
gene expression by transcription factors depends on the communication with the 
basal transcription machinery. Sp1 can directly interact with TBP (249) and 
dTAF(II)110/hTAF(II)130 via the glutamine-rich activation domains A and B 
(250,251,277) and with hTAF(II)55 through the C-terminal domain (252).  It has 
been found that TAF (II) 250 plays an important role in stimulation of Sp1 
transcriptional activity by Rb (278). Furthermore, the multi-subunit complex 
CRSP (cofactor required for Sp1) promotes efficient activation of transcription by 
Sp1 (254). CRSP functions in conjunction with the TBP-associated factors. 
CRSP contains unique subunits and polypeptides that are shared with other 
cofactor complexes (254). There are several reports that describe functional 
interactions between Sp factors and proteins and these include sequence-
specific transcription factors such as Oct-1 (279), NF-κB (280-282), and E2F-1 
(283,284) and also tissue-specific regulators like MEF-2 (285) and GATA 
proteins (286). These interactions with Sp1 can synergistically activate 
transcription of various target genes. 
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In addition to the zinc finger domains, non-conserved domains can also play a 
role, as has been shown for Sp1 and NF-κB in case of the HIV-1 promoter (287). 
The interaction of Smad3 with Sp1 but not with Sp3 demonstrates that distinct 
Sp proteins can specifically co-operate with other transcription factors (288).  
Sp1 site-dependent and growth regulation. Early studies identified       
“Sp1 sites” in the promoters of multiple growth-regulated genes, arguing that 
these sites may be important for cell growth regulation. Several studies have 
established the ability of “Sp1 GC-rich sites” to mediate growth induction of a 
variety of promoters, including those of the genes encoding insulin-like growth 
factor (IGF)-binding protein 2 (289), vascular/endothelial growth factor (VEGF) 
(290), thymidine kinase (291), and serum response factor (292). Growth 
regulation by Sp1-sites has been shown by studying the effects of expressing 
truncated (C-terminal) Sp1 which contains the zinc finger DNA binding domain 
but not the major transactivating domains of Sp1 (293). This “dominant negative” 
Sp1 inhibited HeLa cell growth. This effect was associated with an increase in 
the duration of S-phase, arguing that “Sp1 site”-dependent transcription is 
particularly important for this phase of the cell cycle.  
In another study, transfection of cells with “Sp1 site” decoy 
oligonucleotides inhibited the expression of a range of genes and decreased 
invasiveness and proliferation of A549 lung adenocarcinoma and U251 
glioblastoma cells (294). However, it worth noting that “dominant negative” Sp1 
protein and the decoy oligonucleotides would act generally for all proteins that 
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bind the Sp1 site .  Therefore these studies represent the role of Sp1 site -
dependent transcription and not necessary Sp1 protein in mediating these 
effects. Interestingly, it has been shown that, upregulation of “Sp1 site”-
dependent transcription can be related to positive or negative changes in cell 
growth and this is promoter context-dependent. For example, “Sp1 sites” in the 
rep3a and DHFR promoters support upregulation of transcription following 
growth stimulation of quiescent cells. The opposite is true for “Sp1 sites” in the 
p21waf1/cip1 where transcriptional upregulation is related to growth inhibition (295). 
Sp1 expression and activity is increased in epithelial carcinomas compared with 
benign tumors, such as papillomas, suggesting that Sp1 may be involved in 
tumor progression (296). Another study in several pancreatic cancer cell lines 
has shown that expression of VEGF is correlated with the expression of Sp1 and 
both proteins are coordinately over expressed in pancreatic cancers compared 
to normal pancreatic tissue (297). 
 
MECHANISM OF ESTROGEN-MEDIATED TRANSACTIVATION THROUGH 
Sp1 and GC-RICH SITES 
Estrogen (E2) mediates its effects through interaction with intracellular 
steroid hormone receptor know as the estrogen receptor (ER). Once in the 
nucleus, estrogen binds ER causing conformational changes that lead to 
dissociation of heat shock proteins and formation of transcriptionaly active ER, 
however, steroid hormone receptors are members of the large nuclear receptor 
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(NR) family of transcriptional modulators. Transcription is regulated by NRs 
through intreraction with DNA regulatory sequences that bind discriminately to 
particular classes of NR as well as with co-activator and co-repressor molecules 
to regulate the activity of the RNA polymerase complex (298-300). The  nuclear 
receptor family also includes additional steroid hormone receptors such as the 
progesterone and androgen receptors, receptors for vitamins or metabolites 
such as the vitamin D or retinoic acid receptors, or receptors with no identified 
ligand, termed ‘orphan’ receptors ( Table V). A new form of ER (ERβ) has been 
cloned and characterized and has been shown to share common structural 
features with ERα, and also some variability (Fig. 12) (301,302).  
The structure of ER is shared by all members of the steroid hormone 
receptor family (Figure 12) and contain six functional domains designated A–F 
(303).  The A/B domain is located in the amino-terminal and contains the 
hormone-independent activation function 1 (AF-1) which shows the highest 
variability among all the steroid hormone receptors (304). Domain C contains the 
DNA binding domain (DBD) which consists of two zinc finger motifs. In 
combination with the so-called P-box, zinc finger motifs are responsible for ER 
binding to estrogen response elements (EREs) and, in combination with a D-
box, they are essential for dimerization of ER on EREs (305). The D domain, 
also called the hinge region, is important for co-regulatory protein binding (306). 
E and F domains makeup the carboxy-terminal region of ER which contains the 
ligand binding domain (LBD) and a region implicated in modulating the agonist 
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activity of non-steroidal antiestrogens and binding of coregulatory proteins (307). 
The LBD itself comprises the ligand-dependent transcription activation function 
AF-2 (308), an HSP 90 binding region (309), a nuclear localization signal (310), 
 
 
 
Table V 
Nuclear receptor families of transcription modulators. Modified from (311). 
Class  Receptor  Sub- 
Type  
Denomination Ligand Response 
Element 
Class 
I 
TR α, β Thyroid hormone 
receptor 
Thyroid hormone (T3) Pal, DR-4, 
IP 
 RAR α, β, γ Retinoic acid 
receptor 
Retinoic acid DR-2, DR-
5 
Pal, IP 
 VDR  Vitamin D receptor 1-25(OH)2 vitamin D3 DR-3, IP-9 
 PPAR α, β, γ Peroxisome 
proliferator activated 
receptor 
Benzotriene B4; Wy 
14.643Eicosanoids; 
thiazolidinediones 
(TZDS); 15-deoxy-
12,41-prostaglandin J2; 
polyunsaturated fatty 
acids 
DR-1 
 PXR  Pregnane X 
receptor 
Pregnanes; C21 
steroids 
DR-3 
 CAR/MB
67 
α, β Constitutive 
androstane receptor 
Androstanes; 1,4-bis[2-
(3,5-
dichloropyridyloxy)]benz
ene 
DR-5 
 LXR α, β Liver X receptor Oxysterols DR-4 
 FXR  Farnesoid X 
receptor 
Bile acids DR-4, IR-1 
 RevErb α, β Reverse ErbA Unknown DR-2, 
Hemisite 
 RZR/RO
R 
α, β, γ Retinoid Z 
receptor/retinoic 
acid-related orphan 
receptor 
Unknown Hemisite 
 UR  Ubiquitous receptor Unknown DR-4 
Class 
II 
RXR α, β, γ Retinoid X receptor 9-Cis-retinoic acid Pal, DR-1 
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Table V continued. 
 COUP-
TF 
α, β, γ Chicken ovalbumin 
upstream promoter 
transcription factor 
Unknown Pal, DR-5 
 HNF-4 α, β, γ Hepatocyte nuclear 
factor 4 
Fatty acyl-CoA 
thioesters 
DR-1, DR-
2 
 TLX  Tailles-related 
receptor 
Unknown DR-1, 
Hemisite 
 PNR  Photoreceptor-
specific nuclear 
receptor 
Unknown DR-1, 
Hemisite 
 TR2 α, β Testis receptor Unknown DR-1 to 
DR5 
Class 
III 
GR  Glucocorticoid 
receptor 
Glucocorticoids Pal 
 AR  Androgen receptor Androgens Pal 
 PR  Progesterone 
receptor 
Progestins Pal 
 ER α, β Estrogen receptor Estradiol Pal 
 ERR α, β, γ Estrogen-related 
receptor 
Unknown Pal, 
Hemisite 
Class 
IV 
NGFI-B α, β, γ NGF-induced clone 
B 
Unknown Pal, DR-5 
Class 
V 
SF-
1/FTZ-F1 
α, β Steroidogenic factor 
1Fushi Tarazu 
factor 1 
Oxysterols Hemisite 
Class 
VI 
GCNF  Germ cell nuclear 
factor 
Unknown DR-0 
Class 
0 
SHP  Small heterodimeric 
partner 
Unknown  
 DAX-1  Dosage-sensitive 
sex reversal 
Unknown  
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Fig. 12. Structural domains of human ERα and ERβ. Modified from (312). 
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and another dimerization domain (313). AF-1 and AF-2 are responsible for 
transcriptional activation of ER-regulated genes. These domains can function 
either independently or synergistically, depending on the cellular context. Both of 
these domains interact with distinct components of the basal transcription 
machinery (314), mediate cell context-specific agonist and antagonist activities 
of selective ER modulators (SERMs) (315) and  bind steroid receptor co-
regulatory proteins such as SRC-1, TIF1a, and RIP140 (316-319). 
Results of previous studies suggest that cell-specific activity of AF-1 and 
AF-2 depend in part on the relative availability of co-regulatory proteins which 
could either facilitate or disrupt the interactions of ER AF-1 and AF-2 with the 
basal transcription machinery. Crystal structures of ERs have shown that LBD 
consist of 12α-helices. Helix 12 is of special importance since it undergoes 
extensive repositioning upon ligand binding, the extent of which depends on the 
type of ligand (320).  Interestingly, hydrophobic residues on the surface of helix 
12 have been identified as mediators of receptor–coactivator interaction (321). 
These data in combination with functional studies of ER imply that ligand-
induced conformational changes in steroid receptors affect the recruitment of co-
factors and receptor-mediated transactivation. It has been suggested that 
recruitment of cofactors is affected by ligand-induced conformational changes in 
the ER.  
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Mouse models in which ERs were genetically disrupted or ‘knocked out’ 
exhibit defects in reproductive function as well as alterations in physiological and 
genomic responses (322). Estrogen receptor α knockout (ERKO) females are 
infertile because they are anovulatory; their LH regulation is disrupted and the 
ERKO mouse uterus is insensitive to estrogen. On the other hand, ERβ knock 
out (βERKO) females are sub-fertile and primarily lack efficient ovulatory 
function. Deletion of both ERα and ERβ (both ERKO) produces effects similar to 
these seen in ERKO mice and they also exhibit a unique ovarian pathology.  
Table VI summarizes different phenotypes observed in reproductive tissues of 
ER knockout mice.  
Several mechanisms have been proposed for estrogen-mediated 
transcription. In the classical model, ER homo- or heterodimers bind palindromic 
E2- responsive elements (ERE) (GGTCANNNTGACC) in E2- responsive gene 
promoters (323-325) (Fig. 13). In addition to DNA- binding, ligand-activated ER 
recruits a series of transcriptional-mediating proteins. These proteins include 
TAFs, coactivators, corepressors, cointegrators and other proteins with histone 
acetyltransferase (HAT) and histone deacetylase (HDAC) activetie 
(300,326,327). However, many estrogen responsive genes such as collagenase 
and IGF-1 do not have consensus and nonconsensus ERE in their promoters.  
These genes contain AP1 sites that bind Jun homodimers or Jun-Fos 
heterodimer. 
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Table VI 
 
Different phenotypes in ERs knockout mice.  Adapted from (322). 
 
Component Function Phenotypes 
Pituitary gland Production and secretion of 
gonadotrophins 
ERKO and both ERKO: 
high LH  
βERKO: none 
Ovary Production of progesterone and 
estradiol, ovulation 
ERKO: haemorrhagic cystic, 
high oestrogen and 
testosterone due to high LH, 
anovulatory 
βERKO: reduced ovulations 
both ERKO: lack of 
ovulation, sex-reversed 
follicles 
Uterus Proliferation, secretion ERKO and both ERKO:  
estrogen insensitive – no 
growth or induction of 
oestrogen target genes 
βERKO: normal growth and 
responses to estrogen 
Embryo/uterus Implantation/decidualization ERKO: estrogen 
independent decidualization, 
no implantation 
βERKO: normal 
Mammary 
gland 
Pubertal development, lactation ERKO and both ERKO: 
no pubertal development 
βERKO: normal 
development and lactation 
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Fig. 13. Classical mechanism of ER-mediated transcription. Modified from 
(328).  
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Promoter analysis studies have shown that ER can modulate gene expression in 
a cell context dependent manner (329-333). This regulation involves ER 
interaction with AP-1 sites through protein-protein binding (Fig.14). Promoter 
analysis studies of another set of estrogen responsive genes have identified 
another cis-element that is required for estogenic-inducibility of these genes. 
This GC-rich site (Sp1-site) has been shown to bind the specificity transcription 
factor Sp1 (334-335). Studies in this laboratory have identified two types of 
promoters in which GC-sites are important for estrogen action. First type 
contains Sp1-site in addition to ERE-1/2 site. In this type of promoter both sites 
are essential for estrogen inducibility. The mechanism of transactivation requires 
DNA-binding of ER and direct or indirect interaction of ER with Sp1. Cathepsin 
D, heat shock protein 27 (HSP27), and transforming growth factor α (TGFα) are 
E2-responsive genes which contains GC-rich/ERE1/2 motif (336-338). 
The second type of Sp1-site containing promoter has only GC-rich sites 
that are essential for estrogen inducibility. The mechanism of estrogen action in 
these promoters involves ER interaction with Sp1 protein but not with DNA and 
ERα/Sp1 mediated transactivation dose not require the DBD of ERα (339).  
Research in this laboratory has provided many examples of E2-responsive 
genes in which only Sp1-sites but not EREs are required for estrogen inducibility 
and these include retinoic acid receptor α1 (RAR α1), C-fos, DNA polymerase 
alpha (DNA pol α), bcl-2, CAD, and VEGF (340-345). 
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Fig. 14. Non-classical mechanisms of ER-mediated transcription. Modified 
from (329,335,339). 
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INHIBITORY AhR-ERα CROSSTALK 
The aryl hydrocarbon receptor (AhR) is a member of basic-helix-loop-
helix –PAS (bHLH-PAS) family of transcription factors. It was first identified in 
mouse liver by showing high affinity and specific binding to radiolabeled 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD) (346). Subsequent studies with [3H]TCDD 
have demonstrated that AhR is widely expressed in mammalian tissues, and it 
was suggested that the broad spectrum of biochemical and toxic responses of 
TCDD is due to  initial binding to the AhR (347). The hepatic AhR is a cytosolic 
protein which exists in a complex with HSP90, co-chaperone p23 and 
immunophilin-like protein XAP2 (also AIP or ARA9) (348-350). XAP2 and p23 
are thought to be required for maintaining the stability of the HSP90 complex. 
After ligand binding the AhR complex undergoes a conformation change 
exposing a nuclear localization sequence (NLS). The complex then translocates 
into the nucleus (351,352), dissociates from the protein complex and binds to a 
closely related nuclear bHLH–PAS protein called Arnt (AhR nuclear 
translocator).  
The AhR:Arnt heterodimeric complex binds to xenobiotic or dioxin 
responsive elements (XREs OR DREs) in the promotor region of several TCDD-
inducible genes (302) and confers TCDD- and AhR-responsiveness upon these 
genes (Fig. 15). The core sequence (GCGTG) is necessary for AhR/Arnt 
binding, and the flanking sequences are essential for transcriptional activation 
(353-356). The presence of the AhR and AhR signal transduction pathway in a 
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diverse range of species, tissues and cell types (357-360) and its ability to act as 
a ligand-dependent transcription factor suggests that many of the toxic and 
biological effects of AhR ligands result from differential alteration of gene 
expression in target tissues/cells. 
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Fig.15. Mechanism of transcriptional activation by AhR. Modified from (361).  
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Phosphatase treatment decreases the binding of the AhR/Arnt heterodimer to 
XRE suggesting that the phosphorylation state of AhR/ARNT complex is 
important for transactivation (362). In 1996, an AhR-related factor which is 
termed as the AhR repressor (AhRR) was cloned (363). The AhRR localizes in 
the nucleus and forms a heterodimer with Arnt. Like the AhR/ARNT complex, 
AhRR/ARNT heterodimer recognizes the DRE, but functions as a transcriptional 
repressor. Therefore, AhRR is considered a negative regulator of AhR by 
competing with AhR for Arnt. Three copies of functional DREs have been found 
in the promoter region of mouse AhRR gene which suggests that AhRR is 
inducible in an AhR-dependent manner (363). These results suggest that the 
AhR and AhRR form a regulatory feedback loop. 
AhR structural features and physiological function. AhR and its 
partner molecule, Arnt, are members of a structurally related gene family which 
exhibit characteristic structural motifs designated as bHLH (basic helix–loop–
helix) and PAS (Per, Arnt/AhR, Sim homology) (364,365) (Fig. 16). These 
proteins contain a bHLH motif in their N-terminal region which is involved in DNA 
binding and in hetero- or homodimerization. The sequence next to C-terminal 
region of the bHLH region constitutes the PAS domain, which was initially 
identified as a conserved sequence among Drosophila PER, human ARNT and 
Drosophila SIM proteins. The PAS domain contains two imperfect repeats of 50 
amino acids, PAS A and PAS B, and is considered to function as an interactive 
surface for hetero- or homodimer formation. The ligand binding domain of AhR 
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has been shown to overlap in part with the PAS B region, and also with the 
binding site for HSP90 which keeps AhR structurally competent to bind a ligand 
(366). In addition to the PAS B region, HSP90 interacts with the bHLH region to 
mask the nuclear localization signal (NLS) of AhR, resulting in the cytoplasmic 
maintenance of the hepatic AhR. Binding of ligands to AhR protein results in 
conformational changes of the HSP90/AhR complex to expose the NLS of AhR, 
leading to nuclear translocation of the complex (367). In addition, AhR contains 
a nuclear export signal (NES) in its second helix of the bHLH domain (368,369). 
This NES is necessary for the nuclear export of the AhR protein followed by 
proteasome degradation. 
 In mouse models where the AhR is genetically disrupted there was no 
embryonic lethality and AhR-null mice were born in normal Mendelian genetics. 
(370-372). Nevertheless, the growth rate of the AhR-null mice was significantly 
retarded as compared with wild type mice for the first 3 weeks of life, and the 
mutant mice were defective in liver and immune system development (372). 
Several studies have reported that adult AhR-null mice have many defects such 
as retinoid accumulation in liver and abnormal hepatic and kidney vascular 
structures (373,374). It has also been reported that female AhR-null mice have 
difficulty in maintaining conception, lactation, and rearing pups to weaning (375).  
The AhR knock out mice are resistant to the multiple tissue-specific toxin and 
biochemical responses induced by TCDD this includes the induction of CYP1A1, 
CYP1A2 and CYP1B1. 
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 Fig. 16. Structural features of AhR. Modified from (361). 
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AhR-null mice are also resistant to procarcinogens that are metaboloically 
activated by CYP1A1/1A2 (370,376) 
 AhR ligans are structurally diverse compounds from both synthetic 
and naturally sources. Halogenated aromatic hydrocarbon (HAHs)   (such as the 
polychlorinated dibenzo-p-dioxins (PCDDs), dibenzofurans and biphenyls and 
related chemicals) and the polycyclic aromatic hydrocarbon (PAHs) (such as 
benzo(a)pyrene, 3-methylcholanthrene, benzoflavones, rutacarpine alkaloids, 
aromatic amines and related chemicals) are the most extensively studied 
classes of AhR ligands ( 302,377-381). HAHs have a relatively high binding 
affinity for the AhR (in the pM to nM range) whereas the PAHs have a 
significantly lower affinity (in the high nM to µM range). Structure–activity 
relationship studies with different AhR ligands have shown that the AhR binding 
pocket can accept planar ligands with maximal dimensions of 14×12×5 Ao. 
Thermodynamic and electronic properties of the ligands are also important 
factors that determined binding affinity (302,377-381). 
TCDD is a high affinity AhR-ligand that has been used as a mechanistic 
probe for investing AhR-mediated mechanisms. TCDD is a highly toxic 
compound that induces various drug-metabolizing enzymes and causes 
hepatocarcinogenic responses in rodent models (382). The effects of TCDD and 
related compounds vary widely according to species, sex, age and strain of the 
animal studied.  TCDD toxicity in humans is sometimes seen as acne-like 
problems on the skin or a wasting syndrome (383). TCDD is also a prototypical 
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endocrine disruptor that directly or indirectly modulates multiple endocrine 
signaling pathways. For example TCDD induce toxicities resemble those 
observed for thyroid dysfunction. Several studies have shown that animals 
treated with TCDD have decreased circulating thyroid hormone (T4) level. This 
decrease is linked to induction of glucuronyl transferase activity by TCDD and 
subsequent increased formation and excretion of T4 glucuronides (384,385). 
TCDD also modulates tissue and serum distribution of retinoids in laboratory 
animals. For example, TCDD significantly decreases retinoid levels in the rodent 
liver and this could affect retinoid signaling pathways (386). TCDD also affects 
steroidgenesis in vitro and in laboratory animals’ species (386-390) in a manner 
that may contribute to the profound demasculinization and feminization of rats 
exposed in utero to TCDD (391). 
Antiestrogenic activity of AhR agonists. Several epidemiological 
studies have shown that AhR ligands exhibit antiestrogenic /antitumogenic 
activity. For example women accidentally exposed to TCDD in Seveso, Italy 
exhibit decreased incidence of two estrogen-dependent tumors, namely breast 
and endometrial cancers (392). Another study has shown that cigarette smoking 
protects against uterine cancers (393,394) and this is possibly because cigarette 
smoke condensate contains PAHs and other AhR active compounds. 
Research in this laboratory has extensively investigated and confirmed this 
antiestrogenic/antitumorgenic activity of TCDD and other AhR ligands in rodent 
and in breast cancer cell line models, where TCDD not only inhibits cell 
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proliferation, but also antagonizes the E2-induced expression of various genes 
including cathepsin D, pS2, c-fos, HSP27, TGFα and PR (336,395-399).  
Although TCDD is useful as a mechanistic probe for investigating the 
mechanisms of AhR-mediated antiestogenicity, the potential toxicity of TCDD, 
especially in liver, precludes the use of this compound for treatment of breast 
cancer.  A new class of compounds called selective AhR modulators (SAhRMs) 
have been developed and tested in this laboratory as potential treatment option 
for E2-dependent breast and endometrial cancers in women.  Two such classes 
of SAhRMs include 6-methyl-1,3,8,-trichlorodibenzofuran (6-MCDF) and its 
related alkyl-polychloro dibenzofurans, and diindolylmethane (DIM) and its 
related ring substituted  DIMs.  DIMs are condensation products of indole-3-
carbinol (I3C) a major chemoprotective phytochemical in cruciferous vegetables 
(400,401) (Fig. 17). 
 There are four possible mechanisms that have been proposed for 
inhibitory AhR- ER crosstalk (Fig. 18). Several studies showed that treatment of 
breast cancer cells with AhR agonists cause a depletion of estrogen (402-404) 
through induction of CYP 1A1 and CYP 1B1 and subsequent oxidative 
metabolism of estrogen (mechanism A). However, several SAhRs have been 
shown to inhibit cells and tumor growth without CYP1A1 induction (336,405-
408). Another in vivo study has shown that treatment with TCDD did not affect 
the level of circulating estrogens (409) suggesting that E2 depletion may not be 
necessary for inhibitory AhR/ER crosstalk. Competition for the transcription 
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factors has also been proposed as a possible mechanism for inhibitory AhR/ER 
crosstalk (mechanism B). This mechanism was supported by a study in which 
estrogen treatment inhibited induction of CYP1A1 by TCDD and this was linked 
to competition for limiting level of coregulatory proteins (410). Another study has 
shown that both ER and AhR interact with common coactivator and corepressor 
proteins and these may be preferentially sequestered by the liganded AhR 
complex to inhibit efficient estrogen transactivation (411). 
 The AhR/ARNT complex may bind directly to the inhibitory DRE 
(iDRE) sequences in selected estrogen-responsive gene promoters (mechanism 
B). Promoter analysis of the cathepsin D gene promoter has identified iDRE 
within upstream estrogen responsive GC (N) 19 ERE1/2 motif. The importance of 
this iDRE in mediating inhibitory AhR/ER crosstalk has been confirmed in 
transactivation studies and in gel mobility assays (336). Functional iDREs have 
been identified in several estrogen responsive gene promoters including pS2, 
HSP27, and c-fos where the mechanism of action in these genes is promoter 
specific (396,398,399). The ligand-activated AhR also induces proteasome-
dependent degradation of ER (mechanism D) and in combination with E2; ER 
may be below the levels required for hormone-induced transactivation. A recent 
study in this laboratory has shown that decreased protein levels of AhR and ER 
were observed in different breast cancer cells after treatment with TCDD 
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    Fig. 17. Chemical structure of TCDD and selected SAhRMs. 
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 Fig. 18. Suggested mechanisms of inhibitory AhR/ER crosstalk.  
(A) Estrogen depletion. (B) Competition for common coactivators and transcription 
factors. (C) Presence of functional iDRE in the promoter region. (D) Proteosome-
dependent degradation of ER. Modified from (412). 
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and this protein degradation was blocked by proteasome but not protease 
inhibitors (413). It is possible that inhibitory AhR/ER crosstalk is a multipathway 
mechanism, in which two or more pathways (Fig. 18) are involved in block 
hormone-dependent induction of specific genes. 
 
PANCREATIC CANCER 
An estimated 29,200 new cases of pancreatic cancer will be diagnosed in 
year 2001 in the United States of America (414) and over the past few decades 
there has not been a significant change in the incidence of this disease. The 
five-year survival for pancreatic cancer patient is only 4–5%, making pancreatic 
cancer the fourth leading cause of cancer mortality in the United States (415). 
Due to a lack of specific symptoms and limitations in diagnostic methods, the 
disease often eludes detection during its formative stages. A recent National 
Cancer Institute group (known as a Progress Review Group) articulated the 
crucial questions and challenges facing the field and provided recommendations 
to address key unmet needs in the clinical and basic research arenas (416). 
The pancreas is a grayish pink-colored gland about 12 to 15 cm long, weighing 
about 60 g. It resembles a fish with its head and nieck in the C-shaped curve of 
the duodenum (Fig. 19). The pancreas is composed of two different types of 
glandular tissue, one exocrine and one endocrine. Most of the tissue exocrine, 
with a compound acinar arrangement where the cells are in a grapelike 
formation and they release their secretions (pancreatic juice) into a microscopic 
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duct within each unit. Pancreatic juice contains different digestive enzymes. All 
of them are secreted as zymogens (inactive enzyme). Trypsin (protein digesting 
enzyme) is secreted as trypsinogen which is converted to active trypsin by 
enterokinas of the intestinal lumen. Trypsin can then activate other enzymes 
such as chymotrypsin (another protein digesting enzyme), lipase (lipid digesting 
enzyme), nuclease (RNA and DNA digesting enzyme) and amylase (a starch 
digesting enzyme) (122). Cells along the exocrine ducts of the pancreas also 
have a secretory function; they produce sodium bicarbonate which keeps the pH 
of the body balanced and avoids homeostasis stability loss.  Between the 
exocrine units of the pancreas lie clusters of endocrine cells called pancreatic 
islets (Fig. 19).   They are about 2% of the total mass of the pancreas and each 
islet contains a combination of four primary types of endocrine cells. One type of 
these cells is the alpha cell, which secrets the hormone glucagon. Beta cells 
secret the hormone insulin, delta cells secret the hormone somatostatin and 
pancreatic polypeptide cells (PP) secret pancreatic polypeptides (122). 
Risk factors for pancreatic cancer. The etiology of pancreatic 
adenocarcinoma remains poorly defined, although important clues of disease 
pathogenesis have emerged from epidemiological and genetic studies. 
Pancreatic adenocarcinoma is a disease that is associated with advancing age 
(rare before the age of 40) (417), it culminates in a 40-fold increased risk by the 
age of 80.   
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Fig. 19. Structure of human pancreas. Modified from (122). 
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Cigarette smoking is the most prominent and consistent risk factor in pancreatic 
cancer (417-421). The risk increases with the increasing of cigarette smoking. 
The highest risk ratio, 10-fold, has been seen in males who smoke more than 40 
cigarettes daily (419). The second important risk factor associated with 
pancreatic cancer is diet, although the data for dietary effects are limited (417-
419). Generally, increased risks have been associated with animal protein and 
fat consumption, and decreased risks, with intake of vegetables and fruits. 
Methods of food preparation evaluated in several studies showed an association 
of increased pancreatic cancer risk with high consumption of salt, smoked meat, 
dehydrated food, fried food, and refined sugar (422-425). An inverse association 
was found with the consumption of food containing no preservatives and 
additives, raw food, food prepared by high-pressure cooking, and food prepared 
in an electric or microwave oven (422-425).  
Occupational exposure to some carcinogens is considered the third 
suspected risk factor for pancreatic cancer. High rates of pancreatic cancer have 
been reported in workers in certain occupations, such as chemists, coal and gas 
exploration workers, those in metal industries, leather tanning, textiles, 
aluminum milling, and transportation (426-427). Suggestive findings exist in 
relation to the products of incomplete combustion, (428,429) to certain 
pesticides (430,431) and to other chemicals and chemical processes. Other 
suggested risk factors for pancreatic cancer include some medical conditions, 
chronic pancreatitis, and inherited susceptibility is another suggested risk factor 
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for pancreatic cancer (417-419). On the genetic level, there is an increased risk 
in relatives of pancreatic adenocarcinoma patients (approximately three fold) 
and it is estimated that 10% of pancreatic cancers are due to an inherited 
predisposition (432). However, unlike familial cancer syndromes for breast, colon 
and melanoma, pancreatic adenocarcinoma linked to a familial setting has a 
lower penetrance (<10%) and maintains a comparable age of onset to sporadic 
cases in the general population. Among the genetic lesions that are linked to 
familial pancreatic adenocarcinoma are germline mutations in CDKN2A (which 
encodes two tumor suppressors (INK4A and ARF), BRCA2, LKB1 and MLH1 
(433). Additional genetic defects seem to be operative in rare families in which 
pancreatic cancer is inherited as an autosomal-dominant trait with very high 
penetrance (432). A pancreatic cancer syndrome (so far identified in a single 
family) has been linked to chromosome 4q32-34 (434) and is associated with 
diabetes, pancreatic exocrine insufficiency and pancreatic adenocarcinoma, with 
a penetrance approaching 100%. Patients with hereditary pancreatitis, which is 
associated with germline mutations in the cationic trypsinogen gene PRSS1, 
experience a 53-fold increased incidence of pancreatic adenocarcinoma 
(435,436). 
Molecular genetics of pancreatic adenocarcinoma. The identification 
of signature gene mutations in pancreatic adenocarcinoma was recognized as a 
valuable starting point, for analyzing the genesis and development of this 
disease. Molecular and pathological analysis of evolving pancreatic 
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adenocarcinoma has revealed a characteristic pattern of genetic lesions. 
Understanding how these signature genetic lesions (mutations of KRAS, 
CDKN2A, p53, BRCA2 and SMAD4/DPC4) contribute to the biological 
characteristics and evolution of this disease is of great interest. The progression 
model for colorectal cancer has served as a template for relating sequential, 
defined mutations to increasingly atypical growth states (437). It is believed that 
the pancreatic-duct cell is the progenitor of pancreatic adenocarcinoma. The 
increased incidence of abnormal ductal structures (now designated pancreatic 
intraepithelial neoplasia, PanIN) (417,438) in patients with pancreatic 
adenocarcinoma, and the similar spatial distribution of such lesions to malignant 
tumors, are consistent with the hypothesis that such lesions might represent 
incipient pancreatic adenocarcinoma (439). 
 Histologically, PanINs show a spectrum of divergent morphological 
alterations relative to normal ducts that seem to represent graded stages of 
increasingly dysplastic growth (440). A growing number of studies have 
identified common mutational profiles in simultaneous lesions, providing 
supportive evidence of the relationship between PanINs and the pathogenesis of 
pancreatic adenocarcinoma. Common mutation patterns in PanIN and 
associated adenocarcinomas have been reported for KRAS and for CDKN2A 
(441). In addition, similar patterns of loss of heterozygosity (LOH) at 
chromosomes 9q, 17p and 18q (harbouring CDKN2A, p53 and SMAD4, 
respectively) have been detected in coincident lesions and studies have 
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consistently shown an increasing number of gene alterations in higher-grade 
PanINs (442-445).  
KRAS - Activating KRAS mutations are the first genetic changes that are 
detected in the progression series, occurring occasionally in histologically 
normal pancreas and in about 30% of lesions that show the earliest stages of 
histological disturbance (446). KRAS mutations are found in nearly 100% of 
pancreatic adenocarcinomas; they seem to be a virtual rite of passage for this 
malignancy (447). WAF1 (also known as p21 and CIP1) seems to be 
coordinately induced with the onset of KRAS mutations, perhaps due to 
activation of the mitogen-activated protein kinase (MAPK) pathway (448). 
Activating mutations of RAS-family oncogenes lead to induction of proliferation, 
survival and invasion through the stimulation of several effector pathways (449). 
CDKN2A - The inheritance of mutant CDKN2A tumor-suppressor gene 
confers a 13-fold increased risk of pancreatic cancer (450,451). CDKN2A loss is 
generally seen in moderately advanced lesions that show features of dysplasia. 
Loss of CDKN2A function (caused by mutation, deletion or promoter 
hypermethylation) occurs in 80–95% of sporadic pancreatic adenocarcinomas 
(447). The role of CDKN2A has attracted the attention of many researchers as 
this tumor-suppressor locus, at 9q21, encodes two tumor suppressors (INK4A 
and ARF) via distinct first exons and alternative reading frames in shared 
downstream exons (452). Given this physical juxtaposition and frequent 
homozygous deletion of 9p21 (in ~40% of tumors), many pancreatic cancers 
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sustain loss of both the INK4A and ARF transcripts, thereby disrupting both the 
retinoblastoma (Rb) and p53 tumor-suppression pathways. INK4A inhibits 
CDK4/CDK6-mediated phosphorylation of RB, thereby blocking entry into the S 
(DNA synthesis) phase of the cell cycle; ARF stabilizes p53 by inhibiting its 
MDM2-dependent proteolysis. INK4A seems to be the more important 
pancreatic cancer suppressor at this locus, as germline and sporadic mutations 
have been identified that target INK4A, but spare ARF (447,453,454). Loss of 
INK4A usually occurs only in later stages of pancreatic neoplasia. 
 p53 - The p53 tumor-suppressor gene is mutated, generally by missense 
alterations of the DNA- binding domain in more than 50% of pancreatic 
adenocarcinomas (447). p53 mutations arise in later-stage PanINs that have 
acquired significant features of dysplasia, reflecting the function of p53 in 
preventing malignant progression. p53 loss probably facilitates the genetic 
instability that characterizes this malignancy. These tumors have profound 
aneuploidy and complex cytogenetic rearrangements, as well as intratumoral 
heterogeneity, which is consistent with ongoing genomic rearrangements 
(455,456). Cytogenetic studies indicate that telomere dynamics might contribute 
to this genomic instability (457,458). 
BRCA2 - Although inherited BRCA2 mutations are typically associated 
with familial breast and ovarian cancer syndrome, it is also a significant risk for 
development of pancreatic cancer. Goggins and coworkers (459) has found that 
approximately 17% of pancreatic cancers that occur in a familial setting have 
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mutations in this gene. Loss of wild-type BRCA2 is a late event in those 
individuals who inherit germline heterozygous mutations of BRCA2, which is 
restricted to severely dysplastic PanINs and adenocarcinomas (459). BRCA2 is 
necessary for the maintenance of genomic stability by regulating the 
homologous-recombination-based DNA-repair processes; consequently, BRCA2 
deficiency in normal cells results in the accumulation of lethal chromosomal 
aberrations (460). The loss of p53 and BRCA2, and the detection of abnormal 
mitosis and severe nuclear abnormalities in PanIN-3 lesions, indicate that 
genomic instability is initiated at this stage of tumor progression. 
SMAD4/DPC4 - Loss of SMAD4/DPC4 is a frequent alteration in 
pancreatic adenocarcinoma (461); SMAD4/DPC encodes a transcriptional 
regulator that is a keystone component in the transforming growth factor-β 
(TGF-β) - family signaling cascade (462). The pathogenic role of SMAD4 
inactivation is strongly supported by the identification of inactivating intragenic 
lesions of SMAD4 in a subset of tumours. SMAD4 seems to be a progression 
allele for pancreatic adenocarcinoma and its loss occurs only in later-stage 
PanINs (443,444). Loss of SMAD4 is considered a predictor of decreased 
survival for pancreatic adenocarcinoma patients (445), and this is consistent with 
its role in disease progression. The mechanism by which SMAD4 loss 
contributes to tumorigenesis is likely to involve its role in TFG-β-mediated 
growth inhibition. One study showed that TGF-β inhibits the growth of most 
normal epithelial cells by either blocking the G1–S cell-cycle transition or by 
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promoting apoptosis (462). The cellular responses to TGF-β are partially, but not 
exclusively, SMAD4-dependent (463) and, correspondingly, pancreatic 
adenocarcinomas show a degree of TGF-β resistance. 
Vascular Endothelial Growth Factor and pancreatic cancer. In 
addition to all previous genetic lesions, the progressive growth of pancreatic 
cancer depends on vascularization from the surrounding stromal tissue into the 
tumor tissue. Vascular endothelial growth factor (VEGF) and its receptors 
(VEGFRs) play a critical role in tumor angiogenesis, and VEGF and/or VEGFRs 
are over expressed in multiple tumors including pancreatic cancer (464,465). 
Both physiological and pathological angiogenesis are regulated by vascular 
endothelial growth factors (VEGFs) and their receptors. There are six members 
in the VEGF family which includes VEGF-A, placenta growth factor PlGF, VEGF-
B, VEGF-C, VEGF-D and orf virus VEGF also called VEGF-E. These factors are 
secreted as dimeric glycoproteins, all of which contain the characteristic 
regularly-spaced eight cysteine residues, the so-called cystine knot motif. VEGF 
forms an antiparallel homodimer, which is covalently linked by two disulphide 
bridges.  The receptor-binding face of this dimer consists of residues presented 
from both sub-units and are located at each pole(466).Like most growth factors, 
VEGF utilizes predominantly hydrophobic interactions for binding to both of its 
receptors (466,467). 
VEGF-A is the original VEGF and the major regulator of both 
physiological and pathological neovascularization (468). It has been shown that 
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VEGF has a pronounced mitogenic and angiogenic activities in a variety of in 
vivo models. VEGF stimulates endothelial cells to degrade extracellular matrix 
ECM, migrate and form tubes in vitro (469). Genetic engenering studies have 
shown that embryos lacking a single VEGF allele are growth retarded, exhibit 
developmental anomalies in both the central nervous system and the 
cardiovascular system, and die between E11 and E12. (470,471). Although 
VEGF mRNA is still expressed in heterozygous embryos, angiogenesis and 
blood-island formation are impaired which suggests that embryonic vessel 
formation is VEGF dose-dependent. Gene knock out studies had shown that 
other members of the VEGF gene family are apparently not equally important for 
vascular development and survival. For example, PlGF knockout mice have 
impaired wound healing processes, but they are viable and fertile (472). Many 
isoforms of VEGF have been shown to be produced by alternative exon splicing 
of the VEGF gene. Human VEGF is expressed as a combination of 121, 145, 
165, 189 or 206 amino acid isoforms.  
The action of VEGF is mediated by VEGF receptors (VEGFRs). These 
receptors transducer signals for mediating endothelial cell proliferation, 
migration, and organization into functional vessels. At least three different 
VEGFR genes have been identified: VEGFR-1 (Flt-1), VEGFR-2 (KDRrFlk-1) 
and VEGFR-3 (FLT-4). These receptors form a subfamily within the platelet-
derived growth factor PDGF receptor class. All three consist of seven 
immunoglobulin-homology Ig domains, a transmembrane sequence and an 
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intracellular portion containing a split kinase domain (473). During 
embryogenesis, the VEGFRs are expressed in vascular endothelial cells from 
the stage of blood island formation. In adult tissues VEGFR-1 and VEGFR-2 
localize to vascular endothelial cells, whereas VEGFR-3 is expressed mainly in 
the lymphatic endothelium (474). The ligand specificities of the receptors are 
different. For example VEGFR-1 binds VEGF, VEGF-B and PlGF, VEGFR-2 
binds VEGF, VEGF-C, VEGF-D and the orf virus VEGF, whereas VEGFR-3 
binds VEGF-C and VEGF-D (464). Ligand binding induces receptor dimerization 
and subsequent auto/transphosphorylation and the second Ig domain of 
VEGFR-1 is critical for specific binding of VEGF (475,476). In 1998 another 
VEGFR was identified, namely neuropilin-1 NP-1 which functions as a cell 
surface glycoprotein that mediates axonal repulsion during development. It has 
been identified as an isoform-specific VEGF165 and PlGF-2-receptor (477,478). 
NP-1 enhances the mitogenic effects of VEGFR-2 and may have a signaling 
function of its own. Studies in which VEGFR genes have been genetically 
disrupted have shown indispensable, but distinct roles of VEGFRs in 
vasculogenesis and angiogenesis during embryonic development. In mice 
homozygous for a disrupted VEGFR-1 allele, the endothelial cells 
hyperproliferate and fail to organize into normal vascular channels, leading to 
embryonic death (479). Unlike VEGFR1 knockout mice, the VEGFR-2 knockout 
mice display defects in yolk sac blood-island formation and vasculogenesis and 
hematopoietic cells fail to develop, resulting in death in utero (480). This 
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suggests that VEGFR-2 is necessary for the differentiation and proliferation of 
endothelial and hematopoietic cells. VEGFR-3 knockout mice exhibit a failure in 
remodeling the primary vascular network, abnormal endothelial organization and 
embryonic death (481). Thus, VEGFR-3 seems to be necessary for the 
maturation of the vascular plexus into a hierarchy of large and small vessels. At 
the same time there were no major defects occurred in the differentiation of 
endothelial cells, formation of primary vascular networks or vascular sprouting. 
All these differences distinguish VEGFR-3 functions from those of the other 
VEGF receptors (481). 
Mechanism of VEGF gene regulation - Transcription of VEGF mRNA is 
induced by different condition and by multiple factors (Table VII).  Sp/KLF family 
members play a role in angiogenesis and members of this family are involved in 
regulating of VEGF expression (482). Notably, Sp1 GC-rich sites  are important 
elements in VEGF promoters (483). The relevance of Sp factors to cancer-
related angiogenesis is highlighted by the following findings: First, Sp1 site  
decoy oligonucleotides inhibit expression of VEGF in lung cancer and 
glioblastoma cells (484). Secondly, TNFα and basic FGF upregulate Sp1 levels 
in glioma cells and this upregulation correlates temporally with VEGF synthesis 
(485), Thirdly, mithramycin, an inhibitor of Sp1 DNA-binding, blocks the 
induction of VEGF and its receptors by basic FGF and/or TNFα (485,486), 
Fourthly, downregulation of VEGF in von Hippel-Lindau disease-associated 
tumors is related to the ability of the VHL tumor suppressor to bind to and 
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inactivate Sp1 (487). Fifth, Sp1 antisense oligonucleotides block TNFα induction 
of VEGF and tubular morphogenesis in vascular endothelial cells (488). Finally, 
growth stimulation of vascular endothelial cells leads to a Ras-dependent 
upregulation in the binding of Sp1 and other Sp1 site -binding proteins to the 
cyclin D1 promoter without changes in Sp1 levels (489). 
 
 
 
Table VII 
Regulatory factors of VEGF gene expression. 
Condition or Factor Reference  
Hypoxia  (490-493) 
Hypoglycemia (494,495) 
Growth factors (496-498) 
Hormones (493,499,500) 
Suppressors p53 (501) 
p73 (502) 
V-src oncogene (503) 
VHL tumor suppressor gene product (487) 
Ultraviolet radiation (504,505)  
Mechanical stress (506,507) 
Acidic growth conditions (508-510) 
Cytokines (511,512) 
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In pancreatic cancer cells, analysis of the VEGF gene promoter showed 
that basal expression of VEGF was dependent on proximal GC-rich motifs that 
bind Sp1 protein, thus linking VEGF and Sp factors as potential key factors in 
the growth and metastasis of this cancer. In addition, the expression of VEGF is 
correlated with the expression of Sp1 and both proteins are overexpressed in 
the same cancer cell line and tumors (297). 
Research in this laboratory has demonstrated that constitutive and 
hormonal regulation of several genes, including those involved in 
purine/pyrimidine synthesis and cell cycle progression, are dependent on GC-
rich promoter elements that bind Sp1 or ERα/Sp1 (339,340-342,513,514). In 
breast and endometrial cancer cells basal and hormone-induced VEGF 
expression requires the GC-rich proximal promoter region. However, activation 
of VEGF is dependent on both cell context and Sp factors protein expression. 
For example, estrogen-dependent down regulation of VEGF in HEC1A 
endometrial cancer cell is dependent on ERα/Sp3 interaction with proximal GC-
rich sites, whereas induction of VEGF by estrogen in ZR75 breast cancer cells 
requires ERα/Sp1 and ERα/Sp3 interaction with same GC-rich motifs (345,515). 
Pancreatic cancer treatment. At present radical surgery is the only 
curative therapy for pancreatic cancer. However, only 5–25% of the patients 
present with potentially resectable disease (415). Approximately 50% of patients 
with pancreatic cancer have locally advanced disease, which is nonresectable 
because of involvement of the celiac axis, superior mesenteric artery, or vein. 
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Thirteen to twenty months is the median survival time after pancreatic resection 
with less than 10–20% of patients being long-term survivors. (415,516).  
Chemotherapy - Although cytotoxic chemotherapy has a very low 
objective response rate, it is still considered the conventional treatment for 
advanced pancreatic cancer. The most widely used drugs included 5-fluorouracil 
(5-FU), mitomycin-C, streptozocin, doxorubicin, and nitrosoureas (Table VIII).  
5-FU was the most active and best tolerated of these agents. The response 
rates to 5-FU from studies in the precomputer tomography era, were 
approximately 15 to 25% but with negligible impact on survival or disease-
related symptoms. (517,518). Studies of chemotherapy in pancreatic cancer 
have demonstrated that single agents have limited anti-tumor activity with a 
minimal impact on overall survival. Therefore, there has been interest in studying 
combination therapies in pancreatic cancer. Table IX shows fluoropyrimidine-
based combinations and Gemcitabine-based doublet that has been used in 
pancreatic cancer treatments. 
Chemotherapy plus radiation therapy - In patients with locally advanced 
pancreatic cancer, therapy is directed to achieve both local control of disease as 
well as the treatment of systemic disease. A similar consideration is made in 
patients undergoing therapy after resection in the adjuvant setting. 
Chemotherapeutic agents have been used as radiosensitizers in pancreatic 
cancer since it is a relatively radio-resistant tumor. 
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Table VIII 
Single chemotherapy used to treat pancreatic cancer. 
Treatment  Example Refeference 
Nucleoside analogue  
 
Gemcitabine 519 
Oral Fluoropyrimidines 
 
Capecitabine  520 
Topoisomerase inhibitors 9-nitrocamptothecin (9NC)  
Exatecan 
521,522  
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Table IX 
Combination therapy used to treat pancreatic cancer. 
Type  Combination Reference 
Fluoropyrimidine-based  
Combination 
FAM (5FU, doxorubicin and 
mitomycin)  
 
SMF (streptozocin, mitomycin 
and 5FU) 
(523,524) 
Gemcitabine-based  
doublet  
Gemcitabine/cisplatin  
 
Gemcitabine/oxaliplatin 
 
Gemcitabine/docetaxel 
 
Gemcitabine/5-FU (CIVI) 
 
Gemcitabine/5-FU (bolus) 
 
Gemcitabine/epirubicin 
 
Gemcitabine/irinotecan 
 
Gemcitabine/cisplatin/epirubicin
/ 5-FU 
 
(525,526) 
 
(527) 
 
(528,529) 
 
(530,531) 
 
(532) 
 
(533) 
 
(534,535) 
 
(536) 
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Several randomized studies have suggested an improvement in survival 
for patients treated with modality therapy combining 5-FU-based chemotherapy 
and radiation (537-539). The role of radiation therapy in this setting remains 
controversial. Moreover, the use of ineffective chemotherapy as a radiosensitizer 
resulted in the lack of control of disease outside the pancreatic bed (540) Newer 
chemotherapeutic regimens with better systemic activities are in clinical trials to 
improve local and systemic tumor control. Gemcitabine has exhibit potent radio-
sensitizing properties in preclinical studies (541). Radiation enhancement may 
be achieved by doses lower than those resulting in cell kill. 
Novel systemic therapies - The benefit of chemotherapy, radiation, and 
surgery for patients with pancreatic cancer has been very modest. In an attempt 
to develop more effective systemic therapies for this disease, many researchers 
are focusing on new therapeutic strategies. A better understanding of the 
molecular mechanisms of cancer has identified dysregulated fundamental 
processes in malignant cells. These include molecular aberrations involving cell 
cycle control, signal transduction, apoptosis, angiogenesis, and extracellular 
matrix invasion. A number of drugs have been designed to target these 
molecules with high specificity. In general, two overlapping strategies have been 
adopted for development of new drug for pancreatic cancer: Drugs have been 
developed to target molecules that are critical for cell proliferation, differentiation, 
and induction of apoptosis. Other strategies to sensitize pancreatic tumor cells to 
conventional cytotoxic drugs by circumventing drug resistance and reducing the 
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apoptotic threshold of the pancreatic cancer cells are being persued. Table X 
summarizes some suggested targets for novel therapies in pancreatic cancer. 
Some of the drugs are already in clinical trials as single agents or in combination 
with chemotherapy.  
 
 
 
Table X 
Suggested targets for novel therapies in pancreatic cancer. 
Molecular Target Examples of Therapeutic 
Agent 
Reference 
Ras 
 
 
Growth factor receptors 
 
 
Angiogenesis 
  
 
Cell signaling molecules 
 
 
COX-2 enzyme 
 
 
Matrix metalloproteinase 
 
 
Tumor suppressor genes 
 
Farnesyl transferase 
inhibitors (e.g. R115777) 
 
 Monoclonal antibodies 
(e.g., C225, trastuzamab) 
  
VEGF inhibitors (e.g. 
SU5416, TNP 470) 
  
PI3-K/AKT inhibitor (eg. 
LY294002) 
  
COX-2 inhibitors (e.g., 
celecoxib, rofecoxib) 
 
MMP inhibitors 
(e.g.marmastat) 
 
Gene replacement therapy 
(e.g., p53, p16) 
 
 
(542) 
 
 
(543,544) 
 
 
(545) 
 
 
(546) 
 
 
(547) 
 
 
(548) 
 
 
(549,550) 
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RESEARCH OBJECTIVES  
Several genetic approaches have been used to inhibit gene expression. 
For example gene targeting by homologous recombination is commonly used to 
determine gene function in mammals, but this is a costly and time-consuming 
process. In addition, the function of targeted genes might not be determined by 
this approach due to lethal and redundant phenotypes. Alternatively, the function 
of many genes can be determined by ribozyme and antisense technologies. 
Although successful in some situations, these techniques have been difficult to 
apply universally.  
siRNA-directed silencing has created a revolution in somatic cell genetics, 
allowing inexpensive and rapid analysis of gene function in mammals. RNAi 
technology can be applied to many cell types and because the genome 
sequence for human is available, RNAi technology has the potential to 
determine the function of each gene that is expressed in a cell-type or pathway 
specific manner. siRNA is now being used as a tool in almost every field of 
biomedical research and one of the most dynamic and exciting applications is in 
cancer research for identifying and validating gene function or oncogenic 
properties or  exploring the therapeutic potential for siRNA . This research will 
focus on applications of the siRNA technique for gene silencing to investigate 
several pathways associated with the growth of breast, liver and pancreatic 
cancer cell lines.  
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Objective 1. Sp1 interacts with GC-rich binding sites in multiple gene 
promoters to regulate gene expression. There are an increasing number of 
studies showing that Sp1 also interacts with other nuclear proteins including 
promoter-bound transcription factors and nuclear receptors such as ERα (eg. 
Sp1/ERα). Research in this laboratory has focused on the molecular mechanism 
of the ligand-dependent activation of ERα/Sp1 in breast and endometrial cancer 
cells lines. The first objective is to investigate the role of Sp1 protein in mediating 
hormone-responsivness in MCF-7 and ZR 75 cells using sequence-specific 
siRNA targeted to Sp1 mRNA. 
Objective 2. TCDD and related AhR agonist inhibit expression of 
estrogen-induced genes and proliferation of ER-positive breast cancer cells. In 
AhR-deficient rodent liver cancer cells, AhR expression was associated with 
enhanced cell proliferation. The transcriptionally active AhR:ARNT complex  
interacts with inhibitory DREs in some gene promoter however other  E2- 
responsive genes that do not contain functional inhibitory DREs are inhibited by 
AhR agonist. The molecular mechanisms of inhibitory AhR-ERα crosstalk maybe 
complex and dependent on multiple factors including cell context. The second 
objective is to investigate AhR-ERα crosstalk and other AhR-mediated pathways 
in breast and hepatic cancer cells using RNAi technology. 
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Objective 3. Pancreatic adenocarcinoma is a highly aggressive 
neoplasm that is frequently not detected in patients until the tumor is advanced 
or metastatic. Prevention of pancreatic cancer is difficult because little is known 
about etiology. VEGF and VEGFRs play a major role in tumor angiogenesis in 
addition, VEGF and/or its receptors VEGFRs are over expressed in pancreatic 
cancer. Sp1 protein is expressed in pancreatic tumors and in pancreatic cells in 
culture, and it has been suggesting that Sp1 plays an important role in regulation 
of vascular endothelial growth factor (VEGF) expression in Panc-1 and other 
pancreatic cancer cells.  Sp family proteins play a complex role in regulation of 
cancer cell growth and expression of genes required not only for growth but also 
apoptosis and angiogenesis.  The third objective is to use RNA interference to 
investigate the role of Sp proteins in VEGF expression and cell cycle 
progression of selected pancreatic cancer cells. 
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SMALL INHIBITORY RNA DUPLEXES FOR Sp1 mRNA BLOCK 
BASAL AND ESTROGEN-INDUCED GENE EXPRESSION AND 
CELL CYCLE PROGRESSION IN MCF-7 BREAST CANCER 
CELLS * 
 
Sp1 is a member of the Sp and Krüppel-like family of transcription factors 
that bind GC and CACCC boxes to regulate gene expression (222,551,552).  
Sp1 is widely expressed in multiple tissues (553) and targeted disruption of Sp1 
in mice results in retarded development and embryolethality (256).  Sp1 interacts 
with GC-rich "Sp1 binding sites" in multiple promoters to regulate gene 
expression, and there are an increasing number of studies showing that Sp1 
interacts with other nuclear proteins including promoter-bound transcription 
factors to attenuate tissue-specific expression of selected genes (222,551,552).  
For example, Sp1 and NF-Y cooperatively interact to regulate multiple genes 
through NFY-GC-rich motifs and both proteins also physically interact (554-558).  
Sp1 also binds estrogen receptor α (ERα) and other members of the nuclear 
receptor family of transcription factors (339,559-566).   
                                                                                                                  
_____________________ 
* Reprinted with permission from “Small inhibitory RNA duplexes for Sp1 mRNA block basal and 
estrogen-induced gene expression and cell cycle progression in MCF-7 breast cancer cells” by 
Abdelrahim, M., Samudio, I., Smith, R. 3rd, Burghardt, R., and Safe, S. (2002) J. Biol. Chem. 
277, 28815-28822. Copyright 2002 by The American Society for Biochemistry & Molecular 
Biology. 
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Research in our laboratory has focused on the molecular mechanisms of  
the ligand-dependent activation of ERα/Sp1 in breast and endometrial cancer 
cell lines (340-343,383,513,514,567-571). Promoter analysis studies in breast 
cancer cells have identified GC-rich sites required for hormone activation of 
several genes including E2F1, DNA polymerase α, cyclin D1, insulin-like growth 
factor, growth factor binding protein 4, retinoic acid receptor α1, cathepsin D, 
vascular endothelial growth factor, c-fos, heat shock protein 27, bcl-2 , 
thymidylate synthase, and adenosine deaminase (340-343,383,513,514,567-
570).  Studies in other cell lines have also demonstrated a role for ERα/Sp1 
activation of the progesterone receptor, epidermal growth factor receptor, 
telomerase, and receptor for  advanced glycation end products (512,572-574).  
Activation of ERα/Sp1 does not require the DNA binding domain of ERα 
(promoter DNA-independent) and is primarily dependent on activation function-1 
(AF1) of ERα (569), whereas DNA-dependent activation through ER binding to 
estrogen response elements (EREs) is primarily dependent on AF2 of ERα. 
 Recent studies have demonstrated that RNA interference through small 
inhibitory RNAs (iRNAs) targeted to endogenous or heterologous genes can be 
used to suppress intracellular expression of these genes in mammalian cells, 
and this technique is well suited for mechanistic studies on gene/protein function 
(46,67,89,575-578).  This study investigates the role of Sp1 protein in mediating 
hormone-responsiveness in MCF-7 cells using sequence-specific duplexes of 21 
nucleotides targeted to Sp1 mRNA as well as Lamin B1 and the heterologous 
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firefly luciferase gene (GL2) mRNAs.  Transfection of iRNA for Sp1 (iSp1) 
decreases (40-60%) expression of nuclear Sp1 protein in ER-positive MCF-7 
and ZR-75 human breast cancer cell extracts.  In transfected cells, Sp1 protein 
is barely detectable by immunofluorescence, and both basal and estrogen-
inducible transactivation is decreased in cells transfected with iSp1 and a GC-
rich construct.  These data, combined with results showing that iSp1 inhibits 
hormone-induced MCF-7 cell cycle progression from G0/G1 to S phase, 
demonstrate that ERα/Sp1-mediated transactivation plays a major role in ER-
positive breast cancer cell growth. 
 
MATERIALS AND METHODS 
Cell lines, chemicals and biochemicals. MCF-7 and ZR-75 cells were 
obtained from the American Type Culture Collection (ATCC, Manassas, VA).  
DME/F12 with and without phenol red, 100X antibiotic/antimycotic solution, 
propidium idodide, and E2 were purchased from Sigma (St. Louis, MO). Fetal 
bovine serum (FBS) was purchased from Intergen (Purchase, NY) [γ-32P] ATP 
(300ci/mmol) was obtained from NEN Life Science Products (Boston, MA). Poly 
[d(I-C)] and T4-polynucleotide kinase  were purchased from Roche Molecular 
Biochemicals (Indianapolis, IN). Antibodies for proteins were obtained from 
Santa Cruz Biotechnology (Santa Cruz, CA).  The pSp13 construct contains 
three consensus Sp1 binding sites and the pERE3 construct contains three 
EREs.  The oligonucleotides were linked to the bacterial luciferase gene and 
cloned into XP-2 plasmid obtained from ATCC.  Lysis buffer, luciferase reagent,  
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 and RNase were obtained from Promega Corp.  (Madision, WI).  iRNAs were 
prepared by IDT (Coralville, IA) and targeted the coding region 153-173, 672-
694, and 1811-1833 relative to the start codon of GL2, Lamin B1, and Sp1 
genes, respectively.  Single stranded RNAs were annealed by incubating 20 µM 
of each strand in annealing buffer (100 mM potassium acetate, 30 mM HEPES 
buffer at pH 7.4, 2 mM magnesium acetate) for 1 min at 90°C followed by 1 h at 
37°C.  The iRNA duplexes used in this study are indicated below. 
 GL2 5' – CGUACGCGGAAUACUUCGATT 
  TTGCAUGCGCCUUAUGAAGCU – 5' 
 
 LMN 5' – AACGCGCUUGGUAGAGGUGGATT 
  TTUUGCGCGAACCAUCUCCACCU – 5' 
 
 Sp1 5' – AUCACUCCAUGGAUGAAAUGATT 
  TTUAGUGAGGUACCUACUUUACU – 5' 
 
 Transfection of MCF-7 and ZR-75 cells and preparation of nuclear 
extracts. Cells were cultured in 6-well plates in 2 ml DME/F12 medium 
supplemented with 5% FBS.  After 16-20 h when cells were 50-60% confluent, 
iRNA duplexes and/or reporter gene constructs were transfected using 
Lipofectamin Plus Reagent (Life Technology, Carlsbad, CA).  The effects of iSp1 
on hormone-induced transactivation was investigated in MCF-7 cells treated with 
10 nM E2 and cotransfected with pSp13 (500 ng) or pERE3 (500 ng) and ERα 
expression plasmid (200 ng).  Based on results of preliminary studies 0.75 µg 
iRNA duplex was transfected in each well to give a final concentration of 50 nM. 
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Cells were harvested 36-44 h after transfection by manual scraping in 1X lysis 
buffer (Promega).  For whole cell extracts, cells were frozen in liquid nitrogen for 
30 s, vortexed for 30 s, and centrifuged at 12,000 x g for 1 min. Lysates were 
assayed for luciferase activity using luciferase assay reagent (Promega); β-
galactosidase activity was measured using Tropix Galacto – Light Plus assay 
system (Tropix, Bedford, MA) in a Lumicount Micro-well plate reader (Packard 
Instrument Co.). For nuclear extracts, cells were washed in PBS (2X), scraped in 
1ml 1X lysis buffer, incubated at 4°C for 15 min and centrifuged at 14,000 x g for 
1 min at 20°C.  Cell pellets were initially washed in 1 ml of lysis buffer (3X), lysis 
buffer supplemented with 500 mM KCl was then added to the cell pellet and 
incubated for 45 min at 4°C with frequent vortexing.  Nuclei were pelleted by 
centrifugation at 14,000 x g for 1 min at 4°C, and aliquots of supernatant were 
stored at -80°C and used for Western blot analysis and gel shift assays.    
 Western immunoblot. An aliquot of nuclear protein (30 µg) was diluted 
with loading buffer, boiled, and loaded on 7.5% SDS-polyacrylamide gel. 
Samples were electrophoresed at 150-180 V for 3-4 h, and separated proteins 
were transferred to PVDF membrane (Bio-Rad, Hercules, CA) in buffer 
containing 48 mM Tris-HCl, 29 mM glycine, and 0.025% SDS. Proteins were 
detected by incubation with polyclonal primary antibodies Sp1-PEP2, Lamin B1-
C20, and ERα-G20 (all 1:1000 dilution) against Sp1, Lamin B1, and ERα 
proteins, respectively, followed by blotting with horseradish peroxidase-
conjugated anti-rabbit (for Sp1 and ERα) or anti-goat (for Lamin B) secondary 
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antibody (1:5000 dilution). Blots were then exposed to chemiluminescent 
substrate (NEN Life Science Products) and placed in Kodak X-Omat AR 
autoradiography film. Band intensities were determined by a scanning laser 
densitometer (Sharp Electronics Corp., Mahwah, NJ) using Zero-D Scanalytics 
software (Scanalytics Corp., Billerica, MA). 
 FACS analysis. Cells were transfected with iRNAs for Sp1 or GL2 and, 
after 20-24 h, treated with Me2SO or 20 nM E2 for 18-20 h in serum free 
medium.  Cells were then trypsinized and approximately 2 x 106 cells were 
centrifuged, resuspended after removal of trypsin in 1 ml of staining solution 
containing 50 µg/ml propidium iodide, 4 mM sodium citrate, 30 units/ml RNase 
and 0.1% TX-100, pH 7.8).  Cells were incubated at 37°C for 10 min, then prior 
to FACS analysis, sodium chloride was added to give final concentration of 0.15 
M.  Cells were analyzed on a FACSCalibur flow cytometer (Becton Dickinson 
Immunocytometry Systems, San Jose, CA), using CellQuest (Becton Dickinson) 
acquisition software. Propidium iodide fluorescence was collected through a 
585/42-nm bandpass filter, and list mode data were acquired on a minimum of 
12,000 single cells defined by a dot plot of PI-width versus PI-area. Data 
analysis was performed in ModFit LT (Verity Software House, Topsham, ME) 
using PI-width versus PI-area to exclude cell aggregates. FlowJo (Treestar,Inc., 
Palo Alto, CA) was used to generate plots shown in the Figures. 
Electrophoretic Mobility Shift Assay (EMSA). Consensus Sp1 
oligonucleotide (569,571) was synthesized and annealed, and 5 pmol aliquots 
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were 5’-end-labeled using T4 Kinase and [γ-32P]ATP.  A 30 µl EMSA reaction 
mixture contained approximately 100 mM KCl, 3 µg of crude nuclear protein, 1 
µg poly (dI-dC), with or without unlabeled competitor oligonucleotide, and 10 
fmol radiolabeled probe.  After incubation for 20 min on ice, antibodies against 
Sp1 protein were added and incubated another 20 min on ice. Protein/DNA 
complexes were resolved by 5% polyacrylamide gel electrophoresis in 1X TBE 
(0.09 M Tris–base, 0.09 M boric acid, 2 mM EDTA, pH 8.3) at 120 V at 4°C for 
2-3 h. Specific DNA/protein and antibody supershifted complexes were observed 
as retarded bands in the gel.   
 Immunocytochemistry. MCF-7 cells were seeded in Lab-Tek Chamber 
Slides (Nalge Nunc International, Naperville, IL) at 100,000 cells/well in 
DME/F12 media supplemented with 5% FBS and after 14 h cells were 
transferred into serum free medium for 8-10 h. Cells were then transfected with 
iRNAs and after 36-44 h, the media chamber was detached and the remaining 
glass slides were washed in Dulbecco’s PBS.  After washing, the glass slides 
were fixed with cold (-20°C) methanol for 10 min, then slides were washed in 
0.3% Tween/PBS for 5 min (2X) before blocking with 5% rabbit or goat serum in 
antibody dilution buffer (stock solution:  100 ml PBS-Tween, 1 g BSA, 45 ml 
glycerol, pH 8.0) for 1 h at 20°C. After removal of the blocking solution, rabbit 
Sp1-PEP2 or goat Lamin B1 polyclonal antibodies were added in antibody 
dilution buffer (1:200) and incubated for 12 h at 4°C. Slides were washed for 10 
min with 0.3%Tween in 0.02 M PBS (3X) and incubated with FITC conjugated 
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anti-rabbit or anti-goat secondary antibodies (1:1000 dilution) for 2 h at 20°C.  
Slides were then washed for 10 min in 0.3%Tween/PBS (4X). Slides were 
mounted in ProLonged antifading medium (Molecular Probes, Inc., Eugene, OR) 
and cover slips were sealed using Nailslicks nail polish (Noxell Corp., 
Huntvalley, MD). Fluorescence imaging was performed using Carlzeiss 
Axiophoto 2 (Calzeiss. Inc., Thornwood, NY). Images were captured using 
Adobe Photoshop 5.5 using identical camera settings. 
 Chromatin Immunoprecipitation Assay (ChIP). Cells were transfected 
with iSp1 or iGL2 for 36 h, and then treated with Me2SO.  MCF-7 cells were then 
collected, suspended in 1X PBS with 1 mM PMSF, and formaldehyde was 
added to the medium to give a 1% solution which was incubated with shaking for 
10 min at 20°C.  Glycine was then added (0.125 M) and, after further incubation 
for 10 min, cells were collected by centrifugation and washed with PBS and 1 
nM PMSF.  Cells were then resuspended in swell buffer (85 mM potassium 
chloride, 0.5% NP-40, 1 nM PMSF, 5 µg/ml leupeptin and aprotinin at pH 8.0), 
homogenized, and nuclei were isolated by centrifugation at 1500 x g for 30 s.  
Nuclei were then resuspended in sonication buffer (1% SDS, 10 nM EDTA, 50 
mM Tris at pH 8.1), and sonicated for 45-60 s to obtain chromatin with 
appropriate fragment lengths (500-1000 bp). The sonicated extract was then 
centrifuged at 15,000 x g for 10 min at 0°C, aliquoted and stored at -70°C until 
used.  The crosslinked chromatin preparations were diluted in buffer (1% Triton 
X, 100 mM sodium chloride, 0.5% SDS, 5 mM EDTA and Tris at pH 8.1), and 20 
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µl of Ultralink protein A or G or A/G beads was added per 100 µl chromatin, and 
incubated for 4 h at 4°C.  Beads were collected by centrifugation, and salmon 
sperm DNA, specific antibodies, and 20 µl Ultralink beads were added to the 
supernatant, and the mixture incubated for 6 h at 4°C.  An aliquot was treated at 
65°C to reverse the crosslinks, extracted with phenol:chloroform and DNA was 
precipitated with ethanol.  This aliquot was used as an input control.  
Immunoprecipitated samples were then centrifuged; beads were resuspended in 
dialysis buffer, vortexed for 5 min at 20°C, and centrifuged at 15,000 x g for 10 s.  
Beads were then resuspended in immunoprecipitation buffer (11 mM Tris, 500 
mM lithium chloride, 1% NP-40, 1% deoxycholic acid at pH 8,0) and vortexed for 
5 min at 20°C.  Procedures with the dialysis and immunoprecipitation buffers 
were repeated (3-4X), and beads were then resuspended in elution buffer (50 
nM NaHCO3, 1% SDS, 1.5 µg/ml sonicated salmon sperm DNA), vortexed, 
incubated at 65°C for 15 min, and supernatants were then isolated by 
centrifugation and incubated at 65°C for 6 h to reverse protein-DNA crosslinks.  
Wizard PCR kits (Promega) were used for additional DNA cleanup.  A portion of 
the purified immunoprecipitated DNA and 0.2% of the input control were used for 
αdCTP32 incorporation PCR.  One quarter of a microliter of α-dCTP32 (3000 
Ci/mmol) was added to a 25 µl PCR reaction (3% Me2SO), 1 M betaine, 1.5 mM 
magnesium chloride) and subjected to one cycle of 95°C x 5 min, 5 cycles of 
95°C x 30 s, 60°C x 30 s, 5 cycles of 95°C x 30 s, 55°C x 30 s, 72°C x 30 s, and 
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5 cycles of 95°C x 30 s, 48°C x 30 s, 72°C x 30 s followed by one cycle at 72°C 
for 4 min.  Reactions were loaded on a 10-15% non-denaturing acrylamide gel; 
the gel was then dried and exposed to a phosphor screen for 24 h.  The primers 
used for PCR of the GC-rich region of pSp13 are indicated below. 
 pxp2 luc Fw (6128) 5' – GTTTGTCCAAACTCATCAATG – 3' 
   Rv (105) 5' – CTTTATGTTTTTGGCGTCTTC – 3' 
 
RESULTS 
iRNA for Sp1 (iSp1) specifically decreases nuclear Sp1 protein 
levels in ER-positive human breast cancer cells. Results of preliminary 
studies indicate that iSp1 and lamin (iLMN) were most effective at decreasing 
cellular protein levels by treating cells for 36-44 h with 0.75 µg of the duplex 
oligonucleotides.  The results illustrated in Figures 20A and 20B show that 
transfection of iSp1 in MCF-7 cells significantly decreased Sp1 protein by 
approximately 60% in nuclear extracts, whereas immunoreactive Lamin B1 and 
ERα levels were unchanged.  In contrast, transfection of iLMN decreased Lamin 
B1 but not Sp1 or ERα protein levels, thus demonstrating the specificity of the 
iRNAs.  The results summarized in Figure 1C confirm that iSp1 (but not iLMN) 
also significantly decreased Sp1 protein in ERα-positive ZR-75 cells.  The 
effects of iRNAs on nuclear protein levels were also investigated in gel mobility 
shift assays using extracts from MCF-7 or ZR-75 cells (Figs. 21A and 21B) and 
a consensus GC-rich oligonucleotide [32P]Sp1 that binds Sp1 and other Sp1 
family proteins.   
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Fig. 20.  Interfering RNA for Sp1 (iSp1) decreases Sp1 protein in MCF-7 and 
ZR-75 cells. [A] Effects on Sp1 protein in MCF-7 cells.  Cells were transfected with iSp1 
and iLMN and nuclear extracts were analyzed for Sp1 and ERα proteins by Western 
blot analysis as described in the Materials and Methods.  Results are means ± SD for 3 
replicate determinations for each treatment group, and a significant (p < 0.05) decrease 
in Sp1 protein levels was observed.  [B] Effects on Lamin B1 in MCF-7 cells.  Cells were 
treated as described in [A], and Lamin B1 and ERα proteins were detected by Western 
blot analysis.  Treatment with iLMN significantly (p < 0.05) decreased Lamin B1 protein.  
[C] ZR-75 cells.  Experiments were carried out as described in MCF-7 cells [A], and 
iSp1 significantly (p < 0.05) decreased Sp1 protein in ZR-75 cells. 
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Incubation of nuclear extracts from MCF-7 cells with [32P]Sp1 gave a profile of 
retarded bands (lane 2) associated with Sp1- and Sp3-DNA complexes (571); 
the intensity of the former complex was decreased after incubation with 
unlabeled Sp1 oligonucleotide (lane 5) and supershifted with Sp1 antibodies 
(lane 6).  In cells transfected with iSp1, there was a decrease in retarded band 
intensity (lane 4), whereas iLMN did not affect retarded band intensities.  The 
results obtained for ZR-75 cells (Fig. 21B) were similar to those observed in 
MCF-7 cells and confirms the effectiveness and specificity of iSp1 for selectively 
decreasing Sp1 protein in breast cancer cells. 
 We have also used a chromatin immunoprecipitation assay to further 
investigate the in situ effects of iSp1 on Sp1-DNA interactions.  MCF-7 cells 
were cotransfected with iSp1 or iGL2 and a construct containing three tandem 
GC-rich Sp1 binding sites (pSp13), and after 36-44 h, cells were treated with 
formaldehyde to crosslink DNA-bound proteins.  After immunoprecipitation with 
Sp1 or Sp3 antibodies and removal of the crosslinks, PCR was used to identify 
the GC-rich region of pSp13 as part of the immunoprecipitable complexes.  The 
results showed that iSp1 decreased interaction of Sp1 with the GC-rich promoter 
compared to that observed in cells transfected with iGL2, whereas the intensity 
of PCR products were similar for Sp3 immunoprecipitable complexes.  Thus, 
results of Western blots, gel mobility shift and chromatin immunoprecipitation 
assays demonstrate a significant (40-60%) decrease in Sp1 protein in breast 
cancer cells transfected with iSp1. 
 128
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 21. Binding of [32P] Sp1 with nuclear extracts from breast cancer cells 
treated with iSp1 or iLMN. MCF-7 [A] or ZR-75 [B] cells were treated with solvent, 
iSp1 or iLMN, and binding of nuclear extracts to [32P] Sp1 was determined in gel 
mobility shift assays as described in the Materials and Methods.  [C] ChIP assay.  MCF-
7 cells were transfected with pSp13 and iSp1 or iGL2, and analysis of Sp1 and Sp3 
immunoprecipitable complexes associated with the transfected GC-rich construct were 
determined by ChIP/PCR as described in the Materials and Methods. 
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Fig. 21. Continued. 
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Sp1 protein expression, Sp1 and ERα/Sp1-mediated transactivation 
in MCF-7 cells transfected with iSp1. Transfection with lipofectamin results in 
>40-60% transfection efficiency in MCF-7 cells suggesting that iSp1 is highly 
effective in decreasing Sp1 expression in transfected cells. This was further 
investigated in MCF-7 cells by immunofluorescence analysis of Sp1 or lamin 
protein in MCF-7 transfected with iSp1 or iLMN (Fig. 22).  Panels A and E are 
control panels where the primary antibody for lamin (A) or Sp1 (E) has been 
omitted.  Panel C is a control for lamin (iLMN) showing immunofluorescence of 
Lamin B and phase contrast (panel B).  In cells transfected with iLMN, most of 
the cells exhibited either significantly decreased Lamin B expression 
(transfected cells) or lamin expression was unchanged (non-transfected cells).  
Sp1 staining was observed in untreated MCF-7 cells (panel F) or in cells 
transfected with iLMN (panel G); however, in cells transfected with iSp1, there 
was a marked decrease of Sp1 staining in most cells, whereas the non-
transfected cells were essentially unchanged.  These data demonstrate that 
transfected iSp1 but not iLMN were highly effective in decreasing cellular 
expression of Sp1 and this accounts for the decreases in Sp1 protein in nuclear 
extracts (Figs. 20 and 21). 
 The results in Figure 23A summarize the effects of iLMN, iGL2 and iSp1 
on luciferase activity in MCF-7 cells transfected with pSp13 and the iRNAs.  
iLMN did not significantly decrease activity, whereas iGL2 which is targeted to 
the luciferase mRNA and iSp1 both inhibited luciferase activity.   
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 Fig. 22. Immunofluorescence of Sp1 and Lamin B in MCF-7 cells 
transfected with iSp1 and iLMN. MCF-7 cells were untreated (A, E), transfected with 
iSp1 (H), iLMN (D, G), and stained with Sp1 (F-H) or Lamin B (B-D) antibodies.  
Immunofluorescence was determined as described in the Materials and Methods. 
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In this study (Figs. 23A and 23B), there was a >60-77% decrease in basal 
activity in cells transfected with iSp1.  Moreover, E2 induced luciferase activity in 
MCF-7 cells transfected with pSp13 as previously described (571), and in cells 
cotransfected with iSp1, there was a >80% decrease in hormone-induced  
transactivation.  Thus, iSp1 inhibited both basal and E2-induced luciferase 
activity in MCF-7 cells transfected with pSp13.  In contrast, hormone-induced 
transactivation in MCF-7 cells transfected with pERE3 was not affected by 
cotransfection with iLMN or iSp1, whereas iGL2 decreased activity in cells 
treated with DMSO or E2 (Fig. 4C).  Thus, iSp1 specifically blocks hormone-
induced transactivation in cells transfected with pSp13 but not pERE3. 
iSp1 inhibits hormone-induced MCF-7 cell cycle progression. 
Promoter regions in several genes associated with cell proliferation contain E2-
responsive GC-rich motifs (340-343,383,513,514,567-571); however, the role of 
ERα/Sp1 in mediating cell growth can only be inferred from these studies.  The 
role of Sp1 in hormone-induced cell cycle progression was further investigated 
to determine the effects of iSp1 and iGL2 (a control) on distribution of MCF-7 
cells in G0/G1, G2-M and S phases after treatment with solvent (Me2SO) or 20 
nM E2 for 18-20 h (Fig. 24).  At this time point, iRNA for Sp1 increased the % of 
solvent-treated cells in G0/G1 from 75.3 to 78.3% and decreased the % in S 
phase (from 15.1 to 12.1).   
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 Fig. 23. Effects of iLMN, iSp1 and iGL2 on luciferase activity in MCF-7 cells 
transfected with pSp13 and treated with Me2SO or E2.  [A] Effects of inhibitor RNAs 
on basal activity.  MCF-7 cells were transfected with pSp13 alone or in combination with 
iLMN, iGL2 or iSp1, and treated with Me2SO.  Luciferase activity was determined as 
described in the Materials and Methods.  [B] iSp1-mediated inhibition of transactivation 
in cells transfected with pSp13.  Cells were transfected with pSp13 and iSp1, treated 
with Me2SO or 10 nM E2, and luciferase activity was determined as described in the 
Materials and Methods.  [C] Effects of iSp1 on cells transfected with pERE3.  Cells were 
transfected with pERE3 and iLMN, iGL2 or iSp1, treated with Me2SO or 10 nM E2, and 
luciferase activity was determined as described in the Materials and Methods.  Results 
summarized in [A], [B] and [C] are means ± SD for 3 replicate determinations for each 
treatment group and significant (p < 0.05) decreases in activity are indicated by an 
asterisk. 
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Fig. 23. Continued. 
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 Fig. 24. Effects of iSp1 on hormone-induced cell cycle progression in MCF-
7 cells. Serum-starved MCF-7 cells were treated with Me2SO or E2 alone or 
cotransfected with iGL2 and iSp1, and the % distribution of cells in G1/G0, S and G2/M 
were determined by FACS analysis as described in the Materials and Methods.  Similar 
results were observed in a duplicate analysis. 
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In a parallel study in untreated cells at an earlier time point (8-10 h), a 5% 
decrease in cells in S phase and a similar increase in cells in G0/G1 was 
observed .  More dramatic changes were observed for the effects of iSp1 on E2-
induced proliferation of MCF-7 cells.  For example, in cells treated with Me2SO 
or 20 nM E2, the % of cells in G0/G1:S phase was 75.3:9.57% or 66.1:23.7%, 
respectively, showing a dramatic increase in G0/G1 → S progression after 
treatment with E2, and this has been observed in other studies (579,580).  In 
contrast, the % of cells in G0/G1:S phase in cells treated with iSp1 was 
71.9:17.3% indicating that hormone-induced cell cycle progression was 
markedly decreased by ablating cellular expression of Sp1 protein, whereas 
transfection of the control iGL2 did not affect cell cycle progression.  These 
results demonstrate for the first time that Sp1 protein and ERα/Sp1-mediated 
transactivation are important for hormone-induced proliferation of MCF-7 cells.   
 
DISCUSSION 
 The development of genetic technologies to regulate or delete expression 
of endogenous genes has been extensively used to probe the role of specific 
genes on biological function.  For example, the generation of knock-out/knock-in 
mice and the overexpression of genes in transgenic animal models has provided 
unique insights on gene function in normal physiology and disease processes.  
RNA interference by double-stranded RNA involves the sequence-specific post-
transcriptional silencing of genes which has been widely described and used in 
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plants and animals (46,575-577).  It has recently been shown that small 
interfering RNA duplexes (21 to 25 nucleotides) targeted to specific genes can 
now be introduced into mammalian cells in culture to decrease RNA/protein 
expression (46,67,89,575-578).  Elbashir and coworkers recently reported iRNA 
duplexes for endogenous and exogenous genes decreased their corresponding 
protein and/or protein-dependent activities in several mammalian cell lines 
including NIH 3T3, HeLa, COS-7 and 293 cells (67). 
 This study has used the iRNA approach for investigating the role of Sp1 
protein in the growth and hormone-responsiveness of MCF-7 human breast 
cancer cells.  Although Sp1 is important for basal transcription of genes involved 
in cell growth, expression of several cell cycle regulated genes such as 
dihydrofolate reductase, hypoxanthine/guanine phosphoribosyl transferase were 
unaffected in gd 8.5 day-old embryos (256).  In contrast, transfection of GC-rich 
Sp1 oligonucleotide decoys into A549 human lung adenocarcinoma and U251 
human glioblastoma cells blocked expression of several genes with GC-rich 
promoters and suppressed cell growth.  This approach and others that target 
GC-rich sequences suggest that Sp1 protein may play an important role in cell 
growth (294,581); however, these techniques lack specificity since multiple Sp 
family proteins bind GC-rich motifs that may influence the function of other DNA 
bound transcription factors.   Research in this laboratory has identified E2-
responsive GC-rich motifs in promoters of several genes involved in cell 
proliferation, and these include cyclin D1, thymidylate synthase, c-fos, E2F1, 
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bcl2, and DNA polymerase α (340-343,383,513,514,567-571).  Several 
approaches were previously used to demonstrate the role of ERα/Sp1 as a 
transcription factor complex, and this study was designed to further investigate 
this non-classical mechanism of estrogen action and its involvement in hormone-
induced transactivation and cell proliferation.  The results in Figures 20-22 
clearly demonstrate that transfected iSp1 was highly effective for decreasing 
expression of Sp1 protein in nuclear extracts and not surprisingly, 
immunofluorescence studies indicate that Sp1 protein is barely detectable in 
transfected cells (Fig. 22).  The high efficiency of iSp1 for ablating Sp1 protein in 
transfected cells was observed in MCF-7 cells cotransfected with iSp1 and 
pSp13, an E2-responsive GC-rich construct that serves as a surrogate for other 
GC-rich E2-responsive gene promoters (Fig. 23).  In these transfection studies, 
iSp1 significantly decreased both basal and E2-induced luciferase activities 
confirming the role of ERα/Sp1 in ligand-activated transcription. 
 Treatment of growth-arrested MCF-7 cells with E2 results in cell cycle 
progression which is characterized by a decrease in cells in G0/G1 and an 
increase in cells in S phase (579,580) (Fig. 24).  In untreated cells, iSp1 further 
increased the percentage of cells in G0/G1 (from 75.3 to 78.3%) and decreased 
the number of cell in S phase (from 15.1 to 12.1%).  Since FACS analysis was 
carried out on the total cell population (transfected and non-transfected), the 
response of MCF-7 cells to transfected iSp1 demonstrates the important role of 
Sp1-regulated genes in basal growth of these cells.  The effects of iSp1 were 
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more dramatic in reversing hormone-induced cell cycle progression and blocking 
a high proportion of these cells from progression to S phase.  These data are 
consistent with results of previous studies showing that cyclin D1 and other 
genes important for cell proliferation are regulated by ERα/Sp1  (341-
343,568,571).  Future studies will use iRNAs to further investigate the role of 
Sp1, other Sp-like proteins and coregulatory factors on the growth of MCF-7 and 
other hormone-dependent cell lines and to identify key genes that are integral for 
these responses. 
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ARYL HYDROCARBON RECEPTOR GENE SILENCING WITH 
SMALL INHIBITORY RNA DIFFERENTIALLY MODULATES Ah-
RESPONSIVENESS IN MCF-7 AND HepG2 CANCER CELLS * 
 
The aryl hydrocarbon (AhR) is a ligand-activated nuclear transcription 
factor that is a member of the PAS and basic helix-loop-helix protein families 
(356,364,582).  The transcriptionally active nuclear AhR complex is a 
heterodimer of the AhR and AhR nuclear translocator (ARNT) proteins which 
interact with genomic cis-acting dioxin responsive elements (DREs) in the 
CYP1A1 and other Ah-responsive genes (363,583,584).  The ARNT protein 
which was initially identified as a partner for the AhR (585) is also called 
hypoxia-inducible factor 1β (HIF-1β) and many hypoxia-induced genes are 
regulated by the HIF1α:HIF1β complex interacting with hypoxia responsive 
elements (HREs) (586).  The AhR was initially identified as the intracellular 
receptor for the environmental toxicant 2,3,7,8-tetrachlorodibenzo-p-dioxin 
(TCDD) which binds with high affinity to the AhR (346).  Interactions of TCDD 
and related halogenated aromatic compounds with the AhR mediate their  
 
_____________________ 
* Reprinted with permission from “Aryl hydrocarbon receptor gene silencing with small inhibitory 
RNA differentially modulates Ah-responsiveness in MCF-7 and HepG2 cancer cells” by 
Abdelrahim, M., Smith, R. 3rd, Safe, S. (2003) Mol. Pharmacol. 63, 1373-1381. Copyright 2003 
by The American Society for Pharmacology and Experimental Therapeutics. 
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diverse species-/strain-, tissue- and age-specific biochemical, toxic, carcinogenic 
and anticarcinogenic responses (347,377,378).   
 The physiological role of the AhR-ARNT heterodimer has been 
investigated in transgenic knockout mice which do not express the AhR protein 
(370-372).  Not surprisingly, these knockout animals do not respond to the 
prototypical TCDD-induced biochemical (e.g. CYP1A1 induction) and toxic 
responses (587); however, the three strains of mice deficient in the AhR exhibit 
both common and different phenotypes.  These mice typically have problems in 
liver development, poor fecundity, and weight loss suggesting that the AhR-
ARNT complex regulate constitutive functions in the absence of exogenous 
ligand.  These results are consistent with reports showing that AhR-ARNT alone 
may act as a transcription factor; however, this would not exclude a role for an 
unknown endogenous ligand (588-590). 
 The AhR also binds with moderate to low affinity to chemoprotective 
phytochemicals such as indole-3-carbinol, flavonoids and carotenoids which 
exhibit both AhR agonist and antagonist activities (591-594).  Research in this 
laboratory has identified selective AhR modulators (SAhRMs) which exhibit 
minimal AhR-mediated toxicities but inhibit 17β-estradiol (E2)-induced gene 
expression and mammary tumor growth in rodent models (400,401,595,596).  
The molecular mechanisms of inhibitory AhR-estrogen receptor (ER) crosstalk 
may be complex and dependent on multiple factors including cell context.  This 
study investigates AhR-ERα crosstalk and other AhR-mediated pathways using 
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small interfering RNA (siRNA) for the AhR which selectively degrades AhR 
mRNA and decreases AhR protein expression and function in breast cancer 
cells.  Decreased expression of the AhR in MCF-7 breast cancer cells resulted in 
an increase in the percentage of cells in S phase and a decrease in G0/G1, 
suggesting that in the absence of exogenous ligand, the AhR suppresses growth 
of this cell line.  In contrast, degradation of the AhR in HepG2 liver cancer cells 
decreases G0/G1 → S phase progression indicating a role for the AhR in 
enhancing growth of this cell line, and this is associated with decreased 
expression of cyclin D1, cyclin E, cdk2 and cdk4.  We also observed that in 
MCF-7 cells transfected with siRNA for the AhR TCDD exhibits estrogenic 
activity and this complements results of a previous study in AhR-deficient MCF-7 
cells (597).  Thus, selective gene silencing of the AhR in breast and liver cancer 
cells illustrates the utility of this approach for investigating cellular mechanisms 
and function of the gene targeted for degradation. 
 
MATERIALS AND METHODS 
 Cell lines, chemicals and biochemicals.  MCF-7 and HepG2 cells were 
obtained from the American Type Culture Collection (ATCC, Manassas, VA).  
DME/F12 with and without phenol red, 100X antibiotic/antimycotic solution, 
propidium idodide, and E2 were purchased from Sigma (St. Louis, MO). Fetal 
bovine serum (FBS) was purchased from Intergen (Purchase, NY) [γ-32P]ATP 
(300ci/mmol) was obtained from NEN Life Science Products (Boston, MA). T4-
polynucleotide kinase was purchased from Roche Molecular Biochemicals 
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(Indianapolis, IN). Antibodies for proteins were obtained from Santa Cruz 
Biotechnology (Santa Cruz, CA). The pDRE3 and pERE3 construct contain three 
consensus DRE and ERE motifs, respectively; oligonucleotides containing these 
motifs were linked to the bacterial luciferase gene and cloned into BamHI-HindIII 
cut XP-2 plasmid obtained from ATCC.  Lysis buffer, luciferase reagent, and 
RNase were obtained from Promega Corp.  (Madision, WI).  siRNA duplexes 
were prepared by Dharmacon Research (Lafayette, CO) and targeted coding 
regions of the AhR (1416 to 1434), ARNT (445 to 463), lamin A/C (608 to 626), 
and GL2 (luciferase) (153 to 171).  The siRNA duplexes used in this study are 
indicated below.  Scrambled iRNA was derived from a message transcribed from 
the chloroplast genome of Euglena gracilis (Accession #70810, position 24750-
24768). 
GL2 
 5' – CGU ACG CGG AAU ACU UCG ATT 
 TT GCA UGC GCC UUA UGA AGC U – 5' 
 
LMN 
 5' – CUG GAC UUC CAG AAG AAC ATT 
 TT GAC CUG AAG GUC UUC UUG U – 5' 
 
Scramble 
 5' – GCG CGC UUU GUA GGA UUC GTT 
 TT CGC GCG AAA CAU CCU AAG C – 5' 
 
AhR 
 5' – UAC UUC CAC CUC AGU UGG CTT 
 TT AUG AAG GUG GAG UCA ACC G – 5' 
 
ARNT 
 5' – CCA UCU UAC GCA UGG CAG UTT 
 TT GGU AGA AUG CGU ACC GUC A – 5' 
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 Transfection of MCF-7 and HepG2 cells and preparation of nuclear 
extracts. Cells were cultured in 6-well plates in 2 ml DME/F12 medium 
supplemented with 5% FBS.  When cells were approximately 50-60% confluent, 
siRNA duplexes and/or reporter gene constructs were transfected using 
Oligofectamine Reagent (Invitrogen, Carlsbad, CA).  Based on results of 
preliminary studies, 7 µl of 20 µM stock solution of siRNAs were transfected in 
each well to give a final concentration of 140 nM.  Cells were harvested 48-56 h 
after transfection by manual scraping in 1X lysis buffer (Promega).  Whole cell 
extracts were frozen in liquid nitrogen for 30 s, vortexed for 30 s, and centrifuged 
at 12,000 x g for 1 min to give lysates that were assayed for luciferase activity 
using luciferase assay reagent (Promega).  β-Galactosidase activity was 
determined using Tropix Galacto – Light Plus assay system (Tropix, Bedford, 
MA) in a Lumicount Micro-well plate reader (Packard Instrument Co.). Nuclear 
extracts were prepared using 1X lysis buffer as mentioned before in the previous 
section. Aliquots of supernatant were stored at -80°C and used for gel shift 
assays.    
 Western immunoblot. Forty-eight h after transfection, cells were washed 
once with PBS and collected by scraping in 200 µl of lysis buffer [50 mM 
HEPES, 0.5 M sodium chloride, 1.5 mM magnesium chloride, 1 mM EGTA, 10% 
(v/v) glycerol, 1% Triton X-100, and 5 µl/ml Protease Inhibitor Cocktail (Sigma)].  
The lysates were prepared as mention early in the previous section. Proteins 
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were detected by incubation with polyclonal primary antibodies Sp1 (PEP2), 
lamin A/C (N-18), AhR (N-19), ARNT1 (C-19), CYP1A1 (G-18), cyclin D1 (M-20), 
cyclin E (C-19), cdk2 (M-2), cdk4 (C-22), Rb (C-15) and p27 (C-19) followed by 
blotting with horseradish peroxidase-conjugated anti-rabbit (for Sp1, cyclin D1, 
cyclin E, cdk2, cdk4 and p27), anti-goat (for lamin A, CYP1A1, AhR and ARNT) 
or anti-mouse (for Rb) secondary antibody.  Blots were then exposed to 
chemiluminescent substrate (NEN Life Science Products) and placed in Kodak 
X-Omat AR autoradiography film. Band intensities were determined by a 
scanning laser densitometer (Sharp Electronics Corp., Mahwah, NJ) using Zero-
D Scanalytics software (Scanalytics Corp., Billerica, MA). 
 FACS analysis. Cells were transfected with siRNAs for AhR or scramble 
RNA and, after 36 h, cells were synchronized in serum-free media for 24 h, 
treated with Me2SO or 20 nM E2, 20 nM TCDD or TCDD plus E2 for 18-20 h in 
serum-free medium.  Cells were then trypsinized and approximately 2 x 106 cells 
were centrifuged, resuspended after removal of trypsin in 1 ml of staining 
solution containing 50 µg/ml propidium iodide, 4 mM sodium citrate, 30 units/ml 
RNase and 0.1% TX-100, pH 7.8).  Cells were incubated at 37°C for 10 min, 
then prior to FACS analysis, sodium chloride was added to give final 
concentration of 0.15 M.  Cells were analyzed as mentioned in the previous 
section and data analysis was performed in ModFit LT (Verity Software House, 
Topsham, ME) using PI-width versus PI-area to exclude cell aggregates. FlowJo 
(Treestar,Inc., Palo Alto, CA) was used to generate plots shown in the Figures. 
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 Electrophoretic Mobility Shift Assay (EMSA). Consensus DRE 
oligonucleotide was synthesized and annealed, and 5 pmol aliquots were 5’-end-
labeled using T4 Kinase and [γ-32P] ATP (597).  A 30 µl EMSA reaction mixture 
contained approximately 100 mM KCl, 3 µg of nuclear protein, 500 ng salmon 
sperm DNA (Invitrogen), with or without unlabeled competitor oligonucleotide, 
and 10 fmol radiolabeled probe.  After incubation for 20 min on ice, antibodies 
against AhR protein were added and incubated another 20 min on ice. 
Protein/DNA complexes were resolved by 5% polyacrylamide gel 
electrophoresis in 1X TBE (0.09 M Tris–base, 0.09 M boric acid, 2 mM EDTA, 
pH 8.3) at 120 V at 4°C for 2-3 h. Specific DNA/protein and antibody 
supershifted complexes were observed as retarded bands in the gel.   
 EROD activity. EROD activity was determined as described (598).  
Trypsinized cells were seeded in 48-well plates and grown to 50% confluency.  
Thirty-six h after transfection with siRNAs, cells were treated with Me2SO or 10 
nM TCDD for 18-20 h.  Cells were then washed with PBS; 200 µl of PBS was 
added to each well and cells were incubated at 37°C for 2 min.  Ethoxyresorufin 
(1.25 µg) was added to each well, incubated for 10 min at 37°C, and the reaction 
was stopped by adding 100 µl fluorescamine.  EROD activity and protein 
concentration were determined on a Cytofluor 2350 plate reader as described 
(598).  Each treatment was carried out in triplicate, and results are presented as 
means ± SD. 
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 Statistical analysis. Statistical significance was determined by analysis 
of  variance and Scheffe’s test, and the levels of probability are noted.  The 
results are expressed as means ± S.D. for at least 3 separate (replicate) 
experiments for each treatment. 
 
RESULTS 
 MCF-7 breast cancer cells are ERα-positive and express the AhR and 
ARNT proteins (599,600).  Results summarized in Figure 25A demonstrate that 
AhR levels are decreased in MCF-7 cells transfected with siRNA for the AhR, 
whereas levels were unchanged in control cells and cells treated with siRNA for 
lamin A.  Sp1 protein is used as a loading control for these experiments since it 
is highly expressed and unaffected by treatment with E2 or AhR agonists (600).  
This experiment has been replicated several times and AhR protein levels are 
typically decreased by 60-80% in whole cell extracts depending on the 
transfection efficiency in the individual experiments.  Results in Figure 25B 
demonstrate the specificity of the iRNAs and show that treatment with siRNA for 
lamin A decreases lamin A protein levels by approximately 65%, whereas siRNA 
for the AhR did not affect lamin protein.  Using a similar approach, we also show 
that siRNA for ARNT specifically decreases ARNT protein expression in MCF-7 
cells, whereas siRNA for lamin A did not affect levels of ARNT protein (Fig. 
25C).  MCF-7 cells were treated with siRNA for lamin A, AhR and ARNT, and 
nuclear extracts were incubated with 32P-labeled DRE and analyzed by gel  
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 Fig. 25. siRNAs for AhR (iAhR) and ARNT (iARNT) decrease their 
corresponding proteins in MCF-7 cells.  [A] Effects on AhR protein in MCF-7 cells.  
Cells were transfected with iLMN, iAhR and whole cell extracts were analyzed for AhR 
and Sp1 proteins by Western blot analysis as described in the Materials and Methods.  
Results are means ± SD for 3 replicate determinations for each treatment group, and a 
significant (p < 0.05) decrease in AhR protein levels was observed only in cells treated 
with iAhR.  [B] Effects of siRNAs on lamin A in MCF-7 cells.  Cells were treated as 
described in [A], and lamin A and Sp1 proteins were detected by Western blot analysis.  
Treatment with iLMN A significantly (p < 0.05) decreased lamin A protein.  [C] Effects of 
siRNAs on ARNT protein.  Experiments were carried out as described in [A], and iARNT 
significantly (p < 0.05) decreased ARNT protein in MCF-7 cells, whereas iLMN A did not 
affect ARNT protein levels.  Sp1 protein serves as a loading and reference control 
protein that is not affected by the siRNAs used in this study. 
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Fig. 25. Continued. 
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mobility shift assays (Fig. 26).  In control cells and cells treated with siRNA for 
lamin A, a weak complex was observed after treatment with Me2SO (lanes 2 and 
4), and an intense retarded band was observed using nuclear extracts from cells 
treated with 10 nM TCDD (lanes 3, 5 and 9).  In extracts from cells treated with 
siRNAs for AhR or ARNT, there was a marked decrease in retarded band 
intensities in extracts from Me2SO- (lanes 6 and 10) and TCDD- (lanes 7 and 
11) treated cells.  The specifically-bound complex was decreased after 
incubation with unlabeled DRE (lane 8) and supershifted with AhR antibodies 
(lane 19).  These results complement Western blot analyses of whole cell 
lysates (Figs. 25A – 25C) showing that siRNAs for AhR and ARNT decrease 
expression of their corresponding proteins in MCF-7 cells. 
TCDD induces CYP1A1 mRNA and protein levels in multiple cells/tissues 
(363) including MCF-7 cells as indicated in Figure 27A.  In cells treated with 
siRNA for lamin A, there was a slight decrease in CYP1A1 protein levels in the 
control and TCDD-induced response; however, after treatment with siRNA for 
AhR, CYP1A1 protein levels induced by TCDD were decreased by > 65%. In a 
separate experiment, the effects of siRNAs for lamin A and AhR on induction of 
CYP1A1-dependent EROD activity also showed that only siRNA for the AhR 
decreased induction of EROD activity by TCDD (Fig 27B).  A complementary 
study used an Ah-responsive construct containing three tandem consensus 
DREs linked to a luciferase reporter gene.   
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 Fig. 26. Binding of [32P]DRE with nuclear extracts from breast cancer cells 
treated with iLMN, iAhR or iARNT.  MCF-7 cells were treated with Me2SO (D) or 
TCDD (T) and transfected with C, iAhR, iARNT or iLMN, and binding of nuclear extracts 
to [32P]DRE was determined in gel mobility shift assays as described in the Materials 
and Methods.  Only iAhR or iARNT decreased intensity of the specifically bound 
AhR:ARNT-DRE complex (see arrow).  Similar results were observed in duplicate 
experiments. 
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The results (Fig. 27C) showed that siRNAs for AhR and Arnt inhibited induction 
of luciferase activity by TCDD (compared to control cells), whereas siRNA for 
lamin A did not affect Ah-responsiveness.  As a positive control, siRNA for GL2 
(luciferase) inhibited luciferase activity in cells treated with solvent or TCDD. 
 Previous studies have demonstrated that TCDD and related AhR agonists 
inhibit expression of E2-induced genes and proliferation of ER-positive breast 
cancer cells (336,396,398,399,601,602).  The results in Figure 28 summarize 
FACS analysis of the effects of Me2SO (solvent control), E2, TCDD and their 
combination on MCF-7 cell cycle progression where interactions between the 
AhR- and ERα-mediated pathways are primarily directed at changes in the 
percentage of cells in G0/G1 and S phases.  E2 induced a >11% increase in 
MCF-7 cells in S phase (compared to Me2SO), whereas TCDD alone decreased 
the percentage of cells in S-phase and inhibited E2-induced G0/G1 → S phase 
progression.  In solvent (Me2SO)-treated MCF-7 cells transfected with siRNA for 
AhR, there was a >4.5% increase in cells in S phase compared to cells treated 
with Me2SO alone (Fig. 27A).  These results suggest that in the absence of 
exogenous ligand, the AhR inhibits G0/G1 → S phase progression of MCF-7 
cells.  E2 induced a >18% increase in cells in S phase in cells transfected with 
siRNA for the AhR and this was only decreased by 5% in cells cotreated with E2 
plus TCDD.   
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  Fig. 27. siRNA for the AhR (iAhR) inhibit TCDD-induced transactivation.  [A] 
CYP1A1 protein.  Cells were transfected with iLMN or iAhR, treated with Me2SO or 20 
nM TCDD, and CYP1A1 protein was determined by Western blot analysis as described 
in the Materials and Methods.  Significant (p < 0.05) decreases in activity compared to 
control cells are indicated with an asterisk.  [B] EROD activity.  The treatment groups 
were comparable to those outlined in Figure 3A, and EROD activity was determined as 
described in the Materials and Methods.  Significant (p < 0.05) decreases in activity 
compared to control cells are indicated with an asterisk.  [C] Luciferase activity.  The 
treatment groups included those described in Figure 3A except that scrambled iRNA 
was used as control and iGL2 was also transfected.  Cells were transfected with pDRE3 
and luciferase activity determined as described in the Materials and Methods.  
Significantly (p < 0.05) decreased activity compared to control cells is indicated with an 
asterisk.  Results are exprssed as means ± SD for at least three replicate experiments 
for each treatment group. 
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Fig. 27. Continued. 
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 Fig. 28. Effects of siRNA for the AhR on E2-, TCDD- and E2+TCDD-induced 
cell cycle progression in MCF-7 cells.  Serum-starved MCF-7 cells were treated with 
Me2SO, 20 nM E2, 20 nM TCDD or TCDD+E2, transfected with scrambled RNA or 
iAhR, and the % distribution of cells in G1/G0, S and G2/M were determined by FACS 
analysis as described in the Materials and Methods.  Similar results were observed in a 
duplicate analysis. 
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These results confirm that the AhR is required for activation of growth 
inhibitory AhR-ERα crosstalk by TCDD (602).  A comparison of the effects of 
TCDD alone in MCF-7 cells and in AhR-depleted cells treated with siRNA for the 
AhR indicates that TCDD induces AhR-independent G0/G1 → S phase 
progression and exhibits estrogen-like mitogenic activity.  Therefore, the 
estrogenic activity of TCDD was further investigated in MCF-7 cells 
cotransfected with a construct containing three tandem EREs (pERE3) and 
siRNAs for lamin A, luciferase and the AhR (Fig. 29).  E2 induced luciferase 
activity in cells transfected with siRNA for lamin A or the AhR, and minimal 
activity was observed in cells transfected with siRNA for luciferase (iGL2).  In 
wild-type Ah-responsive MCF-7 cells transfected with siRNA for lamin A, TCDD 
slightly decreased luciferase activity as previously observed using other E2-
responsive constructs in MCF-7 cells (336,396,398,399).  In contrast, TCDD 
significantly increased luciferase activity in cells cotransfected with pERE3 and 
siRNA for the AhR, and this complemented the mitogenic activity of TCDD in 
these same AhR-deficient cells (Fig. 28).  The estrogenic activity of TCDD (and 
E2) in AhR-deficient cells was inhibited after cotreatment with the antiestrogen 
ICI 182,780 (Fig. 29B); minimal interactions (TCDD plus ICI 182,780) were 
observed in cells transfected with siRNA for lamin A.  Moore and coworkers 
(597) previously developed AhR-defective MCF-7 cells which express ARNT but 
low to non-detectable AhR protein.  
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 Inhibitory AhR-ERα crosstalk was also not observed in this cell line, and 
treatment of these cells with TCDD caused an increase in cell growth and 
significantly induced reporter gene activity in cells transfected with an E2-
responsive construct containing the ERE from the vitellogenin A2 gene 
promoter. 
 The growth inhibitory role of the endogenous AhR was in contrast to 
studies in AhR-deficient rodent liver cancer cells where AhR expression was 
associated with enhanced cell proliferation (588,590).  The results in Figure 30A 
demonstrate that siRNAs for AhR and ARNT decrease expression of their 
respective proteins in Ah-responsive human HepG2 liver cancer cells, and 
induction of luciferase by TCDD in cells transfected with pDRE3 was also 
decreased in cells cotransfected with the same siRNAs (Fig. 30B).  siRNA for 
lamin A served as a control for these transfection studies and this 
oligonucleotide did not affect levels of AhR/ARNT protein or luciferase 
inducibility by TCDD.  Similar results were observed using scrambled siRNA.  
FACS analysis of HepG2 cells transfected with scrambled siRNA or siRNA for 
the AhR (Fig. 30C) indicated that in AhR-deficient HepG2 cells, there was an 8% 
decrease in cells in S phase and a comparable increase in G0/G1.  These results 
suggest that in HepG2 cells, the endogenous AhR enhances cell cycle 
progression as previously reported in rodent cancer cell lines (588,590).   
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 Fig. 29. Effects of iLMN, iAhR and iGL2 on luciferase activity in MCF-7 cells 
transfected with pERE3 and treated with Me2SO, 30 nM E2, 30 nM TCDD, 1 µM ICI 
182,780, or their combination. [A] Effects of iAhR on induced luciferase activity.  MCF-
7 cells were cotransfected with pERE3 along with iLMN, iGL2 or iAhR, and treated with 
Me2SO, TCDD or E2.  Luciferase activity was determined as described in the Materials 
and Methods and significant (p < 0.05) induction is indicated with an asterisk.  [B] 
Antiestrogen inhibition of TCDD- and E2-induced transactivation.  Cells were 
transfected with pERE3 and iLMN or iAhR, treated with Me2SO, E2, TCDD, ICI 182,780 
or combinations, and luciferase activity was determined as described in the Materials 
and Methods.  Significant (p < 0.05) induction is indicated with an asterisk and 
significant inhibition by ICI 182,780 is also indicated (**).  Results summarized in [A] 
and [B] are means ± SD for 3 replicate determinations for each treatment group. 
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 Fig. 30. siRNAs for the AhR or Arnt decrease protein expression, TCDD-
induced transactivation, and affect cell cycle progression in human HepG2 cells.  
[A] Decreased protein expression. HepG2 cells were transfected with siRNA for AhR 
(iAhR), lamin A (iLMN), or ARNT (iARNT) and AhR, ARNT or Sp1 proteins were 
determined in the various treatment groups by Western blot analysis.  [B] Decreased 
Ah-responsiveness.  Cells were cotransfected with pDRE3 and scrambled RNA 
(control), iLMN, iGL2, iAhR, or iARNT, treated with Me2SO or 20 nM TCDD, and 
luciferase activity determined as described in the Materials and Methods.  Results 
summarized in [A] and [B] are means ± SD for three replicate detemrinations for each 
treatment group, and significant (p < 0.05) decreases in activity are indicated by an 
asterisk.  [C] Effects of siRNA for the AhR on cell cycle progression of HepG2 cells.  
HepG2 cells were transfected with scrambled RNA or iAhR, and the % distribution of 
cells in G0/G1, S and G2/M were determined by FACS analysis as described in the 
Materials and Methods.  Similar results were observed in a duplicate analysis. 
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Fig. 30. Continued. 
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In contrast, in breast cancer cells (Fig. 28), the AhR is growth inhibitory and this 
demonstrates the importance of cell context on the role for the endogenous AhR 
in Ah-responsive breast and liver cancer cell lines. 
 Since decreased AhR expression in MCF-7 and HepG2 cells affected G1 
→ S phase progression in both cell lines, we further investigated modulation of 
several key cell cycle regulatory proteins that are important in this phase of the 
cell cycle.  The results in Figure 31 show that in HepG2 cells transfected with 
siRNA for the AhR, there were significant decreases in cyclin D1, cyclin E, cdk2 
and cdk4 protein expression, whereas no significant changes in Rb or p27 
proteins were observed.  Immunoblot analysis showed low to non-detectable 
levels of p21 protein in HepG2 (and MCF-7) cells.  Thus, decreased proliferation 
of HepG2 cells transfected with siRNA AhR is consistent with decreased 
expression of several proteins required for G1 → S phase progression.  In 
contrast, expression of these same proteins was unchanged in MCF-7 cells 
transfected with siRNA for the AhR.  This suggests that other genes/proteins 
associated with increased proliferation of AhR-deficient MCF-7 cells must be 
affected, and these are currently being investigated. 
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 Fig. 31. Effects of AhR gene silencing on cell cycle enzymes in MCF-7 and 
HepG2 cells.  MCF-7 or HepG2 cells were transfected with siRNA for lamin A (iLMN) or 
AhR (iAhR) as described for the FACS analysis experiments (Fig. 4 and Fig. 6C), and 
levels of cyclin D1, cyclin E, cdk2, cdk4, Rb and p27 proteins were determined in whole 
cell lysates by Western blot analysis as described in the Materials and Methods.  
Determinations were carried out in triplicate and, in HepG2 cells, relative protein levels 
in AhR-depleted cells compared to cells treated with iLMN are presented as means ± 
SD.  Significant (p < 0.05) decreases in protein levels are indicated by an asterisk.  
Minimal to non-detectable p21 protein was detected in all groups (data not shown). 
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DISCUSSION 
 The development of transgenic animal models in which specific gene(s) 
have been ablated, overexpressed or conditionally expressed has provided 
unique insights into their physiological significance and roles in various diseases 
including cancer.  Analogous approaches have been used for studies in 
mammalian cells using transiently or stably-transfected expression plasmids for 
specific genes or their antisense/dominant negative counterparts.  RNA 
interference associated with double-stranded RNA which is rapidly processed 
into siRNAs has been identified in many eukaryotes (575,576,578).  Recent 
studies have demonstrated that siRNA oligonucleotides can be successfully 
used for gene silencing in mammalian cells (67,89,92,96,603-605).  Initial 
applications of this technique by Elbashir and coworkers (67) in HeLa, NIH3T3, 
COS-7 and 293 cells and subsequent studies in several different mammalian 
cell lines have demonstrated that gene silencing can target multiple genes and 
this approach has numerous applications (604).  For example, research in this 
laboratory (603) has shown that siRNA for Sp1 decreases Sp1 protein 
expression in MCF-7 cells and also blocks E2-dependent transactivation of a 
GC-rich construct through interactions of ERα/Sp1.  Moreover, silencing of Sp1 
inhibited hormone-induced cell cycle progression of MCF-7 cells showing that 
ERα/Sp1-mediated genes play an important role in the growth of breast cancer 
cells. 
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 In this study, we have successfully used siRNA for AhR to decrease AhR 
protein expression in MCF-7 cells, and siRNAs for lamin A and ARNT also 
silence their corresponding genes resulting in 60-80% decreased expression of 
their corresponding proteins (Figs. 25 and 26).  AhR-mediated induction of 
CYP1A1 has been extensively investigated as a model for understanding the 
molecular mechanisms of AhR action (363), and the results in Figure 27 
demonstrate siRNA for the AhR blocks induction of CYP1A1 protein, EROD 
activity and DRE-dependent reporter gene activity and siRNA for ARNT gave 
similar results in some of the assays.  These data confirm the role of AhR:ARNT 
in mediating the induction of CYP1A1 and also illustrate that the siRNA 
approach can be used for targeting the AhR and ARNT. 
 Several studies report that TCDD inhibits E2-induced gene/reporter gene 
activity in breast cancer cells and inhibitory AhR-ERα crosstalk is also observed 
for cell proliferation and cell cycle progression (336,396-399,601,602).  
Treatment of MCF-7 cells with E2 significantly enhances G0/G1.  Treatment of 
MCF-7 cells with E2 significantly enhances G0/G1 → S phase progression of ER-
positive breast cancer cells, and this response is inhibited after cotreatment with 
TCDD (602).  The results summarized in Figure 28 also show that E2 and E2 + 
TCDD primarily act on the G0/G1 → S phase of the cell cycle and that TCDD 
alone is growth inhibitory as previously reported (602).  Not unexpectedly, in 
cells transfected with siRNA for the AhR, the inhibitory effects of TCDD on E2-
induced G0/G1 → S phase progression were dramatically decreased as 
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demonstrated by FACS analysis of the whole cells (transfected plus 
untransfected).  Moreover, in cells transfected with siRNA for the AhR and 
treated with Me2SO (solvent), there was an increase in the percentage of cells in 
S phase and this was also observed in all the treatment groups in the AhR-
depleted cells.  These results show that in the absence of TCDD, the AhR is 
growth inhibitory in MCF-7 cells and this constitutes a function for the 
endogenous AhR in this cell line.  Expression of several proteins required for G1 
→ S phase progression were investigated in AhR-deficient MCF-7 cells (Fig. 
31); significant changes in levels of cyclin D1, cyclin E, cdk2, cdk4, Rb or p27 (or 
p21) proteins were not observed.  Currently, we are using microarrays to identify 
specific AhR-regulated genes that play a role in inhibiting breast cancer cell 
growth. 
 Phenotypic changes observed in AhR knockout mice suggest that the 
AhR complex exhibits exogenous ligand-independent activity as a transcription 
factor, and this is supported by other reports including studies in cell lines with 
defective or mutated AhR expression (588,590).  Ma and Whitlock (588) showed 
that AhR-defected mouse Hepa 1 cells exhibited a different morphology, longer 
doubling times and a higher % of cells in G0/G1 compared to wild-type (AhR-
positive) cells.  Similar results were reported for AhR-defective rat hepatoma 5L 
cells which also exhibit an increased percentage of cells in G0/G1 compared to 
wild-type Ah-responsive cells (590).  The cell context-dependent differences in 
endogenous AhR function in human breast cancer (growth inhibitory) versus 
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rodent liver cancer (growth promoting) cells was confirmed in this study using a 
human hepatoma cell line (HepG2) where siRNA for the decreased AhR protein 
expression, increased the % cells in G0/G1 and decreased cells in S phase (Fig. 
30).  The ligand-independent effects of the AhR in HepG2 cells was further 
investigated by determining expression of several proteins required for G1 → S 
phase progression in HepG2 cells transfected with siRNA for the AhR (Fig. 31).  
In AhR-depleted HepG2 cells, there was significantly decreased expression of 
cyclin D1, cyclin E, cdk2 and cdk4, and this was consistent with the higher 
percentage of HepG2 cells in G0/G1 compared to cells expressing the AhR.  
These results suggest that these four genes/proteins may be regulated by the 
endogenous AhR in liver cancer cells, and the molecular mechanisms of ligand-
independent AhR gene regulation are currently being investigated. 
 FACS analysis of AhR-deficient MCF-7 cells shows that treatment with 
TCDD resulted in a 14% decrease in cells in G0/G1 and a nearly comparable 
increase of cells in S phase.  These data suggest that in AhR-deficient cells, 
TCDD exhibits mitogenic activity and, like E2, induces G0/G1 → S phase 
progression.  The estrogen-like activity of TCDD was surprising; however, 
previous studies in AhR-deficient benzo[a]pyrene-resistant MCF-7 cells also 
showed that TCDD increased cell proliferation and reporter gene activity in cells 
transfected with an E2-responsive construct containing a cathepsin D gene 
promoter insert (597).  The ER agonist activity of TCDD was confirmed in MCF-7 
cells transfected with pERE3 and siRNA for lamin (control) or AhR.  In AhR-
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deficient cells, both TCDD and E2 induced luciferase activity and these 
responses were inhibited by the antiestrogen ICI 182,780.  Thus, TCDD 
activates both the AhR and ER in breast cancer cells; however, because of the 
high affinity of TCDD for the AhR, the ER agonist response is only observed in 
AhR-deficient cells.  A previous report showed that indolo[3,2-b]carbazole, an 
acid catalyzed condensation product of the phytochemical indole-3-carbinol, was 
also an AhR and ER agonist in MCF-7 cells (606).  Unlike TCDD, indolo[3,2-
b]carbazole activated both pathways in Ah-responsive MCF-7 cells, and this 
may be due to the lower affinity of this compound for the AhR (591). 
 In summary, results of this study demonstrate that ligand-independent 
actions of the AhR on cell proliferation are dependent on cell context and both 
growth inhibitory (breast) and growth promoting (liver) functions can be observed 
in cancer cell lines.  The results also demonstrate that TCDD exhibits estrogenic 
activity in AhR-deficient MCF-7 cells and it is possible that activation of ER 
signaling by TCDD may be the predominant response in cells with high ER/AhR 
protein ratios.  Ongoing studies are focused on developing cancer cell lines that 
stably express specific siRNAs that can be used for investigating the function of 
other transcription factors. 
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Sp PROTEIN-DEPENDENT REGULATION OF VASCULAR 
ENDOTHELIAL GROETH FACTOR AND PROLIFERATION OF 
PANCREATIC CANCER CELLS 
 
 Pancreatic ductal adenocarcinoma (PDAC) is a major cause of cancer-
related deaths in developed countries and it is estimated that in 2003, more than 
30,000 new cases will be diagnosed in the United States (121).PDAC is a highly 
aggressive disease that invariably evades early diagnosis (415,417,607,608).  
The mean survival time for patients with metastatic disease is only 3 – 6 months, 
and the 1-year survival time for all pancreatic cancers cases is approximately 
20-30% (121).  Several factors are associated with increased risk for pancreatic 
cancer and these include chronic pancreatitis, prior gastric surgery, smoking, 
diabetes, exposure to certain classes of organic solvents, and radiation 
(412,418-420,426-429,609-616).   
 Heritable germline mutations in several genes are also associated with 
increased risks for pancreatic cancer (433,607,608,612,617,618).  For example, 
Peutz-Jeghers, hereditary pancreatitis, familial atypical multiple melanoma 
(FAMM), familial breast cancer 2, and hereditary nonpolyposis colorectal cancer 
syndromes, which are linked to specific heritable gene mutations, markedly 
increase the risk for pancreatic cancer.  Moreover, familial pancreatic cancer 
syndrome where there is at least one pair of first degree relatives also increases 
the risk for this disease.  However, the gene(s) involved have not been 
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identified.  In addition to heritable mutations, several acquired gene mutations 
have been identified in sporadic pancreatic tumors and typically these mutations 
lead to dysregulated growth and deficiencies in DNA repair (619-624).  For 
example, the K-ras oncogene is primarily mutated in codon 12 in >90% of 
pancreatic tumors and the mutation results in a constitutively active form of ras 
which can lead to increased cell proliferation.  Mutations in the cyclin-dependent 
kinase inhibitor p16, the tumor suppressor gene p53, and SMAD4, a 
downstream target of transforming growth factor β (TGFβ) also exhibit high 
mutation frequencies in pancreatic tumors (433,617). 
 Specificity protein 1 (Sp1) is expressed in pancreatic tumors and in 
pancreatic cells in culture, and there is evidence suggesting that Sp1 plays an 
important role in regulation of vascular endothelial growth factor (VEGF) 
expression in Panc-1 and other pancreatic cancer cells (297).  Sp family proteins 
play a complex role in regulation of cancer cell growth and expression of genes 
required not only for growth but also apoptosis and angiogenesis (552).  In this 
study, we used RNA interference to investigate the role of Sp proteins in VEGF 
expression and cell cycle progression.  Our results show for the first time that 
Sp4 is expressed in pancreatic cancer cells and along with Sp1 and Sp3 plays 
an important role in regulating expression of VEGF.  In contrast, Sp3 but not Sp1 
or Sp4 was identified as a key regulator of G0/G1 → S phase progression and 
retinoblastoma (Rb) protein phosphorylation in Panc-1 cells, and this was linked 
to Sp3-dependent suppression of the cyclin-dependent kinase inhibitor p27.   
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MATERIALS AND METHODS 
 Cell lines, chemicals, biochemicals, constructs and 
oligonucleotides. Panc-1, HepG2, 22RV1, MCF7 cells were obtained from the 
American Type Culture Collection (ATCC, Manassas, VA).  DME/F12 with and 
without phenol red, 100× antibiotic/antimycotic solution, and propidium iodide 
were purchased from Sigma.  Fetal bovine serum was purchased from Intergen 
(Purchase, NY).  [γ-32P]ATP (300Ci/mmol) was obtained from Perkin Elmer Life 
Sciences. Poly (dI-dC) and T4 polynucleotide kinase were purchased from 
Roche Molecular Biochemicals (Indianapolis, IN).  Antibodies for Sp1, Sp3, Sp4, 
Rb, p27, cyclin D1, and cyclin E proteins were obtained from Santa Cruz 
Biotechnology (Santa Cruz, CA).  Lysis buffer, luciferase reagent, and RNase 
were obtained from Promega Corp. (Madison, WI).  Consensus GC-rich 
oligonucleotides and VEGF promoter constructs have previously been described 
(345,515).  The consensus GT-box probe used in electrophoretic mobility shift 
assays (EMSA) was 5'-TCG AGA GGT GGG TGG AGT TTC GCG -3'.  p27 Kip1 
promoter luciferase constructs p27 PF (-3568/-12), p27 No. 2 (-549/-12), and 
p27 Sac II (-311/-12) were kindly provided by Dr. Toshiyuki Sakai (Kyoto 
Prefectural University of Medicine, Japan).  siRNA duplexes were prepared by 
Dharmacon Research (Lafayette, CO) and targeted coding regions of the Sp1 
(1811-1833), Sp3 ( 1681-1701), Sp4 (1181-1201), lamin A/C (608 - 626), and 
luciferase (GL2) (153 - 171).  Previous studies in this laboratory have reported 
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oligonucleotide sequences for Sp1, GL2 and lamin A/C siRNA (344,512,603) 
and the iRNA duplex for Sp3, Sp4 is given below.    
 
         Sp3              5' – GCGGCAGGUGGAGCCUUCACUTT 
   TTCGCCGUCCACCUCGGAAGUGA – 5' 
 
         Sp4              5' – GCAGUGACACAUUAGUGAGCTT  
                               TTCGUCACUGUGUAAUCACUCG – 5'  
 
 
 Transfection of Panc- 1 cells and preparation of nuclear extracts. 
Cells were cultured in 6-well plates in 2 ml of DME/F12 medium supplemented 
with 5% fetal bovine serum.  After 16-20 h when cells were 50-60% confluent, 
iRNA duplexes and/or reporter gene constructs were transfected using 
Oligofectamine Reagent (Invitrogen, Carlsbad, CA).  The effects of iSp1, iSp3, 
and iSp4 on transactivation was investigated in Panc-1 cells cotransfected with 
(500 ng) different VEGF and p27 Kip constructs.  Briefly, iRNA duplex was 
transfected in each well to give a final concentration of 50 nM.  Cells were 
harvested 48-56 h and luciferase activity of lysates (relative to β-galactosidase 
activity) was determined (344,515,603). For EMSA assay, nuclear extracts were 
isolated as previously described (344,345,515,603).  Aliquots were stored at -80 
°C and used for gel shift assays.  
 Western immunoblot. Cells were washed once with PBS and collected 
by scraping in 200 µl of lysis buffer [50 mM HEPES, 0.5 M sodium chloride, 1.5 
mM magnesium chloride, 1 mM EGTA, 10% (v/v) glycerol, 1% Triton X-100, and 
5 µl/ml of Protease Inhibitor Cocktail (Sigma)].  Brain tissue was obtained from 
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B6C3F1C mice, washed with cold PBS and homogenized in 1x lysis buffer 
(Promega).  The lysates from cells and brain tissues were incubated on ice for 1 
h with intermittent vortexing followed by centrifugation at 40,000 g for 10 min at 4 
°C.  Equal amounts of protein from each treatment group were diluted with 
loading buffer, boiled, and loaded onto 10 and 12.5% SDS-polyacrylamide gel.  
Samples were electrophoresed and proteins were detected by incubation with 
polyclonal primary antibodies Sp1 (PEP2), Sp3 (D-20), Sp4 (V-20), lamin A/C 
(N-18), cyclin D1 (M-20), cyclin E (C-19), Rb (C-15), and p27 (C-19) followed by 
blotting with appropriate horseradish peroxidase-conjugated secondary antibody 
as previously described (344,515,603). After autoradiography, band intensities 
were determined by a scanning laser densitometer (Sharp Electronics 
Corporation, Mahwah, NJ) using Zero-D Scanalytics software (Scanalytics 
Corporation, Billerica, MA). 
 FACS analysis. Cells were transfected with iRNAs for Sp1, Sp3, Sp4 or 
GL2 and, after 48-56 h, cells were then trypsinized and ~2 × 106 cells were 
centrifuged and resuspended after removal of trypsin in 1 ml of staining solution 
containing 50 µg/ml propidium iodide, 4 mM sodium citrate, 30 units/ml RNase, 
and 0.1% Triton X-100, pH 7.8.  Cells were incubated at 37 °C for 10 min, and 
then prior to FACS analysis, sodium chloride was added to give a final 
concentration of 0.15 M.  Cells were analyzed as mention early in the previous 
section. 
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 Electrophoretic Mobility Shift Assay (EMSA). Consensus Sp1 and GT-
box oligonucleotides were synthesized and annealed, and 5-pmol aliquots were 
5'-end-labeled using T4 kinase and [γ-32P] ATP.  A 30-µl EMSA reaction mixture 
contained ~100 mM KCl, 3 µg of crude nuclear protein, 1 µg poly (dI-dC), with or 
without unlabeled competitor oligonucleotide, and 10 fmol of radiolabeled probe.  
After incubation for 20 min on ice, antibodies against Sp1, Sp3 and/or Sp4 
proteins were added and incubated another 20 min on ice.  Protein-DNA 
complexes were resolved by 5% polyacrylamide gel electrophoresis as 
previously described (344,515,603). Specific DNA-protein and antibody-
supershifted complexes were observed as retarded bands in the gel.  
 Immunocytochemistry. HepG2 and Panc-1 cells were seeded in Lab-
Tek Chamber slides (Nalge Nunc International, Naperville, IL) at 100,000 
cells/well in DME/F12 medium supplemented with 5% fetal bovine serum.  Cells 
were then transfected with iRNAs, and after 48 h the media chamber was 
detached and the remaining glass slides were washed in Dulbecco's PBS.  The 
immunostanning for Sp4 was determined essentially as previously described for 
Sp1 (603) and fluorescence imaging was performed using Carlzeiss Axiophoto 2 
(Calzeiss, Inc., Thornwood, NY) and Adobe Photoshop 5.5 was used to capture 
the images.   
 Statistical analysis. Statistical significance was determined by analysis 
of variance and Scheffe's test, and the levels of probability are noted.  The 
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results are expressed as means ± S.D. for at least three separate (replicate) 
experiments for each treatment.  
 
RESULTS 
Regulation of VEGF expression by Sp1 and Sp3. The contributions of 
Sp1 and Sp3 proteins on regulation of VEGF expression were investigated in 
Panc-1 pancreatic cancer cells that express high levels of VEGF (297).  RNA 
interference was used to decrease expression of Sp1 or Sp3 in Panc-1 cells 
transfected with small inhibitory RNAs for lamin A/C (iLMN) (non-specific), Sp1 
(iSp1) or Sp3 (iSp3) (344,515,603). The results show that transfected iSp1 
oligonucleotide decreases (>50%) Sp1 protein in whole cell lysates and similar 
results were obtained using iSp3 (Fig. 32A).  Both inhibitory RNAs were highly 
specific and did not affect other Sp proteins as previously reported 
(344,515,603). Gel mobility shift assays also confirmed that iSp1 and iSp3 
decreased retarded bands associated with both proteins (Fig. 32B).  The role of 
Sp1 and Sp3 in regulation of VEGF was investigated using a series of constructs 
containing different inserts from the VEGF gene promoter.  The results (Fig. 32C 
and 1D) show that in Panc-1 cells transfected with pVEGF1, pVEGF5, pVEGF6 
or pVEGF8 and cotransfected with iSp1 or iSp3, there was a decrease in 
luciferase activity that was dependent on the promoter insert.  Significant 
inhibition of activity by iSp1 and iSp3 was observed for the 4 constructs; 
however, iSp1 was more effective using pVEGF1 which contains the -2018 to 
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+54 VEGF promoter insert.  iSp3 was a more effective inhibitor using pVEGF5, 
pVEGF6 and pVEGF8 which contain -133 to +54, -67 to +54 and -66 to -47 
VEGF promoter inserts, respectively.  These data suggest a differential 
interaction of Sp1 and Sp3 with the VEGF promoter with preferential binding of 
Sp3 to the proximal GC-rich sites. 
Sp4-dependent regulation of VEGF. Gel mobility shift assays (Fig. 32B) 
show that although Sp1 and Sp3 are bound to the consensus GC-rich 
oligonucleotide, supershift experiments with Sp1 and Sp3 antibodies show that 
some residual complex remains.  Sp4 protein also binds GC/GT-rich 
oligonucleotides and is primarily expressed in the developing brain in the mouse 
with lower but detectable levels in many other tissues (273,297). Results in 
Figure 33A demonstrate that immunoreactive Sp4 protein can be detected in 
Panc-1 cells as well as brain tissue, MCF-7 breast, and 22Rv1 prostate human 
cancer cells.  In contrast, Sp4 was not detected in the human HepG cancer cell 
line.  Sp4 expression clearly activates pVEGF1 and pVEGF2 (Fig. 33B), and we 
have also observed activation of these VEGF constructs by Sp1 and Sp3 as 
previously reported (297).   
Expression of Sp4 in Panc-1 cells was further investigated in gel mobility 
shift assays using nuclear extracts from Panc-1 cells and a 32P-labeled GT-rich 
oligonucleotide (Fig. 33C, lanes 1 and 2, labeled oligonucleotide alone).  The 
retarded band complex (lane 2) gave supershifted bands after coincubation with 
Sp1, Sp3 and Sp4 antibodies (lanes 3 - 5, respectively).   
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Fig. 32. Activation of VEGF by Sp1 and Sp3 in Panc-1 cells.  [A] siRNAs for 
Sp1 and Sp3 downregulate their corresponding proteins in Panc-1 cells.  Results are 
expressed as means ± SE for three separate experiments, and iSp1 and iSp3 
significantly (P < 0.05, *) downregulated their corresponding proteins.  [B]  EMSA 
analysis of nuclear extracts from Panc-1 cells transfected with iLMN, iSp1 or iSp3.  
Specifically-bound complexes and supershifted complexes are indicated (arrows).  [C 
and D]  Transfection with iSp1, iSp3 or iLMN and various VEGF promoter constructs.  
Results are expressed as means ±  SD for three separate experiments for each 
treatment group, and significant (P < 0.05, *) decreases in activity (compared to control) 
are indicated. 
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Fig. 1. Continued 
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Fig. 32. Continued. 
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Incubation with Sp1 plus Sp3 antibodies did not completely supershift the major 
retarded band complex (lane 6); however, coincubation with Sp1, Sp3 plus Sp4 
antibodies immunodepleted/supershifted the specifically bound bands (lane 7).  
Expression of Sp4 protein was also confirmed by immunostaining with Sp4 
antibodies (Fig. 33D).  Sp4 staining was observed in Panc-1 but not HepG2 
cells.  These results demonstrate that Panc-1 cells express Sp4 protein and the 
antibody supershift experiment (Fig. 33C) suggests that Sp1, Sp3 and Sp4 
constitute the major Sp family proteins expressed in this cell line.  Transfection 
of small inhibitory RNA for Sp4 (iSp4) specifically decreased immunoreactive 
Sp4 (but not Sp1) protein in Panc-1 cells.  The effects of iSp4 on VEGF 
promoter constructs are summarized in Figure 2E.  The results show that iSp4 
inhibited (>50%) transactivation in Panc-1 cells transfected with pVEGF1, 
pVEGF5 and pVEGF6 suggesting that Sp4 also plays a major role in regulation 
of VEGF in this cell line. 
Sp3 as a key regulator of cell cycle progression. Sp1 and other Sp 
proteins also regulate expression of multiple genes associated with cancer cell 
proliferation (552) and the effects of iSp1, iSp3 and iSp4 on growth of Panc-1 
cells was determined by measuring retinoblastoma protein (Rb) phosphorylation 
as a downstream marker of cell growth (Fig. 34A). In cells transfected with iSp1 
or iSp4, there were minimal changes in Rb phosphorylation compared to results 
in control cells (untreated) or cells transfected with iLMN.   
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Fig. 33. Sp4 expression in Panc-1 cells and regulation of VEGF.  [A]  
Western blots.  Whole cell and mouse brain lysates were analyzed for Sp4 and Sp1 by 
Western immunoblot analysis.  [B]  Induction of VEGF promoter constructs by Sp4.  
Empty vector was used to ensure the same amount of DNA was transfected.  Results 
are expressed as means ± SD for three replicate determinations for each treatment 
group, and significant (P < 0.05, *) induction is indicated.  [C]  EMSA assay.  Gel 
mobility shifts were determined using 32P-labeled GT-rich oligonucleotide, nuclear 
extracts from Panc-1 cells, and antibodies for Sp1, Sp3 and Sp4.  [D]  Immunostaining. 
Immunofluorescence was determined in HepG2 (a, b) and Panc-1 (c, d) cells stained 
with Sp4 primary antibody (b, d) or only with the secondary antibody (a, c).  [E]  Effect of 
iSp4 on VEGF expression.  iSp4 significantly (P < 0.05, *) decreased Sp4 protein in 
whole cell lysates from Panc-1 cells.  Results of transfection and Western blots are 
expressed as means ± SD for three replicate determinations for each treatment group, 
and significantly (P < 0.05, *) decreased reporter gene activity after cotransfection with 
iSp4 is indicated. 
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Fig. 33. Continued. 
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Fig. 33. Continued. 
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FACS analysis of cells transfected with iSp1 or iSp4 also showed that the % 
distribution of Panc-1 cells in G0/G1, S or G2/M phases of the cell cycle were 
comparable to those observed in control cells or cells transfected with 
nonspecific small inhibitory RNAs (iGL2).  The effects observed for iSp3 clearly 
demonstrate that this specific Sp family protein plays an important role in Panc-1 
cell growth.  Transfection with iSp3 in Panc-1 cells markedly decreased Rb 
phosphorylation (Fig. 34B).  Moreover, FACS analysis after transfection with 
iSp3 increased the percentage of cells in G0/G1 (62.96%) compared to control 
cells (42.86%) and decreased the percentage of cells in S-phase (15.58%) and 
G2/M (21.45%) compared to control cells (32.97% and 24.18%, respectively).  
These data clearly show that iSp3 primarily inhibits G0/G1 → S phase 
progression and this is consistent with decreased Rb phosphorylation in Panc-1 
cells transfected with iSp3 (Fig. 34A).  
 These results suggest that Sp3 plays a critical role in regulation of genes 
required for G0/G1 → S phase progression, and the identities of the target gene 
products were investigated by Western blot analysis of whole cell lysates from 
Panc-1 cells transfected with iSp3.  The results demonstrate that loss of Sp3 
protein did not affect levels of cyclin D1 or cyclin E protein; however, there was a 
dramatic increase of p27 expression (Fig. 35A).  Only minimal effects on p21 
and other proteins involved in G0/G1 → S phase of the cell cycle were observed.  
The role of Sp3 on p27 expression was further investigated using constructs 
containing p27 promoter inserts linked to a luciferase reporter gene.   
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Fig. 34. Role of Sp proteins in Panc-1 cell proliferation.  [A]  Rb 
phosphorylation.  Immunoblot analysis of Rb and phosphor-Rb (pRb) was determined in 
whole cell lysates of Panc-1 cells transfected with iSp1, iSp3 or iSp4.  [B]  FACS 
analysis.  Cells were transfected with iSp1, iSp3 or iSp4, and their subsequent 
distribution in different phases of  the cell cycle was determined by FACS analysis.  
Results obtained for Sp1 and Sp4 (data not shown) were comparable, and the effects of 
iSp1, iSp3 or iSp4 gave similar results in duplicate analyses. 
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Fig. 35. Sp3-dependent regulation of p27 in Panc-1 cells.  [A]  Western blot 
analysis. Cells were transfected with iSp3 or control (no oligonucleotide), and whole cell 
lysates were determined by Western blot analysis.  Levels of other proteins associated 
with G0/G1 → S phase progression were unchanged (data not shown).  Results are 
expressed as means ± SD for three replicate determinations for each treatment group, 
and significantly (P < 0.05, *) increased levels are indicated.  [B]  p27 promoter activity.  
Panc-1 cells were transfected with p27 promoter constructs and iLMN, iSp1 or iSp3.   
Results are expressed as means ± SD for three replicate determinations for each 
treatment group, and significantly (P < 0.05, *) increased activity is indicated.  [C]  
Immunostaining of p27 and phospho-Rb.  Panc-1 cells were transfected with iGL2 
(panels c and d) or iSp3 (panels e and f) and immunostained with phospho-Rb (panels 
c and e) or p27 (panels d and f) antibodies.  Panels a and b represent cells stained only 
with the secondary antibody. 
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Fig. 35. Continued. 
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The results (Fig. 35B) clearly show that iSp3 but not iSp1 increases 
transactivation in Panc-1 cells transfected with the p27 constructs which contain 
distal and proximal GC-rich sites and confirms the critical role of Sp3 in 
regulating growth of Panc-1 cells through inhibition of p27 expression.  
Confirmation that iSp3 results in upregulation of p27 is given in Figure 35C 
where knockdown of Sp3 results in upregulation of p27 protein (panel F) and 
downregulation of pRb (panel E) compared to cells transfected with the non-
specific control siRNA for luciferase (iGL2) (panels C and D). 
 
DISCUSSION 
 Pancreatic cancer is a complex and devastating disease which is usually 
detected in advanced stages or after metastases.  Not surprisingly, current 
chemotherapies for this disease have limited efficacy and the 1 and 5 year 
survival times are approximately 21 and 5%, respectively (121,415). 
Development of new strategies for detection and treatment of this disease will 
depend on several factors which include a more comprehensive understanding 
of critical genes and pathways that control pancreatic tumor growth.  PDAC cell 
lines have been developed for in vitro studies, and Panc-1 cells were derived 
from a primary tumor (625) and exhibit K-ras, p53 and p16 mutations which are 
typically observed in PDAC (433,618-624). 
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 Previous studies reported that Panc-1 and other pancreatic cancer cell 
lines expressed high levels of Sp1 and Sp3 proteins, and Sp1 protein levels 
correlated with VEGF protein and VEGF promoter activity (297).  The results are 
consistent with other studies showing that basal expression of VEGF is due, in 
part, to interactions of Sp1 with proximal GC-rich sites in the VEGF gene 
promoter (345,483,515). Studies in this laboratory have shown that the -131 to -
47 region of the promoter is important for basal and estrogen-inducible 
expression of VEGF/VEGF promoter constructs through estrogen receptor/Sp 
protein interactions (345,515). Moreover, in ZR-75 breast cancer cells, hormone-
induced transactivation of VEGF was due to both ERα/Sp1 and ERα/Sp3 as 
determined in RNA interference assays (515). As previously reported (297), 
Panc-1 cells expression both Sp1 and Sp3 (Fig. 32A and B), and transfection of 
iSp1 and iSp3 specifically decreases expression of both proteins (Fig. 32C).  
Based on results of gel mobility shift assays (Fig. 32B), there was evidence for 
expression of at least one additional protein that bound the GC-rich 
oligonucleotide (Fig. 32B).  Subsequent Western blot, gel mobility shift and 
immunostaining assays showed that Sp4 protein is also expressed in Panc-1 
cells (Fig. 33) and ongoing studies indicate that Sp4 is widely expressed in 
pancreatic cancer cell lines.  Since all three Sp family proteins can potentially 
regulate VEGF expression in Panc-1 cells, we further investigated activation of 
VEGF promoter constructs in cells transfected with iSp1, iSp3 or iSp4.  The 
results show that all three proteins cooperatively activate VEGF (Figs. 32C and 
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D and 33E) in Panc-1 cells and thereby expands the role of Sp family proteins in 
regulation of VEGF.   
 Sp proteins also regulate genes required for cancer cell proliferation 
(297), and we used RNA interference assays with iSp1, iSp3 and iSp4 to 
investigate their role in Panc-1 cell growth. Transfection with iSp1 or iSp4 
followed by FACS analysis indicated that distribution of the cells in G0/G1, G2/M 
or S phase and Rb phosphorylation was not significantly affected by either 
protein.  In contrast, after transfection with iSp3, there was a decrease in Rb 
phosphorylation (Figs. 34A and 35C), a significant increase in cells in G0/G1, and 
a decrease in S-phase, suggesting that progression of Panc-1 cells through 
G0/G1 → S is Sp3-dependent (Fig. 34B).  Subsequent analysis of cell cycle 
proteins in Panc-1 cells transfected with iSp3 showed that knockdown of Sp3 
protein resulted in increased p27 protein and p27 reporter gene expression (Fig. 
35A - C).  These data suggest a novel mechanism for Panc-1 cell growth which 
is determined, in part, by Sp3-dependent suppression of the cyclin-dependent 
kinase inhibitor p27.  The strong inhibitory effects of Sp3 on the p27 promoter 
contrasts to Sp3-dependent transactivation of VEGF (Fig. 32C and D) and 
illustrates the promoter-dependent inhibitory and activating responses linked to 
this transcription factor in Panc-1 cells.  Currently, we are further investigating 
the relative expression and functions of Sp family proteins in other pancreatic 
cancer cells and tumors to gain further insights on tumor growth and 
angiogenesis and on identifying specific cellular targets for chemotherapy. 
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SUMMARY 
 
The development of genetic technologies to regulate or delete expression 
of endogenous genes has been extensively used to probe the role of specific 
genes in biological and pathological pathways. RNA interference associated with 
dsRNA that is rapidly processed into siRNA has been identified in many 
eukaryotes and siRNA oligonucleotides can be successfully used for gene 
silencing in mammalian cells. We have focused on applications of siRNA 
techniques to investigate the role of several genes in pathways associated with 
growth and progression of breast, liver, and pancreatic cancer cells. 
Two estrogen receptor (ER) positive breast cancer cell lines have been 
used to investigate the molecular mechanisms of the ligand-dependent 
activation of ERα/Sp1. 17β-estradiol (E2)-dependent transactivation of a GC-rich 
construct through interactions with ERα/Sp1 was blocked by siRNA for Sp1. In 
addition, silencing of Sp1 inhibits hormone-induced cell-cycle progression of 
MCF-7 cells, showing that genes activated by ERα/Sp1 play an important role in 
the growth of breast cancer cells. 
 siRNA for the aryl hydrocarbon receptor (AhR) and estrogen receptor 
(ER) were used to investigate inhibitory AhR-ERα crosstalk in breast cancer 
cells. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) inhibits E2-induced 
gene/reporter gene activity in breast cancer cells and this inhibitory crosstalk is 
observed for cell proliferation and cell cycle progression. siRNA for the AhR not 
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only inhibited TCDD-induced CYP1A1 gene expression, but also abrogated 
AhR-ER crosstalk in breast cancer cells. Moreover it was also shown that the 
endogenous AhR functions as an inhibitorof cell growth in human breast cancer 
cells whereas the AhR enhances liver cancer cell growth demonstrating 
important cancer cell context-dependent effects of the AhR. Interestingly, in the 
absence of the AhR, TCDD was estrogenic suggesting that cellular ER/AhR 
ratios may dictate receptor specific activation by this compound. 
Using pancreatic cancer cells, we have investigated the role of several Sp 
family proteins in regulating angiogenesis and growth of pancreatic cancer cells. 
This study has shown for the first time that Sp4 is expressed in different 
pancreatic cancer cell lines and Sp4, Sp1 and Sp3 coordinately activate 
vascular endothelial growth factor (VEGF) in pancreatic cancer cells. The 
specificity of RNAi was critical for delineating the individual and cooperative 
roles of these Sp proteins in regulating VEGF expression. In contrast, Sp3 is the 
key regulator of the cell cycle progression through a novel pathway that involves 
suppression of cyclin-dependent kinase inhibitor p27 expression. These results 
suggest that Sp3 and other Sp family proteins regulate angiogenesis and 
proliferation of pancreatic cancer cells and current studies are investigating 
these pathways in other pancreatic cancer cell lines.  
Finally, along with the rapidly growing literature on using siRNA as a 
functional genomic tool, there is emerging evidence that siRNAs may represent 
novel therapeutic agents for cancer treatment when optimized local and 
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systemic delivery systems are available. Our laboratory and others are 
developing strategies for delivery of siRNAs to specific target tissue and this will 
facilitate the in vivo applications and the therapeutic benefits of this technology. 
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